

SECURITIES AND EXCHANGE COMMISSION

FORM 10-Q

Quarterly report pursuant to sections 13 or 15(d)

Filing Date: 2021-05-17 | Period of Report: 2021-03-31  
SEC Accession No. 0001564590-21-028188

(HTML Version on [secdatabase.com](http://secdatabase.com))

FILER

**SCYNEXIS INC**

CIK: **1178253** | IRS No.: **562181648** | Fiscal Year End: **1231**  
Type: **10-Q** | Act: **34** | File No.: **001-36365** | Film No.: **21927651**  
SIC: **2834** Pharmaceutical preparations

Mailing Address

1 EVERTRUST PLAZA  
13TH FLOOR  
JERSEY CITY NJ 07302-6548

Business Address

1 EVERTRUST PLAZA  
13TH FLOOR  
JERSEY CITY NJ 07302-6548  
201-884-5485

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_**

**Commission File Number 001-36365**

**SCYNEXIS, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)  
  
1 Evertrust Plaza, 13<sup>th</sup> Floor  
Jersey City, New Jersey  
(Address of principal executive offices)

**56-2181648**  
(I.R.S. Employer  
Identification No.)

**07302-6548**  
(Zip Code)

**(201)-884-5485**

**(Registrant's telephone number, including area code)**

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value \$0.001 per share	SCYX	Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of May 1, 2021, there were 20,630,750 shares of the registrant's Common Stock outstanding.



**SCYNEXIS, INC.**  
**QUARTERLY REPORT ON FORM 10-Q**  
**FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021**

**TABLE OF CONTENTS**

	<u>Page</u>
<b><u>PART I FINANCIAL INFORMATION</u></b>	1
<b>Item 1.</b> <a href="#">Financial Statements</a>	1
<a href="#">Unaudited Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020</a>	1
<a href="#">Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020</a>	2
<a href="#">Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020</a>	3
<a href="#">Notes to the Condensed Consolidated Financial Statements (unaudited)</a>	4
<b>Item 2.</b> <a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>	18
<b>Item 3.</b> <a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	25
<b>Item 4.</b> <a href="#">Controls and Procedures</a>	25
<b><u>PART II OTHER INFORMATION</u></b>	26
<b>Item 1A.</b> <a href="#">Risk Factors</a>	26
<b>Item 2.</b> <a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	26
<b>Item 6.</b> <a href="#">Exhibits</a>	26
<b><u>Signatures</u></b>	28

---

## PART I. FINANCIAL INFORMATION

## Item 1. Financial Statements.

## SCYNEXIS, INC.

## UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	March 31, 2021	December 31, 2020
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 92,011	\$ 93,041
Prepaid expenses and other current assets	3,310	5,165
Restricted cash	55	—
Total current assets	<u>95,376</u>	<u>98,206</u>
Other assets	692	573
Deferred offering costs	187	187
Restricted cash	218	273
Property and equipment, net	271	298
Intangible assets	378	—
Operating lease right-of-use asset (See Note 6)	2,950	2,999
<b>Total assets</b>	<b><u>\$ 100,072</u></b>	<b><u>\$ 102,536</u></b>
<b>Liabilities and stockholders' equity</b>		
Current liabilities:		
Accounts payable	\$ 6,516	\$ 4,639
Accrued expenses	2,134	4,141
Warrant liabilities	16,225	17,564
Operating lease liability, current portion (See Note 6)	57	52
Total current liabilities	<u>24,932</u>	<u>26,396</u>
Other liabilities	140	—
Warrant liabilities	33,635	33,592
Convertible debt and derivative liability (See Note 5)	12,226	16,516
Operating lease liability (See Note 6)	3,215	3,274
Total liabilities	<u>74,148</u>	<u>79,778</u>
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$0.001 par value, authorized 5,000,000 shares as of March 31, 2021 and December 31, 2020; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020	—	—
Common stock, \$0.001 par value, 100,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 20,625,637 and 19,663,698 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	21	20
Additional paid-in capital	357,192	349,351
Accumulated deficit	(331,289)	(326,613)
Total stockholders' equity	<u>25,924</u>	<u>22,758</u>
<b>Total liabilities and stockholders' equity</b>	<b><u>\$ 100,072</u></b>	<b><u>\$ 102,536</u></b>

*The accompanying notes are an integral part of the financial statements.*

## SCYNEXIS, INC.

## UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

	Three Months Ended March 31,	
	2021	2020
Revenue	\$ 12,050	\$ —
Operating expenses:		
Research and development	6,948	9,866
Selling, general and administrative	6,696	2,613
Total operating expenses	13,644	12,479
Loss from operations	(1,594)	(12,479)
Other expense (income):		
Loss on extinguishment of debt	2,725	—
Amortization of debt issuance costs and discount	256	278
Interest income	(7)	(147)
Interest expense	214	210
Other income	—	(350)
Warrant liabilities fair value adjustment	(1,296)	(4,768)
Derivative liabilities fair value adjustment	90	(700)
Total other expense (income)	1,982	(5,477)
<b>Loss before taxes</b>	<b>(3,576)</b>	<b>(7,002)</b>
Income tax expense	1,100	—
<b>Net loss</b>	<b>\$ (4,676)</b>	<b>\$ (7,002)</b>
Net loss per share attributable to common stockholders – basic		
Net loss per share – basic	\$ (0.18)	\$ (0.72)
Net loss per share attributable to common stockholders – diluted		
Net loss per share – diluted	\$ (0.23)	\$ (0.72)
Weighted average common shares outstanding – basic and diluted		
Basic	25,802,700	9,744,577
Diluted	26,523,920	9,744,577

The accompanying notes are an integral part of the financial statements.

SCYNEXIS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Three Months Ended March 31,	
	2021	2020
<b>Cash flows from operating activities:</b>		
Net loss	\$ (4,676)	\$ (7,002)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	27	28
Stock-based compensation expense	398	410
Accretion of investments discount	—	(31)
Amortization of debt issuance costs and discount	256	278
Change in fair value of warrant liabilities	(1,296)	(4,768)
Change in fair value of derivative liabilities	90	(700)
Noncash operating lease expense for right-of-use asset	49	48
Loss on extinguishment of debt	2,725	—
Changes in operating assets and liabilities:		
Prepaid expenses, other assets, deferred costs, and other	1,736	1,734
Accounts payable, accrued expenses, and other	(68)	(4,054)
Net cash used in operating activities	<u>(759)</u>	<u>(14,057)</u>
<b>Cash flows from investing activities:</b>		
Maturities of investments	—	6,477
Purchases of property and equipment	—	(4)
Purchase of intangible assets	(200)	—
Purchases of investments	—	(14,235)
Net cash used in investing activities	<u>(200)</u>	<u>(7,762)</u>
<b>Cash flows from financing activities:</b>		
Proceeds from common stock issued	—	214
Payments of offering costs and underwriting discounts and commissions	(62)	(7)
Proceeds from common stock issuance under employee stock purchase plan	6	18
Repurchase of shares to satisfy tax withholdings	(15)	(73)
Net cash (used in) provided by financing activities	<u>(71)</u>	<u>152</u>
Net decrease in cash, cash equivalents, and restricted cash	<u>(1,030)</u>	<u>(21,667)</u>
Cash, cash equivalents, and restricted cash at beginning of period	93,314	42,193
Cash, cash equivalents, and restricted cash at end of period	<u>\$ 92,284</u>	<u>\$ 20,526</u>
<b>Supplemental cash flow information:</b>		
Cash paid for interest	<u>\$ 420</u>	<u>\$ 420</u>
Cash received for interest	<u>\$ 5</u>	<u>\$ 129</u>
<b>Noncash financing and investing activities:</b>		
Common stock issued for settlement of senior convertible notes	<u>\$ 7,452</u>	<u>\$ —</u>
Purchased intangible assets included in accounts payable and accrued expenses	<u>\$ 178</u>	<u>\$ —</u>
Deferred offering and issuance costs included in accounts payable and accrued expenses	<u>\$ —</u>	<u>\$ 40</u>

*The accompanying notes are an integral part of the financial statements.*

SCYNEXIS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

**1. Description of Business and Basis of Preparation**

*Organization*

SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its lead product candidate, ibrexafungerp, as the first representative of a novel oral and intravenous triterpenoid antifungal family for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of \$331.3 million at March 31, 2021 and limited capital resources to fund ongoing operations. These capital resources primarily comprised cash and cash equivalents of \$92.0 million at March 31, 2021. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company’s liquidity could be materially affected over this period by, among other things: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to potentially commercialize ibrexafungerp for the treatment of vaginal yeast infections and; (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Company’s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation.

*Reverse Stock Split*

On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”), which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares. All share and per share amounts presented in these unaudited condensed consolidated financial statements have been retroactively adjusted for the reverse stock split and certain items in the prior period financial statements have been revised to conform to the current presentation. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding.

*Unaudited Interim Condensed Consolidated Financial Information*

The accompanying unaudited condensed consolidated financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”), as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 29, 2021.

*Use of Estimates*

The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses





during the reporting periods. Actual results could differ from those estimates. Significant estimates include: determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.

## 2. Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2020, except as described below.

### *Revenue Recognition*

The Company has entered into arrangements involving the sale or license of intellectual property and the provision of other services. When entering into any arrangement involving the sale or license of intellectual property rights and other services, the Company determines whether the arrangement is subject to accounting guidance in ASC 606, *Revenue from Contracts with Customers* ("Topic 606"), as well as ASC 808, *Collaborative Arrangements* ("Topic 808"). If the Company determines that an arrangement includes goods or services that are central to the Company's business operations for consideration, the Company will then identify the performance obligations in the contract using the unit-of-account guidance in Topic 606. For a distinct unit-of-account that is within the scope of Topic 606, the Company applies all of the accounting requirements in Topic 606 to that unit-of-account, including the recognition, measurement, presentation and disclosure requirements. For a distinct unit-of-account that is not within the scope of Topic 606, the Company will recognize and measure the distinct unit-of-account based on other authoritative ASC Topics or on a reasonable, rational, and consistently applied policy election.

Analyzing the arrangement to identify performance obligations requires the use of judgment. In arrangements that include the sale or license of intellectual property and other promised services, the Company first identifies if the licenses are distinct from the other promises in the arrangement. If the license is not distinct, the license is combined with other services into a single performance obligation. Factors that are considered in evaluating whether a license is distinct from other promised services include, for example, whether the counterparty can benefit from the license without the promised service on its own or with other readily available resources and whether the promised service is expected to significantly modify or customize the intellectual property.

The Company classifies non-refundable upfront payments, milestone payments and royalties received for the sale or license of intellectual property as revenues within its statements of operations because the Company views such activities as being central to its business operations. For the sale of intellectual property that is distinct, fixed consideration and variable consideration are included in the transaction price and recognized in revenue immediately to the extent that it is probable that there would not be a significant reversal of cumulative revenue in the future. For the license of intellectual property that is distinct, fixed and variable consideration (to the extent there will not be a significant reversal in the future) are also recognized immediately in income, except for consideration received in the form of royalty or sales-based milestones, which is recorded when the customer's subsequent sales or usages occur. If the sale or license of intellectual property is not distinct, revenue is deferred and recognized over the estimated period of the Company's combined performance obligation. For contractual arrangements that meet the definition of a collaborative arrangement under Topic 808, consideration received for any units-of-account that are outside the scope of Topic 606 are recognized in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company's business operations, and (iii) the contractual terms of the arrangement.

[Table of Contents](#)

*Basic and Diluted Net Loss per Share of Common Stock*

The Company calculates net loss per common share in accordance with ASC 260, *Earnings Per Share*. Basic net loss per common share for the three months ended March 31, 2021 and 2020 was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, *Earnings Per Share*, the weighted average number of common shares outstanding utilized for determining the basic net loss per common share for the three months ended March 31, 2021 includes the pre-funded warrants to purchase 5,260,000 shares of common stock issued in the December 2020 Public Offering. Diluted net loss per common share for the three months ended March 31, 2021 and 2020 was determined as follows (in thousands, except share and per share amounts):

	Three Months Ended March 31,	
	2021	2020
Net loss	\$ (4,676)	\$ (7,002)
Dilutive effect of warrant liability	(1,323)	—
Net loss allocated to common shares	<u>\$ (5,999)</u>	<u>\$ (7,002)</u>
Weighted average common shares outstanding – basic	25,802,700	9,744,577
Dilutive effect of warrant liability	721,220	—
Weighted average common shares outstanding – diluted	<u>26,523,920</u>	<u>9,744,577</u>
Net loss per share – diluted	\$ (0.23)	\$ (0.72)

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three months ended March 31, 2021 and 2020, as the result would be anti-dilutive:

	Three Months Ended March 31,	
	2021	2020
Outstanding stock options	1,371,606	768,354
Outstanding restricted stock units	96,974	85,754
Warrants to purchase common stock associated with June 2016 public offering	421,867	421,867
Warrants to purchase common stock associated with March 2018 public offering – Series 2	798,810	798,810
Warrants to purchase common stock associated with December 2019 Public Offering	4,472,205	4,472,205
Warrants to purchase common stock associated with December 2020 Public Offering – Series 2	6,800,000	—
Common stock associated with March 2019 Notes	1,138,200	1,138,200
Warrants to purchase common stock associated with Solar loan agreement	12,243	12,243
Total	<u>15,111,905</u>	<u>7,697,433</u>

*Recently Issued Accounting Pronouncements*

In June 2016, the FASB issued ASU No. 2016-13, *Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, *Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)* (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.

In August 2020, the FASB issued ASU No. 2020-06, *Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity* (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.



### *Recently Adopted Accounting Pronouncements*

In December 2019, the FASB issued ASU No. 2019-12, *Income Taxes: Simplifying the Accounting for Income Taxes* (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, *Income Taxes*, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance was adopted by the Company in the first quarter of 2021 and it did not have a material impact on its unaudited condensed consolidated financial statements.

### **3. Prepaid Expenses and Other Current Assets**

Prepaid expenses and other current assets consisted of the following (in thousands):

	<b>March 31, 2021</b>	<b>December 31, 2020</b>
Prepaid research and development services	\$ 1,300	\$ 1,535
Prepaid insurance	115	362
Other prepaid expenses	525	19
Other receivables	1,000	2,876
Other current assets	370	373
Total prepaid expenses and other current assets	<u>\$ 3,310</u>	<u>\$ 5,165</u>

### **4. Accrued Expenses**

Accrued expenses consisted of the following (in thousands):

	<b>March 31, 2021</b>	<b>December 31, 2020</b>
Accrued research and development expenses	\$ 647	\$ 991
Accrued employee bonus compensation	433	2,190
Other accrued expenses	1,054	960
Total accrued expenses	<u>\$ 2,134</u>	<u>\$ 4,141</u>

### **5. Borrowings**

#### *April 2020 Note Purchase Agreement*

On April 9, 2020, the Company entered into the April 2020 Note Purchase Agreement with Puissance Life Science Opportunities Fund VI (“Puissance”) and issued and sold to Puissance \$10.0 million aggregate principal amount of its April 2020 Notes, resulting in net proceeds of approximately \$9.5 million after deducting \$0.5 million for an advisory fee and other issuance costs. At December 31, 2020, the fair value of the April 2020 Notes was \$7.4 million.

In January 2021, Puissance converted the remaining \$6.0 million of the April 2020 Notes for 959,080 shares of common stock. Upon conversion of the \$6.0 million of the April 2020 Notes, the Company recognized a \$2.7 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of \$4.8 million and the fair value of the consideration issued of \$7.5 million.

#### *March 2019 Note Purchase Agreement*

On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance \$16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 (“March 2019 Notes”), resulting in \$14.7 million in net proceeds after deducting \$1.3 million for an advisory fee and other issuance costs.

As of March 31, 2021, the Company’s March 2019 Notes consists of the convertible debt balance of \$9.6 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of \$0.4 million, and the bifurcated embedded conversion option derivative liability of \$2.6 million. In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, *Derivatives and Hedging*, at its initial fair value of \$7.0 million as the interest make-whole provision is settled in shares of common stock. For the three months ended March 31, 2021 and 2020, the Company recognized gains of \$42,000 and \$0.7 million, respectively, on the fair value adjustment for the derivative liability. For each of the three months ended March 31, 2021 and 2020, the Company recognized \$0.3 million in amortization of debt issuance costs and discount related to the March 2019 Notes.

The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At both March 31, 2021 and December 31, 2020, the fair value of the convertible debt and derivative liability for the March 2019 Notes is \$12.9 million.

## [Table of Contents](#)

The March 2019 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the March 2019 Notes being issued to one financially sophisticated investor. The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.

The holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. The initial conversion rate is 73.9096 shares of common stock per \$1,000 principal amount of March 2019 Notes, which is equivalent to an initial conversion price of approximately \$13.53 and is subject to adjustment in certain events described in the March 2019 Note Purchase Agreement. The Holder upon conversion may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate if the holder elects to convert its March 2019 Notes in connection with such a corporate event. Subject to adjustment in the conversion rate, the number of shares that the Company may deliver in connection with a conversion of the March 2019 Notes, including those delivered in connection with an interest make-whole payment, will not exceed a cap of 81 shares of common stock per \$1,000 principal amount of the March 2019 Notes.

On or after March 15, 2022, the Company has the right, at its election, to redeem all or any portion of the March 2019 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the March 2019 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If a “fundamental change” (as defined in the March 2019 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the March 2019 Notes for cash at a repurchase price of 100% of the principal amount of the March 2019 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.

## 6. Commitments and Contingencies

### *Leases*

On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the “Lease”). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of \$7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of \$0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years. The security deposit is classified as restricted cash in the accompanying unaudited condensed consolidated balance sheets.

The consideration in the Lease allocated to the single lease component includes the fixed payments for the right to use the office space as well as common area maintenance. The Lease also contains costs associated with certain expense escalation, property taxes, insurance, parking, and utilities which are all considered variable payments and are excluded from the operating lease liability. The incremental borrowing rate utilized approximated the prevailing market interest rate the Company would incur to borrow a similar amount equal to the total Lease payments on a collateralized basis over the term of the Lease. The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands):

	Three Months Ended March 31, 2021	Three Months Ended March 31, 2020
Operating lease cost	\$ 166	\$ 166
Variable lease cost	(2)	21
Total operating lease expense	<u>\$ 164</u>	<u>\$ 187</u>
Cash paid for amounts included in the measurement of operating lease liability	\$ 170	\$ 167
	<u>March 31, 2021</u>	<u>March 31, 2020</u>
Remaining Lease term (years)	8.34	9.34

Discount rate

15%

15%



## [Table of Contents](#)

Future minimum lease payments for the Lease as of March 31, 2021 are as follows (in thousands):

	<b>March 31, 2021</b>
2021	\$ 347
2022	527
2023	715
2024	730
2025	744
Thereafter	2,789
<b>Total</b>	<b>\$ 5,852</b>

The presentations of the operating lease liability as of March 31, 2021 are as follows (in thousands):

	<b>March 31, 2021</b>
Present value of future minimum lease payments	\$ 3,272
Operating lease liability, current portion	\$ 57
Operating lease liability, long-term portion	3,215
<b>Total operating lease liability</b>	<b>\$ 3,272</b>
Difference between future minimum lease payments and discounted cash flows	\$ 2,580

### *License Arrangement with Potential Future Expenditures*

As of March 31, 2021, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health. In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company. Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total \$19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits.

In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the "Deferred Milestone"). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound. In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of an NDA, triggered by the FDA acceptance for filing of the Company's NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for the Company's NDA for ibrexafungerp for the treatment of VVC. Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged.

### *Clinical Development Arrangements*

The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.

## **7. Stockholders' Equity**



*Authorized, Issued, and Outstanding Common Stock*

The Company's authorized common stock has a par value of \$0.001 per share and consists of 100,000,000 shares as of March 31, 2021, and December 31, 2020; 20,625,637 and 19,663,698 shares were issued and outstanding at March 31, 2021, and December 31, 2020, respectively.

On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Amendment"), which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company's common stock and (b) decreasing the number of authorized shares of the Company's common stock from 250,000,000 shares to 100,000,000 shares.

The following table summarizes common stock share activity for the three months ended March 31, 2021 and 2020 (dollars in thousands):

	Three Months Ended March 31, 2021				
	Shares of Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2020	19,663,698	\$ 20	\$ 349,351	\$ (326,613)	\$ 22,758
Net loss	—	—	—	(4,676)	(4,676)
Stock-based compensation expense	—	—	398	—	398
Common stock issued for conversion of April 2020 Notes	959,080	1	7,452	—	7,453
Common stock issued through employee stock purchase plan	2,184	—	6	—	6
Common stock issued for vested restricted stock units	675	—	(15)	—	(15)
<b>Balance, March 31, 2021</b>	<b>20,625,637</b>	<b>\$ 21</b>	<b>\$ 357,192</b>	<b>\$ (331,289)</b>	<b>\$ 25,924</b>

	Three Months Ended March 31, 2020				
	Shares of Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2019	9,741,372	\$ 10	\$ 284,313	\$ (271,428)	\$ 12,895
Net loss	—	—	—	(7,002)	(7,002)
Stock-based compensation expense	—	—	410	—	410
Common stock issued through employee stock purchase plan	2,215	—	18	—	18
Common stock issued, net of expenses	28,527	—	207	—	207
Common stock issued for vested restricted stock units	15,490	—	(73)	—	(73)
<b>Balance, March 31, 2020</b>	<b>9,787,604</b>	<b>\$ 10</b>	<b>\$ 284,875</b>	<b>\$ (278,430)</b>	<b>\$ 6,455</b>

*Shares Reserved for Future Issuance*

The Company had reserved shares of common stock for future issuance as follows:

	<u>March 31, 2021</u>	<u>December 31, 2020</u>
Outstanding stock options	1,371,606	830,343
Outstanding restricted stock units	96,974	29,087
Warrants to purchase common stock associated with June 2016 Public Offering	421,867	421,867
Warrants to purchase common stock associated with March 2018 Public Offering – Series 2	798,810	798,810
Warrants to purchase common stock associated with December 2019 Public Offering	4,472,205	4,472,205
Warrants to purchase common stock associated with December 2020 Public Offering - Series 1	6,800,000	6,800,000
Warrants to purchase common stock associated with December 2020 Public Offering - Series 2	6,800,000	6,800,000
Prefunded warrants to purchase common stock associated with December 2020 Public Offering	5,260,000	5,260,000
Warrants to purchase common stock associated with Solar loan agreement	12,243	12,243
For possible future issuance for the conversion of the March 2019 Notes	1,138,200	1,138,200
For possible future issuance for the conversion of the April 2020 Notes	—	1,299,790
For possible future issuance under 2014 Equity Incentive Plan (Note 9)	318,097	146,488
For possible future issuance under Employee Stock Purchase Plan	6,652	5,895
For possible future issuance under 2015 Inducement Award Plan (Note 9)	14,050	14,050
Total common shares reserved for future issuance	<u>27,510,704</u>	<u>28,028,978</u>

*Common Stock Purchase Agreement*

On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital pursuant to which the Company has the right to sell to Aspire Capital from time to time in its sole discretion up to \$20.0 million in shares of the Company's common stock over the next 30 months, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement. The aggregate number of shares that we can sell to Aspire Capital under the Common Stock Purchase Agreement may in no case exceed 1,956,547 shares of the Company's common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the Common Stock Purchase Agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the Common Stock Purchase Agreement exceeds \$8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company's common stock. During the three months ended March 31, 2021 and 2020, the Company did not sell any shares of its common stock under the Common Stock Purchase Agreement.

*Convertible Debt and Derivative Liabilities*

In connection with the Company's issuances of its April 2020 Notes and March 2019 Notes, the Company bifurcated the embedded conversion options, inclusive of the interest make-whole provisions and make-whole fundamental change provisions, and recorded the embedded conversion options as long-term derivative liabilities in the Company's balance sheet in accordance with ASC 815, *Derivatives and Hedging*. The convertible debt and derivative liability associated with the March 2019 Notes are presented in total on the accompanying unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. For the three months ended March 31, 2021 and 2020, the Company recorded a loss of \$0.1 million and a gain of \$0.7 million, respectively, due to the change in fair value of the derivative liabilities.

*Warrants Associated with June 2016, March 2018, December 2019, and December 2020 Public Offerings*

The outstanding warrants associated with the June 2016, March 2018, December 2019, and December 2020 public offerings contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, *Distinguishing Liabilities from Equity*, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying unaudited condensed consolidated statements of operations. During the three months ended March 31, 2021 and 2020, the Company recorded gains of \$1.3 million and \$4.8 million, respectively, in the warrant liabilities fair value adjustment. As of March 31, 2021 and 2020, the fair value of the warrant liabilities was \$49.9 million and \$51.2 million, respectively.

*Warrant Associated with Solar Loan Agreement*

On the closing date of the Company’s previous loan agreement with Solar, pursuant to the loan agreement the Company issued to Solar the warrant to purchase an aggregate of up to 12,243 shares of the Company’s common stock at an exercise price of \$36.754 per share. The warrant will expire five years from the date of the grant. The warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders’ equity section of the balance sheet.

**8. Stock-based Compensation**

Pursuant to the terms of the Company’s 2014 Equity Incentive Plan (“2014 Plan”), on January 1, 2021 and 2020, the Company automatically added 786,547 and 389,650 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of March 31, 2021, there were 318,097 shares of common stock available for future issuance under the 2014 Plan.

As of March 31, 2021, there were 14,050 shares of common stock available for future issuance under the Company’s 2015 Inducement Award Plan (“2015 Plan”). During the three months ended March 31, 2021 and 2020, there were zero and 17,500 granted options of the Company’s common stock under the 2015 Plan, respectively. On April 30, 2021, the Company’s board of directors amended the 2015 Plan, and the share reserve for the 2015 Plan was increased from 90,000 to 500,000 shares of common stock.

The activity for the Company’s 2009 Stock Option Plan, 2014 Plan, and 2015 Plan, for the three months ended March 31, 2021, is summarized as follows:

	Number of Shares	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (\$000)
Outstanding — December 31, 2020	830,343	\$ 21.52	7.71	\$ 96
Granted	545,450	\$ 7.57		
Forfeited/Cancelled	(4,187)	\$ 8.48		
Outstanding — March 31, 2021	1,371,606	\$ 16.01	8.33	\$ 355
Exercisable — March 31, 2021	500,625	\$ 29.27	6.72	\$ 37
Vested or expected to vest — March 31, 2021	1,371,606	\$ 16.01	8.33	\$ 355

Restricted stock unit (“RSU”) activity under the 2014 Plan and 2015 Plan for the three months ended March 31, 2021, is summarized as follows:

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Non-vested at December 31, 2020	29,087	\$ 9.52
Granted	73,675	\$ 7.55
Vested	(5,788)	\$ 10.68
Non-vested at March 31, 2021	96,974	\$ 7.95

The fair value of RSUs is based on the market price of the Company’s common stock on the date of grant. RSUs generally vest 25% annually over a four-year period from the date of grant. Upon vesting, the RSUs are net share settled to



[Table of Contents](#)

cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period.

*Compensation Cost*

The compensation cost that has been charged against income for stock awards under the 2014 Plan and the 2015 Plan was \$0.4 million for both the three months ended March 31, 2021 and 2020. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was zero for each of the three months ended March 31, 2021 and 2020.

Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands):

	Three Months Ended March 31,	
	2021	2020
Research and development	\$ 126	\$ 136
Selling, general and administrative	272	274
Total	<u>\$ 398</u>	<u>\$ 410</u>

## 9. Fair Value Measurements

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.

### *Assets and Liabilities Measured at Fair Value on a Recurring Basis*

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of March 31, 2021 and December 31, 2020 for financial instruments measured at fair value on a recurring basis (in thousands):

	Balance	Fair Value Hierarchy Classification		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>March 31, 2021</b>				
Cash	\$ 236	\$ 236	—	—
Restricted cash	273	273	—	—
Money market funds	91,775	91,775	—	—
<b>Total assets</b>	<b>\$ 92,284</b>	<b>\$ 92,284</b>	<b>—</b>	<b>—</b>
Warrant liabilities	\$ 49,860	—	—	\$ 49,860
Derivative liability	2,618	—	—	2,618
<b>Total liabilities</b>	<b>\$ 52,478</b>	<b>—</b>	<b>—</b>	<b>\$ 52,478</b>
<b>December 31, 2020</b>				
Cash	\$ 117	\$ 117	—	—
Restricted cash	273	273	—	—
Money market funds	92,924	92,924	—	—
<b>Total assets</b>	<b>\$ 93,314</b>	<b>\$ 93,314</b>	<b>—</b>	<b>—</b>
Warrant liabilities	\$ 51,156	—	—	\$ 51,156
Derivative liabilities	5,954	—	—	5,954
<b>Total liabilities</b>	<b>\$ 57,110</b>	<b>—</b>	<b>—</b>	<b>\$ 57,110</b>

The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.

Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical volatility of the Company, using its closing common stock prices, is utilized to reflect future volatility over the expected term of the warrants. At March 31, 2021, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 69.6% to 82.5% and 77.6%, respectively. Additionally, the expected term associated with the December 2019 Public Offering warrants is an unobservable unit given that the expiration of the warrants is the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023. The Company utilized a probability assessment to estimate the likelihood of occurrence for the two potential expiration dates and allocated the probability of occurrence percentage to the fair values calculated based on the two potential expected



terms. The weighted average expected term is 0.9 years as of March 31, 2021 for the December 2019 Public Offering warrants with a range of 0.66 to 2.2 years.

## [Table of Contents](#)

The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company's stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of March 31, 2021, these inputs were 61.5%, 1,451 basis points, and 15.1%, respectively. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The discount for lack of marketability, 7.1% as of March 31, 2021, is applied to the value of the March 2019 Notes. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis.

A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

	<b>Warrant Liabilities</b>
Balance – December 31, 2020	\$ 51,156
Gain adjustment to fair value	(1,296)
Balance – March 31, 2021	<u>\$ 49,860</u>

  

	<b>Derivative Liabilities</b>
Balance – December 31, 2020	\$ 5,954
Adjustment for conversion of April 2020 Notes	(3,426)
Gain adjustment to fair value	90
Balance – March 31, 2021	<u>\$ 2,618</u>

## **10. License Agreement Revenue**

In February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the "Agreement") with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, "Hansoh"), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the "Territory"). The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory. Under the terms of the Agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in the Territory.

Pursuant to the terms of the Agreement, the Company received as consideration for the licenses a nonrefundable upfront cash payment of \$10.0 million and is entitled to an additional payment that was payable upon the transfer of certain data related to the manufacturing license. In addition, the Company will also be eligible to receive up to \$110.0 million in potential development and commercial milestones. In addition, during the term of the licensing agreement, the Company is entitled to low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances. The Company is also eligible to receive a milestone related to the successful completion of a manufacturing batch by Hansoh.

The Company evaluated the Agreement and concluded that it was subject to ASC 606 as the Company viewed the Agreement as a contract with a customer as the activities were central to its business operations. As such, the Company assessed the terms of the Agreement and identified one performance obligation for the licenses to research, develop, manufacture and commercialize ibrexafungerp in the Territory, including the underlying know-how related to such licenses. The Company also evaluated options for additional goods and services included in the Agreement related to (1) optional technical assistance related to development, regulatory or manufacturing activities and (2) an optional supply agreement for ibrexafungerp. Such options for additional goods or services were not considered to contain material rights as pricing approximated standalone selling prices and therefore the Company concluded that such options did not represent performance obligations and will be accounted for as separate transactions if and when they occur in the future.

The Company determined that the transaction price of \$12.1 million included the fixed upfront cash payment of \$10.0 million, an additional amount that was payable upon the transfer of certain data related to the manufacturing license, and \$1.1 million related to withholding tax obligations that Hansoh remitted on behalf of the Company. The remaining amounts related to the successful completion of a manufacturing batch by Hansoh and potential development milestones represent variable consideration and were

constrained as it was concluded that it was not probable that a significant reversal in cumulative revenue recognized will not occur and therefore not included in the transaction price as of March 31, 2021. Potential

commercial milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were determined to relate to the license. The transaction price was recorded in revenue during the quarter March 31, 2021 at a point in time upon control of the license transferring to Hansoh. The Company will reevaluate the transaction price at the end of each reporting period as uncertain events or resolved, or as other changes in circumstances occur.

Additionally, pursuant to the Agreement, both the Company and Hansoh agreed to make reasonable efforts to account for applicable taxes, fees, duties, levies, or similar amounts imposed on net income, franchise taxes and profits arising directly or indirectly from the activities of the Agreement. To the extent Hansoh is required by applicable laws to withhold or deduct any tax on any payment to the Company, Hansoh agreed to make certain increases on payments to the Company to ensure that the Company receives a sum equal to what the Company would have received had there been no deduction or withholding. As a result, the Company has recorded revenue and tax withholding expense primarily associated with the up-front payment received by the Company on a gross basis. For the three months ended March 31, 2021, the Company recognized \$1.1 million in revenue and \$1.1 million in income tax expense to account for the tax withholding expense primarily on the \$10.0 million up-front that the Company is responsible to remit under applicable tax law.

In July 2016, the Company entered into an asset purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the asset purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized. For the three months ended March 31, 2021, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained as of March 31, 2021. Additionally, in October 2014 the Company entered into a license agreement with Waterstone Pharmaceutical HK Limited (or "Waterstone") and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds. The Company is entitled to receive potential milestones and royalties from Waterstone; however, there was no revenue recognized by the Company associated with this agreement given the variable consideration was fully constrained as of March 31, 2021.

## **11. Subsequent Events**

In May 2021, the Company entered into an agreement with a third party to sell a portion of its unused New Jersey net operating losses (NOLs) for approximately \$4.2 million.

In May 2021, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Hercules Capital, Inc. ("Hercules"), as administrative agent and collateral agent (in such capacity, the "Agent") and a lender, and Silicon Valley Bank, as a lender ("SVB," and collectively with Hercules, the "Lenders") for an aggregate principal amount of \$60.0 million (the "Term Loan"). Pursuant to the Loan Agreement, the Term Loan is available to the Company in four tranches, subject to certain terms and conditions.

Under the terms of the Loan Agreement, the Company received an initial tranche of \$20.0 million from the Lenders on the Closing Date. The second tranche of the Term Loan, consisting of up to an additional \$10.0 million, will become available to the Company upon receipt of approval from the Food and Drug Administration of ibrexafungerp for the treatment of vaginal yeast infections (the "First Performance Milestone") and will be available, if specified conditions are met, during the period beginning on June 1, 2021 through June 30, 2022. The third tranche of the Term Loan, consisting of an additional \$5.0 million, will be available to the Company upon (a) the First Performance Milestone and (b) the achievement of the primary endpoint from the Phase 3 study of ibrexafungerp in patients with recurrent vulvovaginal candidiasis, and will be available, if specified conditions are met, from September 30, 2021 through June 30, 2022. The fourth tranche of the Term Loan, consisting of up to an additional \$25.0 million, will be available to the Company from January 1, 2022 through December 31, 2023 in \$5.0 million increments, subject to certain terms and conditions, including in maintaining a ratio of total outstanding Term Loan principal to net product revenues for ibrexafungerp below a certain specified level for a given draw period.

The Term Loan will mature on March 3, 2025 (the "Maturity Date"); provided that, the Maturity Date shall be automatically extended to May 1, 2025 subject to the occurrence of certain conditions set forth in the Loan Agreement. The Term Loan bears interest at a variable annual rate equal to the greater of (a) 9.05% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 5.80% (the "Interest Rate"). The Company may make payments of interest only through November 1, 2023, which may be extended to May 1, 2024 upon the achievement of the First Performance Milestone prior to November 1, 2023, and which is further extendable in quarterly increments until the Maturity Date, subject to continued compliance with the financial covenant of the Loan Agreement (the "interest-only period"). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date.

The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring the Company to maintain certain levels of trailing three-month net

product revenue solely from the sale of ibrexafungerp commencing on June 30, 2022. The financial covenant will be waived at any time in which the Company maintains unrestricted and unencumbered cash in accounts maintained with SVB equal to at least 50.0% of the total outstanding Term Loan principal amount, subject to certain requirements.

In connection with the entry into the Loan Agreement, the Company issued to each of Hercules and SVB a warrant (collectively, the “Warrants”) to purchase shares of SCYNEXIS’s common stock, par value \$0.001 per share (the “Shares”). The amount of shares that may be purchased for the Warrants, collectively between Hercules and SVB, will not exceed 0.04 multiplied by the aggregate amount of the term loan advances, divided by the exercise price of the Warrants.

## **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

*Operating results for the three months ended March 31, 2021, are not necessarily indicative of results that may occur in future interim periods or future fiscal years. Some of the statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management and involve significant elements of subjective judgment and analysis. Words such as “expects,” “will,” “anticipate,” “target,” “goal,” “intend,” “plan,” “seek,” “estimate,” “potential,” “should,” “could,” variations of such words, and similar expressions are intended to identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed under the heading “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2021, and in Part II, Item 1A of this Quarterly Report on Form 10-Q. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this Quarterly Report on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements.*

### **Overview**

SCYNEXIS, Inc. is pioneering innovative medicines to potentially help millions of patients worldwide in need of new options to overcome and prevent difficult-to-treat and drug-resistant infections. We are developing our lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. In December 2020, we announced that we had received the acceptance letter from the U.S. Food and Drug Administration (FDA) for our New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection) with a Prescription Drug User Fee Act (PDUFA) action goal date of June 1, 2021. The FDA has conditionally approved “Brexafemme” as the brand name for oral ibrexafungerp for vaginal yeast infections. We are also continuing late-stage clinical development for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.

Ibrexafungerp, the first representative of a novel class of antifungal agents called triterpenoids and designated by the suffix “-fungerp”, is a structurally distinct glucan synthase inhibitor and has shown *in vitro* and *in vivo* activity against a broad range of human fungal pathogens such as *Candida* and *Aspergillus* species, including multidrug-resistant strains, as well as *Pneumocystis*, *Coccidioides*, *Histoplasma* and *Blastomyces* species. *Candida* and *Aspergillus* species are the fungi responsible for approximately 85% of all invasive fungal infections in the United States (U.S.) and Europe. To date, we have characterized the antifungal activity, pharmacokinetics, and safety profile of the oral and IV formulations of ibrexafungerp in multiple *in vitro*, *in vivo*, and clinical studies. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to ibrexafungerp for the indications of VVC (including the treatment of VVC episodes and the prevention of recurrent VVC), invasive candidiasis (IC) (including candidemia), and invasive aspergillosis (IA), and has granted Orphan Drug designations for the IC and IA indications. These designations may provide us with additional market exclusivity and expedited regulatory paths.

### **Ibrexafungerp Update**

We previously announced that the FDA has accepted for filing our NDA for ibrexafungerp for the treatment of VVC, also known as vaginal yeast infections. The FDA has granted this application Priority Review, a designation which is granted to applications for potential drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment of serious conditions when compared to standard applications. Under the PDUFA, the FDA has set a target action date of June 1, 2021. Additionally, the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application. The NDA is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated statistically superior efficacy and a favorable tolerability profile in women with VVC. We are currently in discussions with the FDA to finalize its recommended wording for different sections of the Prescribing Information to provide adequate information about efficacy, safety and potential contraindications, warnings and precautions of ibrexafungerp for the treatment of VVC.

Enrollment is complete in the CANDLE study, a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of oral ibrexafungerp for the prevention of recurrent VVC, for which there is no approved therapy in the U.S. We expect the last-patient/last-visit for the CANDLE study by the end of 2021. We anticipate

both top-line data and a potential supplemental NDA submission for the prevention of recurrent VVC in the first half of 2022, resulting in a potential approval in late 2022.

Enrollment is ongoing in our refractory invasive fungal infections (rIFI) program, which comprises two open-label Phase 3 studies (FURI and CARES) designed to support a potential future NDA submission through the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), as well as our Phase 2 study (SCYNERGIA study) of oral ibrexafungerp in combination with voriconazole (SoC) in patients with IA. Similar to interim analyses of data previously reported, we intend to analyze the data of patients that have completed the treatment course in our FURI and CARES studies and announce these findings when complete.

Enrollment is ongoing in our Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of the IV liposomal formulation of ibrexafungerp in healthy subjects. The study is being conducted in South Africa and dosing started in March 2021.

### **Impact of COVID-19 Pandemic on Our Business**

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. The full extent of the future impacts of COVID-19 on our operations is uncertain. We have continued to monitor the COVID-19 situation closely and have not identified any significant adverse effects on our business.

### **Corporate Update**

In May 2021, we entered into a Loan and Security Agreement (the Loan Agreement) with Hercules Capital, Inc. (Hercules), as administrative agent and collateral agent (in such capacity, the Agent) and a lender, and Silicon Valley Bank, as a lender (SVB, and collectively with Hercules, the Lenders) for an aggregate principal amount of \$60.0 million (the Term Loan) and we recently received \$20.0 upon closing of the Loan Agreement. Pursuant to the Loan Agreement, the Term Loan is available to us in four tranches, subject to certain terms and conditions.

In May 2021, we appointed a Chief Commercial Officer, who will play a significant role in the anticipated U.S. launch of and commercialization of Brexafemme, the expected trade name for ibrexafungerp.

In May 2021, we entered into an agreement with a third party to sell a portion of our unused New Jersey NOLs for approximately \$4.2 million.

In February 2021, we partnered with Amplity Inc. (Amplity) for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC. Under the terms of the 5-year agreement, we will utilize Amplity's commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services. Amplity is deferring a portion of its direct service costs in the first two years (2021 and 2022), which we will repay over three years starting in 2023. Amplity has the potential to earn a performance-based success fee in the 2023-2025 time frame by exceeding certain revenue targets.

In February 2021, we entered into an Exclusive License and Collaboration Agreement (the Hansoh Agreement) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, Hansoh), pursuant to which Hansoh obtains an exclusive license from us to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the Hansoh Agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China. We received a \$10.0 million upfront payment in the first quarter of 2021 and will also be eligible to receive development and commercial milestones, plus low double-digit royalties on net product sales.

### **Liquidity**

We have operated as a public entity since we completed our initial public offering (IPO) in May 2014. We also completed a follow-on public offering of our common stock in April 2015 and public offerings of our common stock and warrants in June 2016, March 2018, December 2019, and December 2020. As of March 31, 2021, we had received an aggregate of \$253.2 million in net proceeds from the issuance of our common stock and warrants in these six offerings. Our principal source of liquidity is cash and cash equivalents, which totaled \$92.0 million as of March 31, 2021, and availability to issue up to \$19.4 million of our common stock under our common stock purchase agreement with Aspire Capital. We recently received \$20.0 million under our Term Loan and could potentially be eligible to receive up to an additional \$40.0 million, subject to certain terms and conditions.



## [Table of Contents](#)

We have incurred net losses since our inception, including the year ended December 31, 2020, and the three months ended March 31, 2021. As of March 31, 2021, our accumulated deficit was \$331.3 million. We anticipate that we will continue to incur losses for at least the next several years. We expect we will continue to incur significant research and development expense as we continue to execute our research and drug development strategy, but that our research and development expenses will decrease primarily given the completion of the VANISH Phase 3 registration program and the completion of enrollment in the CANDLE Phase 3 study. Consistent with our operating plan, we also expect that we will continue to incur significant selling, general and administrative expenses to support our public reporting company operations, and that our selling, general and administrative expenses will increase to support a potential commercial launch for the VVC indication and our ongoing operations. As a result, we will need additional capital to fund our operations, which we may obtain through one or more of equity offerings, debt financings, other non-dilutive third-party funding (e.g., grants, and New Jersey Technology Business Tax Certificate Transfer (NOL) Program), strategic alliances and licensing or collaboration arrangements. We may offer shares of our common stock pursuant to our shelf registrations, and the common stock purchase agreement with Aspire Capital.

### **Collaborations and Licensing Agreements**

We are party to a number of licensing and collaboration agreements with partners in human health, including: (1) Merck, a pharmaceutical company, under which we exclusively licensed the rights to ibrexafungerp in the field of human health, and agreed to pay Merck milestones upon the occurrence of specified events as well as tiered royalties based on worldwide sales of ibrexafungerp when and if it is approved (in 2014, Merck assigned to us the patents related to ibrexafungerp that it had exclusively licensed to us and, as contemplated by the agreement, we will continue to pay milestones and royalties); (2) Hansoh, a pharmaceutical company, which we exclusively provide a license from us to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan, under which we are entitled to receive development and commercial milestones and royalties (3) R-Pharm, CJSC, or "R-Pharm," a leading supplier of hospital drugs in Russia, granting it exclusive rights in the field of human health to develop and commercialize ibrexafungerp in Russia and several non-core markets, under which we are entitled to receive potential milestones and royalties and reimbursement for certain development costs incurred by us; (4) Waterstone, an international pharmaceutical business, granting Waterstone exclusive worldwide rights to development and commercialization of SCY-635 for the treatment of viral diseases in humans, under which we are entitled to receive potential milestones and royalties; and (5) Cypralis Limited, or "Cypralis," a life sciences company, transferring to it certain cyclophilin inhibitor assets of ours, under which we are eligible to receive milestone payments upon the successful progression of certain Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization.

### **Components of Operating Results**

#### *Revenue*

Revenue primarily consists of a non-refundable upfront payment received under our license agreement with Hansoh.

#### *Research and Development Expense*

Research and development expense consists of expenses incurred while performing research and development activities to discover, develop, or improve potential product candidates we seek to develop. This includes conducting preclinical studies and clinical trials, manufacturing and other development efforts, and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of:

- costs related to executing preclinical and clinical trials, including development milestones, drug formulation, manufacturing and other development;
- salaries and personnel-related costs, including benefits and any stock-based compensation, for personnel in research and development functions;
- fees paid to consultants and other third parties who support our product candidate development and intellectual property protection;
- other costs in seeking regulatory approval of our products; and
- allocated overhead.

Our ibrexafungerp project was the only significant research and development project during the periods presented. We expect to continue to incur significant research and development expense for the foreseeable future as we continue our effort to develop ibrexafungerp, and to potentially develop our other product candidates, subject to the availability of additional funding.



[Table of Contents](#)

The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.

*Selling, General and Administrative Expense*

Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation. This includes personnel in executive, finance, human resources, business development, marketing, and administrative support functions. Other expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for accounting, auditing, tax and legal services, consulting costs for general and administrative purposes, information systems maintenance and marketing efforts.

*Other Expense (Income)*

All of our other expense (income) recognized in the three months ended March 31, 2021 and 2020, consists of amortization of debt issuance costs and discount, interest income, interest expense, other income, the warrant liabilities fair value adjustment, the derivative liabilities fair value adjustment, and the loss recognized for the extinguishment of debt.

*Income Tax Expense*

All of our income tax expense recognized in the three months ended March 31, 2021 consists of tax withholding expense associated with the upfront payment received from Hansoh.

**Results of Operations for the Three Months Ended March 31, 2021 and 2020**

The following table summarizes our results of operations for the three months ended March 31, 2021 and 2020, together with the changes in those items in dollars and percentage (dollars in thousands):

	Three Months Ended March 31,			
	2021	2020	Period-to-Period Change	
Revenue	\$ 12,050	\$ —	\$ 12,050	— %
Operating expenses:				
Research and development	6,948	9,866	(2,918)	(29.6) %
Selling, general and administrative	6,696	2,613	4,083	156.3 %
Total operating expenses	13,644	12,479	1,165	9.3 %
Loss from operations	(1,594)	(12,479)	10,885	(87.2) %
Other expense (income):				
Loss on extinguishment of debt	2,725	—	2,725	— %
Amortization of debt issuance costs and discount	256	278	(22)	(7.9) %
Interest income	(7)	(147)	140	(95.2) %
Interest expense	214	210	4	1.9 %
Other income	—	(350)	350	(100.0) %
Warrant liabilities fair value adjustment	(1,296)	(4,768)	3,472	(72.8) %
Derivative liabilities fair value adjustment	90	(700)	790	(112.9) %
Total other expense (income):	1,982	(5,477)	7,459	(136.2) %
<b>Loss before taxes</b>	<b>(3,576)</b>	<b>(7,002)</b>	<b>3,426</b>	<b>(48.9) %</b>
Income tax expense	1,100	—	1,100	— %
<b>Net loss</b>	<b>\$ (4,676)</b>	<b>\$ (7,002)</b>	<b>\$ 2,326</b>	<b>(33.2) %</b>

*Revenue.* Revenue in the three months ended March 31, 2021, consists primarily of a non-refundable upfront payment received under our license agreement with Hansoh.

*Research and Development.* For the three months ended March 31, 2021, research and development expenses decreased to \$6.9 million from \$9.9 million for the three months ended March 31, 2020. The decrease of \$2.9 million, or 30%, for the three months ended March 31, 2021, was primarily driven by a decrease of \$2.1 million in clinical development expense, a decrease of \$0.9 million in chemistry, manufacturing, and controls (CMC) expense, and a decrease of \$0.5 million in preclinical expense, offset in part by an increase in salary related costs of \$0.3 million and a net increase in other research and development expense of \$0.3 million.

The \$2.9 million decrease in clinical development expense for the three months ended March 31, 2021, was primarily driven by a decrease of \$0.9 million and \$0.7 million in expense associated with two drug-drug interaction clinical studies and the VANISH Phase 3 program, respectively, that were both substantially complete at the beginning of the current quarter. Additionally, we incurred a decrease of \$0.4 million and \$0.3 million in expense associated with the SCYNERGIA study and a Phase 1 study to support the submission of the NDA for the treatment of vaginal yeast infections, respectively. The \$0.9 million decrease in CMC for the three months ended March 31, 2021, was primarily driven by a \$1.2 million expense recognized during the three months ended March 31, 2020 for drug product shipped in the period. The \$0.5 million decrease in preclinical expenses was primarily driven by a \$0.5 million decrease in certain pharmacokinetic and preclinical expenses incurred during the prior comparable quarter. The increase in salary related costs of \$0.3 million was primarily due to the increased employee headcount in comparison to the prior comparable quarter.

*Selling, General & Administrative.* For the three months ended March 31, 2021, selling, general and administrative expenses increased to \$6.7 million from \$2.6 million for the three months ended March 31, 2020. The increase of \$4.1 million, or 156%, for the three months ended March 31, 2021 was primarily driven by a \$1.7 million increase in commercial related expense, an increase of \$1.0 million in business development expense, an increase of \$0.5 million in expense associated with increased information technology costs, and an increase of \$0.3 million in salary related costs.

*Loss on Extinguishment of Debt.* For the three months ended March 31, 2021, we recognized \$2.7 million in loss on extinguishment of debt associated with the January 2021 conversion of our remaining April 2020 convertible notes.

*Amortization of Debt Issuance Costs and Discount.* For both the three months ended March 31, 2021 and 2020, we recognized \$0.3 million in amortization of debt issuance costs and discount. The 2021 and 2020 debt issuance costs and discount for both April 2020 Notes and March 2019 Notes primarily consisted of an allocated portion of advisory fees and other issuance costs.

*Interest Income.* For the three months ended March 31, 2021 and 2020, we recognized \$7,000 and \$0.1 million, respectively, in interest income. The decrease was primarily due to the maturity of all our short-term investments during 2020.

*Interest Expense.* For both the three months ended March 31, 2021 and 2020, we recognized \$0.2 million in interest expense. The interest expense recognized in both periods is primarily associated with the April 2020 and March 2019 convertible notes.

*Other Income.* For the three months ended March 31, 2020, we recognized \$0.4 million in other income associated with certain research and development tax credits.

*Warrant Liabilities Fair Value Adjustment.* For the three months ended March 31, 2021 and 2020, we recognized gains of \$1.3 million and \$4.8 million, respectively, in the fair value adjustment related to the warrant liabilities primarily due to the decrease in our stock price during the quarter.

*Derivative Liabilities Fair Value Adjustment.* For the three months ended March 31, 2021 and 2020, we recognized a loss of \$0.1 million and a gain of \$0.7 million, respectively, in the fair value adjustment related to the derivative liabilities primarily due to the increase and decrease, respectively, in our stock price during the quarter.

*Income Tax Expense.* For the three months ended March 31, 2021, we recognized \$1.1 million of tax withholding expense primarily associated with the upfront payment received from Hansoh.

## **Liquidity and Capital Resources**

### *Sources of Liquidity*

Through March 31, 2021, we have primarily funded our operations from net proceeds from debt and equity issuances and through revenue from development services. As of March 31, 2021, we had cash and cash equivalents of \$92.0 million, compared to cash and cash equivalents of \$93.0 million as of December 31, 2020. The decrease in our cash and cash equivalents was primarily due to our increase in selling, general and administrative expenses to support a potential commercial launch of ibrexafungerp for the treatment of vaginal yeast infections and the continued development costs associated with ibrexafungerp, offset in part by a \$10.0 million cash receipt from Hansoh. We have incurred annual net losses since our inception, and we incurred a net loss during the three months ended March 31, 2021. As of March 31, 2021, our accumulated deficit was \$331.3 million.

We expect that we will continue to incur losses for at least the foreseeable future. Consistent with our operating plan, we expect our research and development expenses to decrease primarily given the completion of the VANISH Phase 3 registration program and the completion of enrollment in our CANDLE study and we expect our selling, general and administrative expenses to increase to support a potential commercial launch for the treatment of VVC and our ongoing operations. As a result, we may need additional capital to fund our operations, which we may obtain through one or more of

## [Table of Contents](#)

equity offerings, debt financings, or other non-dilutive third-party funding (e.g., grants, and New Jersey Technology Business Tax Certificate Transfer (NOL) Program), strategic alliances and licensing or collaboration arrangements. We may offer shares of our common stock pursuant to our shelf registrations, and the common stock purchase agreement entered into on April 10, 2020 with Aspire Capital.

### *Cash Flows*

The following table sets forth the significant sources and uses of cash for the three months ended March 31, 2021 and 2020 (in thousands):

	Three Months Ended March 31,	
	2021	2020
Cash, cash equivalents, and restricted cash, January 1	\$ 93,314	\$ 42,193
Net cash used in operating activities	(759)	(14,057)
Net cash used in investing activities	(200)	(7,762)
Net cash (used in) provided by financing activities	(71)	152
Net decrease in cash, cash equivalents, and restricted cash	(1,030)	(21,667)
Cash, cash equivalents, and restricted cash, March 31	\$ 92,284	\$ 20,526

### *Operating Activities*

The \$13.3 million decrease in net cash used in operating activities for the three months ended March 31, 2021, as compared to the three months ended March 31, 2020, was primarily due to the cash receipt of \$10.0 million from Hansoh during the current quarter which offset our increase in selling, general and administrative expenses to support a potential commercial launch of ibrexafungerp for the treatment of vaginal yeast infections and the continued development costs associated with ibrexafungerp. Consistent with our operating plan, we expect that our research and development expenses will decrease primarily given the completion of the VANISH Phase 3 registration program and the completion of enrollment in the CANDLE Phase 3 study and we expect our selling, general and administrative expenses to increase to support a potential commercial launch for the treatment of vaginal yeast infections and our ongoing operations.

Net cash used in operating activities of \$0.8 million for the three months ended March 31, 2021, primarily consisted of the \$4.7 million net loss adjusted for non-cash charges that included the gain on change in fair value of the warrant liabilities of \$1.3 million, the loss on change in fair value of the derivative liabilities of \$0.1 million, stock-based compensation expense of \$0.4 million, amortization of debt issuance costs and discount of \$0.3 million, and the loss on extinguishment of debt of \$2.7 million, plus a net favorable change in operating assets and liabilities of \$1.7 million. The net favorable change in operating assets and liabilities was primarily due to a decrease in accounts payable, accrued expenses, and other of \$0.1 million and offset in part by a decrease in prepaid expenses, deferred costs, and other of \$1.7 million. The \$0.1 million decrease in accounts payable, accrued expenses, and other was primarily due to the increase in accounts payable of \$1.9 million as of March 31, 2021, offset in part by the decrease of \$1.8 million in accrued employee bonus compensation as a result of the payment of the 2020 related employee bonus compensation in 2021 and a \$0.2 million decrease in accrued research and development expenses. The decrease in prepaid expense, deferred cost, and other of \$1.7 million was primarily due to the collection of a \$2.9 million receivable in February 2021 offset by a \$1.0 million other receivable recognized for the three months ended March 31, 2021.

Net cash used in operating activities of \$14.1 million for the three months ended March 31, 2020, primarily consisted of the \$7.0 million net loss adjusted for non-cash charges that included the gain on change in fair value of the warrant liabilities of \$4.8 million, the gain on change in fair value of the derivative liability of \$0.7 million, and stock-based compensation expense of \$0.4 million, plus a net unfavorable change in operating assets and liabilities of \$2.3 million. The net unfavorable change in operating assets and liabilities was primarily due to a decrease in accounts payable, accrued expenses, and other of \$4.1 million and offset in part by a decrease in prepaid expenses, deferred costs, and other of \$1.7 million. The \$4.1 million decrease in accounts payable, accrued expenses, and other was primarily due to the decrease of \$1.4 million in accrued employee bonus compensation as a result of the payment of the 2019 related employee bonus compensation during the three months ended March 31, 2020 and the decrease in accounts payable of \$2.0 million as of March 31, 2020. The decrease in prepaid expense, deferred cost, and other of \$1.7 million was primarily due to a \$1.2 million decrease in prepaid research and development costs associated with drug product shipped during the period.

### *Investing Activities*

Net cash used in investing activities of \$0.2 million for the three months ended March 31, 2021 consisted solely of purchases of intangible assets. Net cash used in investing activities of \$7.8 million for the three months ended March 31, 2020 consisted of purchases and maturities of short-term investments of \$14.2 million and \$6.5 million, respectively.



## [Table of Contents](#)

### *Financing Activities*

Net cash used in financing activities of \$0.1 million for the three months ended March 31, 2021, consisted primarily of \$0.1 million in payments of offering costs and underwriting discounts and commissions associated with our December 2020 public offering.

Net cash provided by financing activities of \$0.2 million for the three months ended March 31, 2020, consisted primarily of gross proceeds from common stock issued under our at-the-market facility of \$0.2 million.

### *Future Funding Requirements*

As disclosed in Note 1 to our unaudited condensed consolidated financial statements, to date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize ibrexafungerp. In addition, we expect to incur significant expenses in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, product candidates. We anticipate that we will need substantial additional funding in connection with our continuing future operations.

Based upon our existing operating plan, we believe that our existing cash and cash equivalents, the sale of a portion of our New Jersey NOLs, and the anticipated sales of Brexafemme will enable us to fund our operating requirements into 2023. These funds will also be sufficient to enable us to commercially launch Brexafemme for the treatment of vaginal yeast infections, if approved, and complete the development activities for the CANDLE study. However, we are continually evaluating our operating plan and assessing the optimal cash utilization for our ibrexafungerp development strategy. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenses necessary to complete the development of product candidates.

Our future capital requirements will depend on many factors, including:

- the progress, and costs, of the clinical development of ibrexafungerp;
- the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;
- the ability of product candidates to progress through clinical development successfully;
- our need to expand our research and development activities;
- the costs associated with securing, establishing and maintaining commercialization and manufacturing capabilities;
- our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
- our need and ability to hire additional management and scientific and medical personnel;
- our need to implement additional, as well as to enhance existing, internal systems and infrastructure, including financial and reporting processes and systems and the associated compliance costs; and
- the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future.

Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of net proceeds from equity offerings, debt financings or other non-dilutive third-party funding (e.g., grants, and New Jersey Technology Business Tax Certificate Transfer (NOL) Program), strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities as we did in April 2015, June 2016, March 2018, December 2019, and December 2020, as well as through our common stock purchase agreement with Aspire Capital, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through sales of assets, other third-party funding, strategic alliances and licensing or

collaboration arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.



## **Off-Balance Sheet Arrangements**

During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.

## **Critical Accounting Policies and Significant Judgments and Estimates**

Our management's discussion and analysis of our financial condition and results of operations is based on our interim condensed consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, as well as the reported revenues and expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies, significant judgments, and estimates are described within Note 2 to our unaudited interim condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q as well as Note 2 and Item 7 to our Annual Report on Form 10-K for the year ended December 31, 2020.

## **Item 3. Quantitative and Qualitative Disclosure about Market Risk.**

This item is not applicable to smaller reporting companies.

## **Item 4. Controls and Procedures.**

### *Management's Evaluation of our Disclosure Controls and Procedures*

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

As of March 31, 2021, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of March 31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.

### *Changes in Internal Control Over Financial Reporting*

During the quarter ended March 31, 2021, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### Item 1A. Risk Factors.

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On May 13, 2021, we entered into a Loan Agreement with Hercules, as administrative agent and collateral agent (in such capacity, the Agent) and a lender, and Silicon Valley Bank, as a lender (SVB, and collectively with Hercules in such capacity, the Lenders) for an aggregate principal amount of up to \$60.0 million.

In connection with the entry into the Loan Agreement, we issued to each of Hercules and SVB a warrant (collectively, the Warrants) to purchase shares of our common stock (the Shares). The number of Shares that may be purchased equals: for the Warrant issued to Hercules, 0.02666 multiplied by the aggregate amount of term loan advances, divided by the exercise price of the Warrant; and for the Warrant issued to SVB, 0.01333 multiplied by the aggregate amount of term loan advances, divided by the exercise price of the Warrant. Accordingly, the number of Shares for which each Warrant is exercisable will increase as the term loan is funded. The Warrants will be exercisable for a period of seven years from the date of issuance at a per-share exercise price equal to \$7.04, subject to certain adjustments as specified in the Warrant.

The issuance of the Warrants by us to the Lenders was made in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, as they were issued to two accredited investors.

### Item 6. Exhibits.

Exhibit Number	Description of Document
3.1	<a href="#">Amended and Restated Certificate of Incorporation (Filed with the SEC as Exhibit 3.1 to our current report on Form 8-K, filed with the SEC on May 12, 2014, SEC File No. 001-36365, and incorporated by reference here).</a>
3.2	<a href="#">Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.2 to our Form 10-Q, filed with the SEC on August 7, 2019, SEC File No. 001-36365, and incorporated by reference here).</a>
3.3	<a href="#">Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.1 to our Form 8-K, filed with the SEC on July 16, 2020, SEC File No. 001-36365, and incorporated by reference here).</a>
3.4	<a href="#">Amended and Restated By-Laws (Filed with the SEC as Exhibit 3.4 to our Registration Statement on Form S-1, filed with the SEC on February 27, 2014, SEC File No. 333-194192, and incorporated by reference here).</a>
4.1	Reference is made to Exhibits 3.1 through 3.3.
10.1	<a href="#">Exclusive License and Collaboration Agreement, made as of February 11, 2021, by and between SCYNEXIS, Inc., Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Limited</a>
10.2	<a href="#">Master Services Agreement, effective as of February 4, 2021, by and between SCYNEXIS, Inc. and Amplify, Inc.</a>
31.1	<a href="#">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15(d)-14(a) of the Exchange Act.</a>
31.2	<a href="#">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.</a>
32.1	<a href="#">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 13a-14(b) or 15d-14(b) of the Exchange Act.</a>
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Schema Linkbase Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document



[Table of Contents](#)

101.LAB XBRL Taxonomy Labels Linkbase Document

101.PRE XBRL Taxonomy Presentation Linkbase Document

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SCYNEXIS, INC.

By: /s/ Marco Taglietti, M.D.  
Marco Taglietti, M.D.  
Chief Executive Officer  
(Principal Executive Officer)

Date: May 16, 2021

By: /s/ Eric Francois  
Eric Francois  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

Date: May 16, 2021

[\*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) is the type of information that SCYNEXIS, Inc. treats as private or confidential.

## EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT

This **EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT** (this “**Agreement**”) is made as of February 11, 2021 (the “**Effective Date**”), by and between **SCYNEXIS, INC.**, a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302, USA (“**Scynexis**”), and **Hansoh (Shanghai) Health Technology Co., Ltd.**, a corporation organized and existing under the laws of the People’s Republic of China having a place of business at Room 102, Block 1 No. 298 Xiangke Road, China (Shanghai) Pilot Free Trade Zone, China (“**Hansoh Healthtech**”) and **Jiangsu Hansoh Pharmaceutical Group Company Limited**, a corporation organized and existing under the laws of the People’s Republic of China having a place of business at No. 9 Dongjin Road, Huaguoshan Avenue, Lianyungang, Jiangsu, China (“**Jiangsu Hansoh**” and together with Hansoh Healthtech, “**Hansoh**”). Scynexis and Hansoh are referred to in this Agreement individually as a “**Party**” and collectively as the “**Parties.**”

### RECITALS

**WHEREAS**, Scynexis is a biopharmaceutical company focused on the research and development of novel therapies for difficult-to-treat and often life-threatening infections, and is developing ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor, for the treatment of fungal infections;

**WHEREAS**, Hansoh is a pharmaceutical company having experience in the development and commercialization of pharmaceutical products in the Greater China region; and

**WHEREAS**, Hansoh wishes to obtain an exclusive license from Scynexis to develop and commercialize, and a non-exclusive license to manufacture, ibrexafungerp and Product in the Greater China region, and Scynexis is willing to grant such a license to Hansoh, all in accordance with the terms and conditions set forth herein.

### AGREEMENT

**NOW, THEREFORE**, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

### ARTICLE 1 DEFINITIONS

Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized shall have the meanings set forth below:

**1.1** “**Active Ingredient**” means any clinically active material that provides pharmacological activity in a pharmaceutical product (excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants or controlled release technologies).

**1.2** “**Affiliate**” means, with respect to a Party, any person or entity that directly or indirectly controls, is controlled by or is under common control with such Party. As used in this definition, “control” (and, with correlative meanings, the terms “controlled by” and “under common control with”) means, in the case of a corporation, the ownership of more than fifty percent (50%) of the outstanding voting securities thereof or, in the case of any other type of entity, an interest that results in the ability to direct or cause the direction of the management and policies of such entity or the power to appoint more than fifty percent (50%) of the members of the governing body of such entity.

**1.3** “**Applicable Laws**” means all statutes, ordinances, regulations, rules or orders of any kind whatsoever of any Governmental Authority that may be in effect from time to time and applicable to the activities contemplated by this Agreement.

**1.4** “**Arising Product IP**” means any data, results, know-how, improvement, inventions, process, method, composition of matter, article of manufacture, discovery or finding, patentable or otherwise, that is (a) invented or generated as a result of a Party exercising its rights or carrying out its obligations under this Agreement, whether directly or through its Affiliates, sublicensees, agents or contractors, and (b) related to the Compound or Product or the composition of matter, formulation, method of make or use thereof, including all rights, title and interest in and to the intellectual property rights therein.

**1.5** “**Business Day**” means a day other than Saturday, Sunday or any day on which banks located in New York City, U.S. or Jiangsu, China are authorized or obligated to close. Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified.

**1.6** “**Calendar Quarter**” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31.

**1.7** “**Calendar Year**” means each twelve (12) month period commencing on January 1 and ending on December 31.

**1.8** “**cGMP**” means all applicable current Good Manufacturing Practices, including, as applicable, the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, European Directive 2003/94/EC and Eudralex 4, the principles detailed in the ICH Q7 guidelines, and the equivalent Applicable Laws in the relevant country or region, each as may be amended and applicable from time to time.

**1.9** “**Change of Control**” means, with respect to a Party, (a) a merger, reorganization, consolidation or other transaction involving such Party and any entity that is not an Affiliate of such Party as of the Effective Date, which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or other transaction, or (b) any entity that is not an Affiliate of such Party as of the Effective Date becoming

the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party or otherwise acquiring the power (whether through ownership interest, contractual right or otherwise) to direct or cause the direction of the management or policies of such Party.

**1.10** “**Clinical Trial**” means any clinical testing of the Product in human subjects.

**1.11** “**Commercialization**” or “**Commercialize**” means all activities directed to marketing, distribution, detailing or selling of pharmaceutical products (including importing and exporting activities in connection therewith).

**1.12** “**Commercially Reasonable Efforts**” means (a) where applied to carrying out specific tasks and obligations of a Party under this Agreement, expending (on its own and/or acting through any of its Affiliates, sublicensees or subcontractors) reasonable, diligent, good faith efforts and resources to accomplish such task or obligation as a similarly situated company would normally use to accomplish a similar task or obligation under similar circumstances; and (b) where applied to the Development and/or Commercialization of the Product under this Agreement, the use of reasonable, diligent, good faith efforts and resources, in an active and ongoing program, as normally used by a similarly situated company for a priority product discovered or identified internally, which product is at a similar stage of development or life cycle and is of similar market potential, taking into account relevant factors including measures of patent coverage, relative safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of such product, the regulatory structure involved, and other relevant factors. Commercially Reasonable Efforts will be determined on a Region-by-Region basis for a particular Product, and it is anticipated that the level of effort will be different for different Region, and will change over time, reflecting changes in the status of the Product and the Region(s) involved.

**1.13** “**Compound**” means Scynexis’ novel glucan synthase inhibitor known as ibrexafungerp (formerly SCY-078), having the chemical structure set forth on **Exhibit A**, and any existing or future metabolites (to the extent pharmaceutically active against glucan synthase), salts, esters, free acid forms, free base forms, crystalline forms including co-crystalline forms, amorphous forms, pro-drugs forms, racemates, polymorphs, chelates, tautomers, solvates or optical isomers thereof.

**1.14** “**Confidential Information**” of a Party means all Know-How, unpublished patent applications and other proprietary information and data of a financial, commercial, business, scientific or technical nature of such Party that is: (a) disclosed by or on behalf of such Party or any of its Affiliates or otherwise made available to the other Party or any of its Affiliates, whether made available orally, in writing or in electronic form; or (b) learned by the other Party pursuant to this Agreement; and in each case (a) or (b) is marked as “Confidential”, “Proprietary” or with similar designation at the time of disclosure or by its nature can reasonably be expected to be considered Confidential Information by the recipient. Subject to the exceptions set forth in Article 10, the terms of this Agreement are the Confidential Information of both Parties.

**1.15** “**Control**” or “**Controlled**” means, with respect to any Know-How, Patents or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise) to grant to the other Party a license, sublicense, access or other right (as



applicable) under such Know-How, Patents, or other intellectual property rights, on the terms and conditions set forth herein, in each case without breaching the terms of any agreement with a Third Party.

**1.16** “**Development**” or “**Develop**” means all development activities to obtain and maintain Regulatory Approval for the Product, including all pre-clinical studies and Clinical Trials of the Product, distribution of Product for use in Clinical Trials (including placebos and comparators), statistical analyses, the preparation of regulatory filings and all regulatory affairs related to any of the foregoing.

**1.17** “**Dollars**” or “**\$**” means U.S. dollars, the lawful currency of the U.S.

**1.18** “**FDA**” means the U.S. Food and Drug Administration or its successor.

**1.19** “**Field**” means prophylactic, palliative, therapeutic or diagnostic uses for all human diseases and disorders, including acute and recurrent vulvovaginal candidiasis (VVC), invasive fungal infections including but not limited to invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections, and other potential Indications as discussed by both Parties in the JSC.

**1.20** “**First Commercial Sale**” means, with respect to any Product in any Region within the Territory, the first sale of such Product to a Third Party end user or prescriber for distribution, use or consumption in such country or jurisdiction after the Regulatory Approvals have been obtained for such Product in such country or jurisdiction and where the sale results in a Net Sale. For clarity, First Commercial Sale shall not include any sale or transfer of the Product prior to receipt of all Regulatory Approvals, including any pricing or reimbursement approvals. For further clarity, any Product used in (i) promotional or advertising purposes, (ii) preclinical studies, Clinical Trials (including post-marketing studies) or other research or scientific testing purposes, (iii) “treatment IND sales,” (iv) as free samples or on a “named patient sales”, “compassionate use sales” or otherwise at or below cost or with a nominal mark-up on the full burdened manufacturing cost of the Product, in each case ((i) through (iv)) shall not constitute a “First Commercial Sale”.

**1.21** “**FTE Rate**” means a rate of [\*] per FTE per year, pro-rated on an hourly basis of [\*] per FTE hour, based on [\*] hours per year for an FTE and is subject to adjustments on an annual basis as of January 1 of each year, beginning in 2022, by factors which reflect any change in the Consumer Price Index for All Urban Consumers (CPI-U) All Items (U.S. city average), as reported by the U.S. Bureau of Labor Statistics, for January 1 of such year when compared to the comparable statistics for January 1 of the preceding year.

**1.22** “**GAAP**” means U.S. generally accepted accounting principles, consistently applied.

**1.23** “**GCP**” means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of Clinical Trials, including, as applicable (a) as set forth in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonized Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other applicable guidelines for good clinical practice for trials on medicinal products in the Territory, (b) the

Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c) 21 C.F.R. Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, and (d) the equivalent Applicable Laws in the Territory, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.

**1.24** “**Generic Product**” means, with respect to a particular Product in a particular jurisdiction, any pharmaceutical product that (a) contains the same qualitative and quantitative composition of Active Ingredient(s) as such Product in the same pharmaceutical form as such Product; (b) is deemed consistent with such Product in quality and efficacy by the applicable Regulatory Authorities in such jurisdiction in the Territory and has obtained regulatory approval in such jurisdiction for an Indication for which such Product obtained Regulatory Approval from the applicable Regulatory Authority in such jurisdiction, on an expedited or abbreviated basis in a manner that relied on or incorporated data submitted by Hansoh, its Affiliates or sublicensees, under the provisions of Section 505(j) of the U.S. Federal Food, Drug, and Cosmetic Act, Articles 10.1, 10.2, 10.3 or 10a of EU Pharma Directive 2001/83, or similar laws in the applicable jurisdiction; (c) is bioequivalent to and may be legally substituted in filling a prescription for such Product, as determined by the applicable Regulatory Authority in such jurisdiction; and (d) is sold in such jurisdiction by a Third Party that is not a sublicensee of Hansoh or its Affiliates and did not purchase such product in a chain of distribution that included Hansoh or any of its Affiliates or sublicensees.

**1.25** “**GLP**” means all applicable Good Laboratory Practice standards, including, as applicable, as set forth in the then current good laboratory practice standards promulgated or endorsed by the U.S. Food and Drug Administration as defined in 21 C.F.R. Part 58, or the equivalent Applicable Laws for the applicable Region in the Territory, each as may be amended and applicable from time to time.

**1.26** “**Governmental Authority**” means any court, commission, authority, department, ministry, official or other instrumentality of, or being vested with public authority under any law of, any country, region, state or local authority or any political subdivision thereof, or any association of countries.

**1.27** “**IFRS**” means the International Financial Reporting Standards, as promulgated by the International Standards Accounting Board.

**1.28** “**IND**” means any investigational new drug application, clinical trial application, clinical trial exemption or similar or equivalent application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.

**1.29** “**Indication**” means a separate and distinct disease, disorder or medical condition that a medical or pharmaceutical product is intended to treat, prevent, cure, or ameliorate. The use of the Product in a separate and/or distinct patient population supported by the results of a Clinical Trial shall be deemed a separate Indication. A labelling change based on the results of a Clinical

Trial that removes a requirement for certain specified prior treatment shall be also deemed a separate Indication For clarity, each of the following shall be deemed a separate Indication: Acute VVC (vulvovaginal candidiasis), Recurrent VVC, invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections.

**1.30** “**Initial Support**” means a total of [\*] of support and assistance provided by Scynexis to Hansoh under this Agreement.

**1.31** “**Know-How**” means any proprietary scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, safety information, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data.

**1.32** “**Knowledge**” means, with respect to a Party, actual knowledge after reasonable investigation by such Party’s board members, officers and relevant senior employees.

**1.33** “**Licensed IP**” means Licensed Know-How and Licensed Patents.

**1.34** “**Licensed Know-How**” means all Know-How Controlled by Scynexis or its Affiliates as of the Effective Date or at any time during the Term that is necessary or useful for the Development, Manufacture or Commercialization of the Compound or Product in the Field in the Territory; provided however that “Licensed Know-How” shall exclude: (a) any Know-How of a Third Party that becomes an Affiliate of Scynexis after the Effective Date as a result of a Change of Control of Scynexis; (b) any Know-How that is in-licensed or acquired by Scynexis or its Affiliates from a Third Party after the Effective Date, unless Hansoh agrees in writing to (i) comply with the applicable terms and conditions of the agreement under which Scynexis or its Affiliates obtain Control of such Know-How; and (ii) pay appropriate amounts, subject to a good faith discussion, that Scynexis or its Affiliates would be obligated to pay in connection with the grant, maintenance or exercise of a sublicense to Hansoh under such Know-How. Scynexis shall include Hansoh in early discussions to the extent any such Know-How is related to the Territory that Scynexis or its Affiliates plans to in-license or acquire from a Third Party and shall consult with Hansoh on strategy, appropriate terms and conditions and appropriate allocation of fees for such Know-How through JSC meetings or other appropriate communications, such as formal email or teleconference. For the avoidance of doubt, “Licensed Know-How” shall include any Know-How Controlled by Scynexis or its Affiliates contained in Arising Product IP.

**1.35** “**Licensed Patents**” means all Patents in the Territory Controlled by Scynexis or its Affiliates as of the Effective Date or at any time during the Term that claim the Compound or Product, including composition of matter, formulation, method of make or use in the Field in the Territory and including any Patents claiming any Arising Product IP; provided however that “Licensed Patents” shall exclude: (a) any Patent of a Third Party that becomes an Affiliate of Scynexis after the Effective Date as a result of a Change of Control of Scynexis; (b) any Patent that is in-licensed or acquired by Scynexis or its Affiliates from a Third Party after the Effective Date, unless Hansoh agrees in writing to (i) comply with the applicable terms and conditions of

the agreement under which Scynexis or its Affiliates obtain Control of such Patent; and (ii) pay appropriate amounts, subject to a good faith discussion, that Scynexis or its Affiliates would be obligated to pay in connection with the grant, maintenance or exercise of a sublicense to Hansoh under such Patent. Scynexis shall include Hansoh in early discussions to the extent any such Patents is related to the Territory that Scynexis or its Affiliates plans to in-license or acquire from a Third Party and shall consult with Hansoh on strategy, appropriate terms and conditions and appropriate allocation of fees for such Patent through JSC meetings or other appropriate communications, such as formal email or teleconference. Licensed Patents includes the Patents set forth in **Exhibit B**.

**1.36** “**Manufacture**” and “**Manufacturing**” mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality control, quality assurance testing and release, post-marketing validation testing, inventory control and management, storing and transporting the Compound and/or Product.

**1.37** “**Manufacturing Cost**” means, with respect to the Compound and Product supplied by Scynexis to Hansoh hereunder:

(a) if the Compound or Product is Manufactured by Scynexis’ Third Party contract manufacturer, (i) Scynexis’ actual Third Party cost of the manufacture and supply of such Compound or Product, plus (ii) the actual, reasonable and documented cost (including internal cost but excluding overhead cost) incurred by Scynexis in connection therewith, including for manufacturing oversight, quality assurance and supply management related thereto; and

(b) if the Compound or Product is Manufactured by Scynexis itself or its Affiliate, the actual, fully-burdened cost for the manufacture and supply of such Compound or Product, including raw materials, direct labor and benefits, and the proportionate share of indirect manufacturing costs. Such fully-burdened cost shall be calculated (i) if applicable, on a theoretical full-capacity basis (with reasonable changeover and maintenance downtime) with the percentage allocable to Manufacturing Cost representing the number of units or runs of the Compound or Product produced or performed (or reserved for the production of the Compound or Product) as a percentage of the total number of units or runs, including those of other products, that could be manufactured in such facility during a Calendar Year; and (ii) in accordance with GAAP, IFRS or equivalent internal standard policies and procedures of the applicable selling Party consistently applied.

**1.38** “**NDA**” means a New Drug Application as defined by the FDA or equivalent application for approval (but not including pricing and reimbursement approvals) to market a pharmaceutical product in the applicable country or jurisdiction.

**1.39** “**Net Sales**” means the gross price billed or invoiced on sales of the Product by Hansoh, its Affiliates, or sublicensees (each a “**Selling Party**”) for sale of the Product to a Third Party in the Territory, less following deductions, to the extent reasonable, customary and allocable to the sale of such Product:

(a) trade or quantity discounts actually granted and deducted solely on account of sales of the Product;

(b) chargebacks or rebates actually paid to individual or group purchasers, including wholesalers, distributors, buying groups, health care insurance carriers or other health care organizations, of the Product that are solely on account of the Product;

(c) adjustments, allowances or credits to customers actually given and not in excess of the selling price of such Product, on account of rejection, outdating, recalls or return of such Product, including for damaged or defective Products;

(d) sales tax, excise tax, value added tax, customs duties, tariffs and other governmental charges (other than income tax) actually incurred, paid or collected and remitted to the relevant tax authority for the sale of the Product;

(e) freight and transportation cost, including insurance, directly related to the delivery or return of the Product to the Third Party; and

(f) actual non-collectable receivables written off in accordance with applicable accounting standard and not to exceed [\*] of gross sales of such Product in any Calendar Year (if such amount is subsequently collected, it shall be included in Net Sales).

Each of the amounts set forth above shall be determined from the books and records of the Selling Party, maintained in accordance with GAAP, IFRS or equivalent internal standard policies and procedures of the applicable Selling Party consistently applied. For the avoidance of doubt, if a single item falls into more than one of the categories set forth in clauses (a)-(f) above, such item may not be deducted more than once.

Unless mandated by the Applicable Laws or by a Governmental Authority to sell at a lower price, no Selling Party shall sell or dispose any Product for less than fair market value or for any substantive consideration other than monetary consideration on arm's length terms, except that Selling Party may provide the Products either for free or at or below cost for the following purposes: (i) promotional or advertising purposes, (ii) pre-clinical studies, Clinical Trials (including post-marketing studies) or other research or scientific testing purposes, (iii) treatment IND sales, or (iv) as free samples or on a named patient use or compassionate use basis, and each case ((i) through (iv)) shall not be included in Net Sales except to the extent that the Selling Party invoices or receives amounts therefor after the First Commercial Sale has occurred.

Sales between Selling Parties shall be disregarded for purposes of calculating Net Sales except if such Selling Party is an end user.

If a Product contains any Active Ingredient(s) that is not a Compound, then the Net Sales of such Product (a "**Combination Product**"), for the purpose of calculating royalties payments owed under this Agreement, shall be the Net Sales attributable to the Compound, which shall be calculated as follows: first, the actual Net Sales of such Combination Product shall be determined using the above provisions, and then such amount shall be multiplied by the fraction  $A/(A+B)$ , where A is the inventory cost (during the relevant royalty paying period in the relevant Region) of the Product that contains only the Compound as its Active Ingredient when sold separately in finished form (the "**Mono Product**"), and B is the total inventory cost (during the relevant royalty paying period in the relevant Region) of other Active Ingredient(s) in the Combination Product when sold separately in finished form. If there is no separate sale of either the Mono Product or

other Active Ingredient(s), then A and B shall be their fair market values as reasonably and mutually determined by the Parties after good faith discussion or, in the absence of agreement, pursuant to arbitration under Section 14.3.

**1.40** “**NMPA**” means National Medicine Products Administration of China (formerly known as the China Food and Drug Administration), or its successor.

**1.41** “**Patents**” means all national, regional and international patents and patent applications, including provisionals, converted provisionals or non-provisionals, divisions or divisionals, continuations, continuations-in-part, additions, re-issues, renewals, extensions, substitutions, re-examinations or restorations, registrations and revalidations, and supplementary protection certificates and equivalents to any of the foregoing.

**1.42** “**Phase 1 Clinical Trial**” means the clinical study of the Product in healthy volunteers or patients to estimate the initial safety and tolerability of the Product and to determine the metabolism and the pharmacokinetic and pharmacodynamic actions of the Product, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness and on the Product’s activity, or any human clinical trial of the Product that would otherwise satisfy the requirements of 21 § CFR 312.21(a) or corresponding foreign regulations in the Region and Territory.

**1.43** “**Phase 2 Clinical Trial**” means a controlled clinical study conducted to evaluate the effectiveness and to explore the therapeutic efficacy of the Product for a particular Indication or Indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the Product and to determine the dose and regimen for Phase 3 Clinical Trials, or any human clinical trial of the Product that would otherwise satisfy the requirements of 21 § CFR 312.21(b) or corresponding foreign regulations in the Region and Territory.

**1.44** “**Phase 3 Clinical Trial**” means a controlled clinical study that is performed after preliminary evidence suggesting effectiveness of the Product has been obtained, and is intended to demonstrate or confirm the therapeutic benefit of the Product and to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the Product and to provide an adequate basis for marketing approval and for the Product’s labeling and summary of Product characteristics, or any human clinical trial of the Product that would otherwise satisfy the requirements of 21 § CFR 312.21(c) or corresponding foreign regulations in the Region and Territory.

**1.45** “**Product**” means any pharmaceutical product that contains a Compound as an Active Ingredient, alone or in combination with other Active Ingredients (other than any Active Ingredient that is proprietary to Scynexis but is not a Compound), in any formulation or dosage form and for any mode of administration.

**1.46** “**Regulatory Approval**” means, with respect to the Product in a country or jurisdiction, all approvals from the Governmental Authorities necessary to market and sell the Product in such country or jurisdiction.

**1.47** “**Regulatory Authority**” means any applicable Government Authority responsible for granting Regulatory Approvals for Product, including the FDA, NMPA, and any corresponding national or regional regulatory authorities.

**1.48** “**Regulatory Exclusivity**” means any exclusive marketing rights or data exclusivity rights (other than Patents) conferred by any Regulatory Authority with respect to a pharmaceutical or medical product, including without limitation orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, pediatric exclusivity, rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997, in EU member states under national implementations of Article 10 of Directive 2001/83/EC, and rights similar thereto in other country or jurisdiction.

**1.49** “**Regulatory Materials**” means any regulatory application, submission, notification, communication, correspondence, registration, approval and other filings made to, received from or otherwise conducted with a Regulatory Authority regarding the Product, including any NDA and Regulatory Approval.

**1.50** “**Territory**” means the Greater China, including mainland China, Hong Kong, Macau, and Taiwan, each of which shall be referred to as a “**Region**.”

**1.51** “**Third Party**” means an entity other than Scynexis, Hansoh and Affiliates of either of them.

**1.52** “**U.S.**” means United States of America, including all possession and territories thereof.

**1.53** “**Valid Claim**” means a claim of a pending patent application or an issued and unexpired Patent (as may be extended through supplementary protection certificate or patent term extension or the like) that has not been revoked, held invalid or unenforceable by a patent office, court or other Governmental Authority of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise.

**1.54** **Additional Definitions.** The following table identifies the location of definitions set forth in various Sections of the Agreement:

<b>Defined Terms</b>	<b>Section</b>
“ <b>Acute VVC</b> ”	8.3(b)(iv)
“ <b>Alliance Manager</b> ”	3.1
“ <b>Bankruptcy Code</b> ”	13.3(a)(ix)
“ <b>Bankruptcy Rejection</b> ”	13.3(a)(ix)
“ <b>Challenged Patent</b> ”	13.2(d)
“ <b>Clinical Trial Participation Plan</b> ”	5.6
“ <b>Commercialization Plan</b> ”	7.3
“ <b>Development Plan</b> ”	4.3

Defined Terms	Section
“Executive Officers”	3.2(f)
“FCPA”	15.6(a)
“FCPA Covered Person”	15.6(a)
“FURI Clinical Trial”	5.6
“Hansoh Indemnitee(s)”	12.2
“ICC”	14.3(a)
“IDL”	5.2(b)(i)
“Indemnified Party”	12.3
“Indemnifying Party”	12.3
“Infringement”	9.3(b)
“Initial Technology Transfer”	4.4
“Joint Steering Committee” or “JSC”	3.2(a)
“Losses”	12.1
“Oral Formulation”	6.2(a)
“Pharmacovigilance Agreement”	5.8
“Prior CDA”	10.6
“Product Marks”	9.7(c)
“Recovery”	8.9(b)
“Recurrent VVC”	8.3(b)(iv)
“Remedial Action”	5.11
“Royalty Term”	8.5(b)
“Scynexis Indemnitee(s)”	12.1
“Scynexis Trademarks”	9.7(a)
“SEC”	10.5(b)
“Term”	13.1
“Third Party Claim”	9.4(a)
“Upstream Agreement”	2.4(a)(i)

## ARTICLE 2 LICENSES

**2.1 License Grant to Hansoh.** Subject to the terms and conditions of this Agreement, Scynexis hereby grants to Hansoh (a) an exclusive (even as to Scynexis but subject to Scynexis’ retained rights as set forth in Section 2.3), royalty-bearing license, with the right to grant sublicenses solely in accordance with Section 2.2, under the Licensed IP to research, Develop, use, promote, sell, offer for sale, import and otherwise Commercialize or exploit the Compound and Product in the Field in the Territory; and (b) a non-exclusive, royalty-free, fully-paid up license, with the right to grant sublicenses solely in accordance with Section 2.2, under the Licensed IP to Manufacture the Compound and Product inside or outside of the Territory solely for Development and Commercialization use in the Field in the Territory; provided however that (i) Hansoh may



not exercise such license granted in 2.1(b) to Manufacture the finished Product outside the Territory without Scynexis' prior written consent (not to be unreasonably withheld, conditioned or delayed), and (ii) Hansoh shall notify and discuss (through the JSC) with Scynexis if Hansoh wishes to exercise its license granted in 2.1(b) to Manufacture starting materials or components of the Product outside of the Territory, and Hansoh may do so in its or its Affiliate's own facility without Scynexis' prior written consent (but doing so in any Third Party's facility shall require Scynexis' prior written consent, such consent not to be unreasonably withheld). Scynexis shall not, and shall ensure that its Affiliates and sublicensees (other than Hansoh) shall not, either directly or indirectly, research, Develop, use, promote, sell, offer for sale, import and otherwise Commercialize or exploit the Compound and Product in the Field in the Territory, except as provided in Section 2.3.

## **2.2 Right to Sublicense.**

**(a)** Subject to the terms and conditions of this Agreement, Hansoh shall have the right to grant sublicenses through one or multiple tiers of the license granted to it under Section 2.1: (i) to its Affiliates, with prior notice to (but not consent from) Scynexis, which sublicense shall continue only for so long as such entity remains an Affiliate of Hansoh; (ii) to Third Party subcontractors without notice to or consent from Scynexis to perform the subcontracted activities; and (iii) to Third Parties the right to Manufacture the finished Product or the right to Commercialize the Product in a Region, which shall require Scynexis' express prior written consent (not to be unreasonably withheld).

**(b)** Each sublicense shall be consistent with the terms and conditions of this Agreement and shall contain at least the following terms and conditions:

**(i)** requiring each such sublicensee to protect and keep confidential any Confidential Information of the Parties in accordance with Article 10 of this Agreement;

**(ii)** requiring each such sublicensee to assign or license to Hansoh all Arising Product IP developed by such sublicensee so that Hansoh can comply with its obligations to license the same to Scynexis in accordance with Section 9.1 (provided that a such sublicense agreement may be subject to customary provisions which provide for the sublicensee to own Know How and Patents that has general application to such sublicensee's general business, so long as such sublicense agreement provides a sublicenseable license to Hansoh under such generally applicable Know-How or Patent that is sufficient to allow Hansoh to comply with its obligation under Section 9.1); and

**(iii)** not expressly imposing any obligation or liability on Scynexis.

**(c)** Hansoh shall provide a redacted copy of each sublicense agreement to Scynexis within [\*] after the grant of a sublicense; provided that, such redaction is consistent with the SEC requirements and guidelines governing redaction of information from material agreements. Upon written request from Scynexis, Hansoh will use Commercially Reasonable Efforts to provide Scynexis a complete and unredacted copy of each requested sublicense agreement, subject to Scynexis, Hansoh and the Sublicensee first entering into a confidentiality agreement if required by the Sublicensee to cover the disclosure of such sublicense prior to

providing Scynexis with such copy. Hansoh shall remain directly responsible for all of its obligations under this Agreement that have been delegated or sublicensed to any sublicensee. Any sublicensee conduct, act, omission or state of affairs that would have constituted a breach of this Agreement shall be imputed to Hansoh and deemed a breach of this Agreement as if such conduct, act, omission or state of affairs had been directly attributable to Hansoh. Hansoh shall not grant a sublicense to any sublicensee that has been debarred or disqualified by a Regulatory Authority.

**2.3 Retained Rights.** Notwithstanding the exclusive license granted to Hansoh under Section 2.1(a), Scynexis hereby expressly retains the right to use the Licensed IP in the Field in the Territory in order to perform its obligations under this Agreement. Each Party retains all rights under Know-How, Patents or other intellectual property Controlled by such Party not expressly granted to the other Party pursuant to this Agreement. For clarity, Scynexis retains the exclusive right to practice, license and otherwise exploit the Licensed IP outside the scope of the license granted to Hansoh under Section 2.1, including the exclusive right to develop, make, have made, use, sell, offer for sale and import the Compound and Product outside the Field in the Territory or for any use outside of the Territory. Scynexis also retains the right to make and have made the Compound and Product in the Territory solely for any use outside the Field and/or solely for Development, Manufacture and/or Commercialization of the Compound and Product outside of the Territory.

#### **2.4 Upstream Licenses.**

(a) Hansoh acknowledges and agrees that:

(i) Scynexis obtained the right to certain Licensed IP from Third Parties under the agreements set forth on **Exhibit C** and previously disclosed to Hansoh for review (each, an “**Upstream Agreement**”);

(ii) the licenses granted to Hansoh in Section 2.1 under such Licensed IP constitutes sublicenses under the Upstream Agreement;

(iii) each such sublicense is subject to the terms and conditions of the applicable Upstream Agreement; and

(iv) certain Licensed IP is non-exclusively licensed to Scynexis under the Upstream Agreement, and therefore the exclusive license granted by Scynexis to Hansoh under such Licensed IP is exclusive only with respect to Scynexis, and is not exclusive with respect to the upstream licensor or its other licensees and sublicensees.

(b) Scynexis shall, and shall ensure that its Affiliates shall, use Commercially Reasonable Efforts to maintain the Upstream Agreements in full force and effect in accordance with their terms and conditions and without any further amendment that would materially and adversely affect the sublicense granted by Scynexis to Hansoh under such Upstream Agreement pursuant to the terms and conditions of this Agreement, except with Hansoh’s prior written consent. In the event that Scynexis, or any of its Affiliates or sublicensees (other than Hansoh) is in breach or default of an Upstream Agreement, and the Third Party licensor or counterparty to such Upstream Agreement terminates or is expected to terminate Scynexis’ rights under such Upstream Agreement, then Scynexis shall promptly notify Hansoh in writing of such expectation

or termination, as applicable, and shall use best efforts to ensure that Hansoh's rights, as a sublicensee under such Upstream Agreement and within the scope of this Agreement, shall continue. This provision will not restrict or eliminate Hansoh's remedies under this Agreement or otherwise available for Hansoh under law or equity. Hansoh agrees to comply with the terms and conditions of the Upstream Agreements to the extent applicable and shall not take or fail to take any action that would cause Scynexis to be in material breach of any Upstream Agreement.

**2.5 No Implied Licenses; Negative Covenant.** Except as expressly set forth herein, no license or other right or interest under any Know-How, Patent or other intellectual property of either Party is granted (by implication or otherwise) to the other Party under this Agreement. Hansoh shall not, and shall not permit any of its Affiliates or sublicensees to, practice any Licensed IP outside the scope of the license granted by Scynexis to Hansoh under Section 2.1 of this Agreement.

**2.6 Territory Restriction.** Hansoh hereby covenants and agrees that it shall not, and shall ensure that its Affiliates and sublicensees shall not, either directly or indirectly, promote, market, distribute, import, sell or have sold any Product, including via the Internet or mail order, to any Third Party or address or Internet Protocol address or the like outside the Territory, or to any Third Party that Hansoh, or any of its Affiliate or sublicensee knows (or is reasonably expected to know) has previously exported or is likely to export the Product outside the Territory. Hansoh shall not engage, and shall ensure that its Affiliates and sublicensees shall not engage, in any advertising or promotional activities relating to any Product directed primarily to customers or other buyers or users located in any country or jurisdiction outside the Territory, or solicit orders from any prospective customer or other buyer or user located in any country or jurisdiction outside the Territory. If Hansoh or its Affiliates or sublicensees receive any order for the Product from a prospective customer or other buyer or user located in a country or jurisdiction outside the Territory, Hansoh shall immediately refer that order to Scynexis and shall not accept any such orders. Hansoh shall not, and shall ensure that its Affiliates and sublicensees shall not, deliver or tender (or cause to be delivered or tendered) any Product outside the Territory.

### ARTICLE 3 GOVERNANCE

**3.1 Alliance Managers.** Within [\*] after the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative having the appropriate qualifications (including a general understanding of pharmaceutical development, manufacture and commercialization issues) to act as its alliance manager under this Agreement (the "**Alliance Manager**"). The Alliance Managers shall serve as the primary contact points between the Parties regarding the activities contemplated by this Agreement. The Alliance Managers shall facilitate the flow of information and otherwise promote communication, coordination and collaboration between the Parties, providing single point communication for seeking consensus both internally within each Party's respective organization, including facilitating review of external corporate communications, and raising cross-Party and/or cross-functional issues in a timely manner. Each Party may replace its Alliance Manager by written notice to the other Party.

### 3.2 Joint Steering Committee.

(a) **Formation.** Within [\*] after the Effective Date, the Parties shall establish a joint steering committee (the “**Joint Steering Committee**” or the “**JSC**”) to oversee the Development, Manufacture and Commercialization of the Compound and Product in the Field in the Territory under this Agreement. Each Party shall appoint two (2) representatives to the JSC, each of whom shall be an officer or employee of the applicable Party having sufficient seniority within such Party to make decisions arising within the scope of the JSC’s responsibilities. Each Party may replace its JSC representatives upon written notice to the other Party. Each Party shall appoint one of its JSC representatives to act as a co-chairperson of the JSC.

(b) **Role.** The JSC shall (i) provide a forum for the discussion of the Parties’ activities under this Agreement; (ii) review and discuss the overall strategy for the Development, Manufacture and Commercialization of the Product in the Field in the Territory, provided that Hansoh will give due consideration to recommendations made by Scynexis; (iii) review and discuss the Development Plan and amendments thereto, including planning and execution of any clinical trials, regulatory filings and/or registration of the Product in the Field in the Territory, provided that Hansoh will give due consideration to recommendations made by Scynexis; provided further that the JSC shall review, discuss and approve (with Scynexis not to unreasonably withhold approval) clinical trial protocols; (iv) review, discuss and approve the Clinical Trial Participation Plan and amendments thereto; (v) review and discuss (but not approve) the Commercialization Plan and amendment thereto; (vi) review and discuss the Manufacturing and supply of the Compound and Product by Scynexis to Hansoh and coordinate Manufacturing technology transfer under Section 6.2; (vii) coordinate safety data reporting and review, discuss and approve any combination study and/or new Indications; (viii) establish joint subcommittees (such as Development subcommittee) as necessary or advisable to further the purpose of this Agreement; and (viii) perform such other functions as expressly set forth in this Agreement or allocated to it by the Parties’ written agreement.

(c) **Limitation of Authority.** The JSC shall only have the powers expressly assigned to it in this Article 3 and elsewhere in this Agreement and shall not have the authority to: (i) modify or amend the terms and conditions of this Agreement; (ii) waive either Party’s compliance with the terms and conditions of this Agreement; or (iii) determine any such issue in a manner that would conflict with the express terms and conditions of this Agreement.

(d) **Meetings.** The JSC shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less frequently than once every Calendar Quarter until the First Commercial Sale of the Product in the Territory. Thereafter, the JSC shall hold meeting no less frequently than once every two (2) Calendar Quarters. Notwithstanding the foregoing, the Parties shall in good faith consider whether the foregoing frequency for JSC meetings is appropriate and may mutually agree to adjust the frequency of JSC meetings. Each Party may call additional ad hoc JSC meetings as the needs arise with reasonable advance notice to the other Party. Meetings of the JSC may be held in person, by audio or video teleconference. The co-chairpersons of the JSC shall jointly prepare the agenda and minutes for each JSC meeting. Each Party shall be responsible for all of its own expenses of participating in the JSC meetings. No action taken at any JSC meeting shall be effective unless at least one representative of each Party is participating in such JSC meeting.

(e) **Non-Member Attendance.** Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend the JSC meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide prior written notice to the other Party. Such Party shall also ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement.

(f) **Decision-Making.** Each Party will act based on its good faith judgement taking into consideration the best mutual interests of the Parties and to avoid taking any actions pursuant to this Agreement that may materially and adversely affect the development and commercialization of the Products in the other Party's territory. All decisions of the JSC shall be made by unanimous vote, with each Party having one vote irrespective of the number of representative(s) in attendance. If after reasonable discussion and good faith consideration of each Party's view on a particular matter before the JSC, the JSC cannot reach a decision as to such matter within [\*] after such matter was brought to the JSC for resolution, such matter shall be referred to the Chief Executive Officer of Scynexis and the Chief Executive Officer of Hansoh or his/her designee (the "**Executive Officers**") for resolution. The Executive Officers shall promptly meet and use good faith efforts to resolve such matter. If the Executive Officers cannot resolve such matter within [\*] after such matter has been referred to them, then Hansoh shall have final decision making authority over matters concerning primarily the Development or Commercialization of the Compound and/or Product in the Field in the Territory, provided, however, that:

(i) Hansoh's decision must be consistent with the terms and conditions of this Agreement, including its obligations to use Commercially Reasonable Efforts to Develop and Commercialize the Compound and Product in the Field in the Territory;

(ii) any decision that may reasonably be expected to adversely affect the Development, Manufacture or Commercialization of the Compound and Product outside the Field and/or outside the Territory must be mutually agreed by the Parties; provided that if Hansoh reasonably believes that such decision is required in order to comply with Applicable Laws in the Territory or otherwise required by the applicable Regulatory Authority, then the Parties will discuss such requirement in good faith with SCYNEXIS not to unreasonably withhold its agreement;

(iii) the protocols (including any amendment thereto) of all Clinical Trials to be conducted by Hansoh, its Affiliates and sublicensees will be discussed in good faith and mutually agreed by both Parties prior to any patient enrollment. If Hansoh reasonably believes that protocol language or amendment is required in order to comply with Applicable Laws in the Territory or otherwise required by the applicable Regulatory Authority, the Parties shall discuss such requirement in good faith. Scynexis shall provide timely response to Hansoh after Hansoh provides the protocol (or any amendments thereto) to Scynexis for review and comment. In the event Hansoh has acted promptly to provide the protocols or amendments to Scynexis for review sufficient in advance of required deadlines, and there is a significant delay without providing any comments from Scynexis, Hansoh may proceed with the protocol (or such amendment thereto) to avoid missing material deadlines (i.e. for regulatory filings). For protocol review and approval process, Scynexis shall designate specific employees or officers from Scynexis to be responsible

for this task to avoid the delay on reviewing and approving protocols due to unavailability of JSC members or delay in scheduling JSC meetings.

For clarity, the JSC shall have no decision making authority with respect to the Development, Manufacture or Commercialization of the Compound and Product outside the Field and/outside the Territory.

**3.3 Discontinuation of JSC.** The activities to be performed by the JSC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. The JSC shall continue to exist until the first to occur of: (a) the Parties mutually agreeing to disband the JSC; or (b) Scynexis providing written notice to Hansoh of its intention to disband and no longer participate in the JSC. Once the Parties mutually agree or Scynexis has provided written notice to disband the JSC, the JSC shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the contact persons for the exchange of information under this Agreement and decisions of the JSC shall be decisions as between the Parties, subject to the same respective decision-making rights and limitations set forth in Section 3.2(f) and other terms and conditions of this Agreement.

## **ARTICLE 4 DEVELOPMENT**

**4.1 General.** Hansoh shall be responsible for and, subject to the terms and conditions of this Agreement (including Section 3.2(f) for matters subject to JSC decision making authority), shall have the sole decision-making authority over the Development of the Compound and Product in the Field in the Territory, including the performance of Clinical Trials of the Product in the Field in the Territory necessary for Regulatory Approval.

**4.2 Development Diligence.** Hansoh shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for at least one Product in the Field in the Territory.

**4.3 Development Plan.** All Development of the Compound and Product by or on behalf of Hansoh under this Agreement shall be conducted pursuant to a written Development plan that summarizes the general timeline and other necessary details of all clinical and regulatory activities to be conducted by or on behalf of Hansoh to obtain Regulatory Approval of the Product in the Field in each Region in the Territory (the “**Development Plan**”). As of the Effective Date, the Parties have agreed to the initial Development Plan, which is attached hereto as **Exhibit D**. From time to time, but at least once every twelve (12) months, Hansoh shall propose updates or amendments (with a level of details no less than the initial Development Plan) to the Development Plan to the JSC for review and discussion, and, if applicable, approval, subject to Sections 3.2(b) and 3.2(f).

**4.4 Development Technology Transfer and Assistance.** As of the Effective Date, the Parties have agreed to the technology transfer plan attached hereto as **Exhibit E**, which summarizes the general timeline and other necessary details for Scynexis to provide and transfer to Hansoh the Licensed Know-How (including pre-clinical, clinical and CMC data but excluding Manufacturing-related Licensed Know-How, the transfer of which is governed by Section 6.2) and copies of Regulatory Materials related to the Compound or Product that is reasonably necessary

or useful for Hansoh to submit and obtain approval of an IND for the Product in the Territory (the “**Initial Technology Transfer**”) and (b) the process for transferring updates to or additional Licensed Know-How and Regulatory Materials related to the Compound or Product during the Term. If Scynexis has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for ibrexafungerp for the treatment of VVC, the Parties agree that a copy of the NDA and related data package (i.e. all pre-clinical, clinical and data) and Regulatory Materials will suffice for such Initial Technology Transfer. Within [\*] after the Effective Date, Scynexis shall transfer such Licensed Know-How and Regulatory Materials to Hansoh in accordance with such technology transfer plan, and Hansoh shall cooperate with Scynexis to facilitate the receipt of such transfer of Licensed Know-How. Scynexis shall provide the Licensed Know-How only in the English language, and Hansoh shall be responsible for the translation of the Licensed Know-How into the Chinese language, if necessary in Hansoh’s sole discretion, at Hansoh’s own cost and expense. Pursuant to such technology transfer plan, Scynexis shall also provide Hansoh with reasonable technical assistance to help Hansoh to understand and use such Licensed Know-How and Regulatory Materials in connection with the Development of the Compound and Product, including reasonable access to Scynexis’ technical personnel involved in the research and Development of the Compound and Product. Hansoh shall reimburse Scynexis for both reasonable out-of-pocket cost and internal cost (calculated by reference to the number of hours of support provided at the hourly FTE Rate) actually incurred by Scynexis to provide such technical assistance, except for the internal cost for Initial Support, which shall be provided at Scynexis’ cost. For clarity, such cost shall be estimated by Scynexis and approved by Hansoh in writing prior to reimbursement (such approval shall not be unreasonably withheld).

**4.5 Development Cost.** Hansoh shall be solely responsible for all the costs and expenses it incurs to Develop the Product in the Field in the Territory.

**4.6 Data Exchange and Use.** In addition to its adverse event and safety data reporting obligations pursuant to Section 5.7, each Party shall promptly provide the other Party with copies of all data and results and all supporting documentation (e.g. protocols, CRFs, analysis plans) generated from its Development of the Compound and Product in the Field inside or outside of the Territory. Hansoh shall have the right to use or reference such data, results and documentation provided by Scynexis in connection with its activities in the Territory, including for the purpose of obtaining and maintaining Regulatory Approval for and Commercializing the Product in the Field in the Territory. Scynexis shall have the right to use the data provided by Hansoh for the purpose of obtaining and maintaining Regulatory Approval for and Commercializing the Product outside Field and/or outside the Territory.

**4.7 Development Records.** Hansoh shall maintain complete, current and accurate records of all Development activities conducted by or on behalf of Hansoh hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Hansoh shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and cGMP). Scynexis shall have the right to review and copy such records maintained by Hansoh at reasonable times and to obtain access to the original to the extent necessary for regulatory and patent purposes or for other legal proceedings. Scynexis acknowledges that such records will be in the Chinese language and that

Hansoh has no obligation to provide such records in the English language. To the extent Scynexis believes translation into English is necessary, Scynexis shall be responsible for such translation at its own cost and expense. Scynexis acknowledges that the language of the original records shall govern.

**4.8 Development Status.** Hansoh shall keep Scynexis reasonably informed as to the progress and results of its and its Affiliates' and sublicensees' Development of the Compound and Product. Without limiting the foregoing, the status, progress and results of the Development of the Compound and Product in the Field in the Territory shall be discussed at regularly scheduled meetings of the JSC (or a joint Development subcommittee established by the JSC). In order to allow a meaningful discussion at the JSC meetings, at least [\*] before each JSC meeting, Hansoh shall provide the JSC with a Development report, which may be in the form of a slide deck or a document prepared by Hansoh for its internal reporting purpose and shall cover subject matter at a level of detail reasonably agreed by the JSC. In addition, Hansoh shall make available to Scynexis such additional information about its Development activities as may be reasonably requested by Scynexis from time to time.

## **ARTICLE 5 REGULATORY**

**5.1 General.** The Development Plan shall set forth the general regulatory strategy for seeking Regulatory Approvals for the Product in the Field in the Territory. Hansoh shall be responsible for and, subject to the terms and condition of this Agreement (including Section 3.2(f)), shall have the sole decision-making authority over all regulatory activities necessary or reasonable useful for obtaining and maintaining Regulatory Approvals for the Product in the Field in the Territory, which regulatory activities shall be performed at Hansoh's own cost and expense and in accordance with the general regulatory strategy set forth in the Development Plan. Through the JSC, Hansoh shall keep Scynexis informed of regulatory developments related to the Product in the Territory, including any decision by any Regulatory Authority in the Territory regarding the Product.

### **5.2 Regulatory Approval Holder.**

(a) To the extent permitted by Applicable Laws and subject to Section 5.2(b) below, Hansoh shall apply for Regulatory Approvals of the Product in the Field in each Region in the Territory in its own name, and Hansoh shall be the named as the holder of such Regulatory Approvals in the Territory.

(b) With respect to the Product in mainland China,

(i) if the Product is supplied by Scynexis and approved by NMPA as an imported drug under an Imported Drug License (the "IDL"), then Scynexis shall initially be the holder of the IDL until Hansoh is permitted by Applicable Laws in mainland China to be the holder of the IDL, at which time Scynexis shall promptly transfer the IDL to Hansoh. While Scynexis is the holder of the IDL, Scynexis shall appoint Hansoh as its exclusive regulatory agent (and Hansoh agrees to act as the regulatory agent of Scynexis) to communicate and handle (at Hansoh's own



cost and expense) regulatory activities relating to the IDL with the NMPA and other Regulatory Authorities in mainland China; and

(ii) if the Product is Manufactured by or on behalf of Hansoh in mainland China after completion of Manufacture technology transfer and approved by NMPA as a domestic product, then Hansoh shall be the holder of such Regulatory Approval.

### 5.3 Regulatory Materials.

(a) Hansoh shall provide Scynexis with drafts of substantive Regulatory Materials relating to the Product a reasonable time (no less than [\*] for initial submission of IND, NDA and similar applications in any event, and no less than [\*] for other substantive Regulatory Materials) prior to submission for review and comment, and shall consider and implement in good faith any comments received from Scynexis. In addition, Hansoh shall provide Scynexis with copies of any substantive Regulatory Materials relating to the Product submitted to or received from any Regulatory Authority in the Territory within a reasonable period of time after submission or receipt, and shall notify Scynexis of substantive communication relating to the Product with any Regulatory Authority in the Territory as soon as practical after such communication, but in each case within [\*] in any event. Scynexis acknowledges that the Regulatory Materials submitted in the Territory are typically in the Chinese language, and, without limiting Hansoh's obligations to provide translation pursuant to Section 5.3(b) below, upon the reasonable request of Scynexis, the Parties may agree to engage a translator to translate certain substantive Regulatory Materials within a reasonable period of time and to mutually agree on the allocation of cost for such translation.

(b) When Scynexis is the holder of the IDL (or other Regulatory Materials, such as IND, related to the Product as an imported drug) and appoints Hansoh as its regulatory agent to interact with NMPA and other Regulatory Authorities pursuant to Section 5.2(b)(i), all relevant and substantial Regulatory Materials and communications with Regulatory Authorities (including meeting requests and minutes, request for information, response, etc.) shall be provided by Hansoh to Scynexis followed promptly by full English translations (except for documents and materials and portions thereof originally provided to Hansoh in English) prepared at Hansoh's own cost and expense. For other Regulatory Materials, Hansoh shall provide an English summary prepared at Hansoh's cost within a reasonable period of time that is reasonably sufficient to allow Scynexis to understand and be able to review and comment on such Regulatory Materials.

**5.4 Regulatory Assistance.** Upon Hansoh's reasonable request, Scynexis shall provide Hansoh with reasonable assistance in connection with Hansoh's regulatory activities for the Product in the Field in the Territory, including the preparation and submission of Regulatory Materials for IND and NDA. Hansoh shall reimburse Scynexis for both reasonable out-of-pocket cost and internal cost (calculated at the FTE Rate) actually incurred by Scynexis to provide such regulatory assistance, except for the internal cost for Initial Support, which shall be provided at Scynexis' cost. For clarity, such cost shall be estimated by Scynexis and approved by Hansoh in writing prior to reimbursement (such approval shall not be unreasonably withheld).

**5.5 Regulatory Meetings.** Hansoh shall provide Scynexis with reasonable advance notice (no less than [\*] in any event) of any meeting or discussion with any Regulatory Authority

in the Territory related to the Product. Hansoh shall lead such meeting or discussion, provided however that at Scynexis' written request, Hansoh shall permit one (1) Scynexis representative to attend and participate in such meeting or discussion as an observer at the cost and expense of Scynexis to the extent allowed by the applicable Regulatory Authority. If Scynexis elects not to attend such meeting or discussion, Hansoh shall promptly provide Scynexis with a written English summary of such meeting or discussion.

**5.6 Participation in Scynexis' Invasive Fungal Infections Trial and Other Trials Conducted by Scynexis.** The Parties recognize that they may benefit from Hansoh's participation in Scynexis' refractory invasive fungal infections study (the "**FURI Clinical Trial**"). As such, Hansoh may participate in the FURI Clinical Trial in accordance with a clinical development plan approved by Scynexis (the "**Clinical Trial Participation Plan**"). As of the Effective Date, the Parties have agreed on the initial Clinical Trial Participation Plan, which is attached hereto as **Exhibit F**. The Parties shall discuss and approve through the JSC any necessary updates to the Clinical Trial Participation Plan in good faith. For other ongoing trials and future global trials for the Product or for other Indications, the Parties shall have good faith discussions on whether Hansoh's participation can benefit both Parties and allow Hansoh to participate if Parties mutually agree.

**5.7 Right of Reference.** Each Party hereby grants to the other Party the right of reference to all Regulatory Materials pertaining to the Product submitted by or on behalf of such Party. Hansoh may use such right of reference to Scynexis' Regulatory Materials for the purpose of seeking, obtaining and maintaining Regulatory Approval of the Product in the Field in the Territory. Scynexis may use such right of reference to Hansoh's Regulatory Materials for the purpose of seeking, obtaining and maintaining Regulatory Approval of the Product outside the Field and/or outside the Territory. If requested by the receiving Party, the granting Party will provide a signed statement to this effect in accordance with 21 C.F.R. §314.50(g)(3) or any foreign counterpart to such regulation in the Territory.

**5.8 Adverse Events Reporting.** Promptly following the Effective Date, but in any event no later than the initiation of any Clinical Trial of the Product in the Field in the Territory, the Parties shall enter into a pharmacovigilance and adverse event reporting agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Product, such as safety data sharing, adverse events reporting and prescription events monitoring (the "**Pharmacovigilance Agreement**"). Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws. Scynexis shall establish and maintain the global safety database for the Product. Scynexis shall hold the primary responsibility for reporting quality complaints, adverse events and safety data related to the Product outside of the Territory to such global database and to the applicable Regulatory Authorities outside of the Territory, as well as responding to safety issues and to all requests of Regulatory Authorities outside of the Territory related to the Product, in each case at its own cost and to the extent required by the Applicable Laws. Hansoh shall hold the primary responsibility for reporting quality complaints, adverse events and safety data related to the Product in the Territory to such global database (which report shall be made in or translated into English by Hansoh at its own cost and expense and shall include all necessary details to enable Scynexis manage such global database) and to the applicable Regulatory Authorities in the Territory, as well as responding to safety issues and to all requests of Regulatory Authorities in

the Territory related to the Product, in each case at its own cost and to the extent required by the Applicable Laws. Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees and sublicensees to comply with such obligations.

## **5.9 Regulatory Audits and Inspection.**

(a) Upon [\*] advance written notice on a reasonable mutually agreed date, Scynexis or its representatives shall have the right to audit the regulatory, safety, quality and compliance systems, procedures and practices of Hansoh, its Affiliates, sublicensees or subcontractors (including preclinical and clinical trial sites) that relates to the Product and pertains to any data provided by Hansoh to Scynexis and submitted by Scynexis to Regulatory Authorities outside the Territory, on Scynexis's own cost and expenses. Except for for-cause and follow up audits, such audits shall be conducted no more than once a year and shall not unreasonably interfere with Hansoh's, its Affiliate's, sublicensee's or subcontractor's normal business operation.

(b) Hansoh shall promptly notify Scynexis of any audit or inspection of Hansoh, its Affiliates, and sublicensees or subcontractors (including preclinical and clinical trial sites) of which it has received notice, by any Regulatory Authority that relates to the Product and pertains to any data provided by Hansoh to Scynexis and submitted by Scynexis to Regulatory Authorities outside the Territory, and shall provide Scynexis with all information pertinent thereto (including all copies of all notices, filings and correspondences received from or submitted to the Regulatory Authority in connection therewith). Scynexis shall have the right, but not the obligation, to be present at any such audit or inspection. In general, Hansoh shall accommodate reasonable requests of Regulatory Authorities outside the Territory to conduct audits and inspections of Hansoh, its Affiliates, sublicensees or subcontractors (including preclinical and clinical trial sites) relating to the Product and shall ensure that such Affiliates and sublicensees permit and cooperate, and contractually obligate (and use Commercially Reasonable Efforts to enforce such contractual obligations) subcontractors to permit and cooperate with such audits and inspections with a possible exception of audit and inspection of manufacturing facilities provided that Hansoh is not supplying product outside of the Territory.

**5.10 No Harmful Actions.** If Scynexis believes that Hansoh is taking or intends to take any action with respect to the Product that could have a material adverse impact upon the regulatory status of the Product outside the Field and/or outside the Territory, Scynexis shall have the right to bring the matter to the attention of the JSC and the Parties shall promptly meet to discuss in good faith to resolve such concern. Without limiting the foregoing, unless the Parties otherwise agree, Hansoh shall not communicate with any Regulatory Authority having jurisdiction outside the Territory regarding the Product, unless so ordered by such Regulatory Authority, in which case Hansoh shall immediately notify Scynexis of such order to the extent allowed by such Regulatory Authority or Applicable Law.

**5.11 Remedial Actions.** Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Product may be subject to any recall, corrective action or other regulatory action by any Regulatory Authority or other Governmental Authority (a "**Remedial Action**"). The Parties shall assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a

Remedial Action. Hansoh shall have sole discretion with respect to any matters relating to any Remedial Action in the Territory, including the decision to commence such Remedial Action and the control over such Remedial Action. The cost and expenses of any Remedial Action in the Territory shall be borne solely by Hansoh.

## **ARTICLE 6 MANUFACTURE AND SUPPLY**

### **6.1 Manufacture and Supply by Scynexis to Hansoh.**

(a) Before the completion of Manufacture technology transfer pursuant to Section 6.2 below, Scynexis shall, either by itself or through its Affiliates or Third Party contract manufacturers, use Commercially Reasonable Efforts to Manufacture and supply, and Hansoh shall purchase from Scynexis, all of Hansoh's and its Affiliates' and sublicensees' requirements of the Compound and Product for Development and Commercialization use in the Field in the Territory, subject to the terms and conditions set forth below and other terms and conditions mutually agreed upon by the Parties in supply agreement(s).

(b) Hansoh shall pay for the Compound and Product supplied by Scynexis at a price equal to the Manufacturing Cost plus a [\*] mark up. This price does not include any sales, use, excise, value added, transfer or other taxes or duties levied or assessed by any Governmental Authority on the transfer and sale of the Compound and Product to Hansoh, all of which shall be borne and paid by Hansoh. Any Compound and Product supplied by Scynexis shall be delivered to Hansoh EXW (Incoterms 2020) at Scynexis' (or its Affiliate's or contract manufacturer's) facility, and Hansoh shall be invoiced for the Compound and Product upon such delivery. Hansoh shall pay the amount invoiced [\*] after the receipt of the invoice, and shall be responsible for arranging shipping, insurance, export and import clearance, all at Hansoh's own cost and expense.

(c) The Parties will negotiate and enter into one or more supply agreements and related quality agreements for the Manufacture and supply of the Compound and/or Product as appropriate by Scynexis to Hansoh, which agreements shall be consistent with the terms and conditions of this Agreement, the terms and conditions set forth in **Exhibit G** and shall include mutually agreed and customary terms for such agreements, such as detailed mechanism for forecast and ordering (which shall require placing binding purchase order at least [\*] in advance for supply with existing drug substance inventory at pilot scale up to [\*] tablets, at least [\*] in advance for supply that requires drug substance synthesis at pilot scale, and at least [\*] in advance for greater than pilot scale supply, and half of the purchase price shall be paid upfront when placing the purchase order and the remaining half shall be paid upon delivery). In the event that, in order to speed up Product Development, Hansoh requires supply of the Compound or Product before the negotiation of the supply agreement is completed, Hansoh may submit purchase order to Scynexis (subject to the same lead time requirement set forth above), and Scynexis shall use Commercially Reasonable Efforts to supply the Compound and Product to Hansoh.

### **6.2 Manufacture Technology Transfer and Assistance.**

(a) Within [\*] after the Effective Date, Scynexis shall provide Hansoh with access to the Manufacture-related documents and Know-How set forth in **Exhibit H** attached

hereto, which consists of all Manufacturing methods, Know-How and processes relevant for the Manufacture of the Compound and Product in the oral tablet formulation that is developed and Controlled by Scynexis or its Affiliate as of the Effective Date (the “**Oral Formulation**”).

(b) Promptly after the Effective Date, the Parties shall coordinate and agree to a Manufacturing technology transfer plan pursuant to which Scynexis shall provide Hansoh with reasonable technical assistance to enable Hansoh to Manufacture the Compound and Product (including both API and drug product in the Oral Formulation). Such technical assistance may include (i) access to Scynexis’ technical personnel involved in the Manufacture of the Compound and Product, (ii) providing Hansoh with a reasonable level of technical assistance and consultation in connection with the transfer to Hansoh of Manufacture-related documents and Know-How, and (iii) responding to questions raised by Hansoh in connection with the Manufacture-related documents and Know-How. In addition, upon Hansoh’s request and subject to a three way confidentiality agreement with Scynexis’ Third Party contract manufacturer, Scynexis shall also introduce Hansoh to Scynexis’ Third Party contract manufacturer and facilitate the discussion and negotiation between Hansoh and such contract manufacturer regarding technology transfer and/or direct supply relationship. Hansoh shall reimburse Scynexis for both reasonable out-of-pocket cost and internal cost (calculated at the FTE Rate) actually incurred by Scynexis to provide such manufacture technical assistance, except for the internal cost for Initial Support, which shall be provided at Scynexis’ cost. For clarity, such cost shall be estimated by Scynexis and approved by Hansoh in writing prior to reimbursement.

(c) As of the Effective Date, Scynexis is in the early stage Development of an intravenous formulation for the Product. As the Development of the intravenous formulation advances, Hansoh’s access to Manufacture-related documents and Know-How related to the Manufacture of the Product in intravenous formulation and the timelines and mechanism for the transfer therefor shall be discussed and agreed by the Parties at the JSC. Scynexis shall transfer such Manufacture-related documents and Know-How related to the Manufacture of the Product in intravenous formulation that is developed and Controlled by Scynexis or its Affiliates without additional payment required (except as set forth in Sections 1.34 and 1.35), except for reasonable out-of-pocket cost and internal cost (calculated at the FTE Rate) actually incurred by Scynexis to provide such manufacture technical assistance. For clarity, the second payment of Manufacturing technology transfer fee under Section 8.1(b) does not require the transfer of the Manufacture of the Product in intravenous formulation to take place before such payment is due.

### **6.3 Manufacture by Hansoh.**

(a) Unless the Parties agree otherwise, after the completion of the Manufacturing technology transfer pursuant to Section 6.2 above and obtaining the necessary Regulatory Approval for the change in source of supply, Hansoh shall, either by itself or through its Affiliates, sublicensees or Third Party contractors, Manufacture and supply all of Hansoh’s and its Affiliates’ and sublicensees’ requirements for the Compound and Product for Development and Commercialization use in the Field in the Territory, at Hansoh’s own cost and expense.

(b) Without limiting Section 9.1, each Party shall keep the other Party informed on any improvement or modification it or its subcontractor (i.e. CROs or CMOs) makes to the Manufacture process for the Compound and Product. Upon the other Party’ request, the Party that

made an improvement shall make such improvement or modification available to the other Party and such Party or its subcontractors shall provide the other Party with reasonable technical assistance in order for the other Party to implement such improvement or modification in the Manufacture of the Compound and Product.

(c) From time to time, the Parties may discuss and coordinate their Manufacture and supply of the Compound and Product and, if mutually agreed by the Parties in a separate supply agreement, one Party may supply all or part of the other Party's requirement and/or act as a backup supplier for the other Party.

## ARTICLE 7 COMMERCIALIZATION

**7.1 General.** Hansoh shall, either by itself or through its Affiliates, sublicensees or Third Party contractor(s), be solely responsible for and, subject to the terms and condition of this Agreement (including Section 3.2(f)), and shall have the sole decision-making authority over, the Commercialization of any Product(s) in the Field in the Territory, at Hansoh's own cost and expense, including developing and executing a commercial launch plan, product marketing and promotion, marketing access and pricing strategy, negotiating with applicable Governmental Authorities regarding the price and reimbursement mechanisms, booking sales, product distribution, providing customer support (including handling medical queries), and performing other related functions.

**7.2 Commercialization Diligence.** Hansoh shall use Commercially Reasonable Efforts to Commercialize at least one Product in the Field in the Territory in which it receives Regulatory Approval.

**7.3 Commercialization Plan.** No later than [\*] before the anticipated First Commercial Sale for the Product in the Field in the Territory, Hansoh shall provide the JSC for review and discussion a Commercialization plan that summarizes the general timeline and other necessary details of major Commercialization activities planned for such Product in the Field in the Territory (the "**Commercialization Plan**"). Thereafter, from time to time, but at least once every year during the Term of this Agreement, Hansoh shall prepare updates or amendments to the Commercialization Plan to reflect changes in such plans, and shall submit such updates and amendments to the JSC for review and discussion before adopting such update or amendment. The Commercialization of the Product in the Field in the Territory shall be conducted pursuant to the Commercialization Plan.

**7.4 Coordination of Commercialization Activities.** The Parties recognize that they may benefit from the coordination of certain activities in support of the Commercialization of the Product across their territories. As such, the Parties may coordinate such activities where appropriate, including scientific and medical communication and product positioning. If the Parties agree to jointly conduct any specific Commercialization activities for the benefit of the Product in both Parties' territories, the Parties shall negotiate and agree on the details of such activities, including allocation of responsibilities, budget and cost sharing.

**7.5 Pricing.** Hansoh shall discuss the pricing strategy of the Product in the Territory at JSC prior to discussion with Regulatory Authorities or parties involved in reimbursement decisions. Hansoh shall consider in good faith any comments received from Scynexis with respect to pricing of the Product and shall keep Scynexis reasonably informed through the JSC on the status of pricing or reimbursement approval for the Product in a Region in the Territory. Notwithstanding the foregoing, Hansoh shall have the sole right to determine the price of the Product sold in the Territory (including in any Region in the Territory); provided that Hansoh shall not price the Product in a manner to induces the sale of other products sold by Hansoh in the Territory.

**7.6 Commercialization Reports.** Hansoh shall keep Scynexis reasonably informed, through discussions at the JSC meetings, of its, its Affiliates' and sublicensees' Commercialization activities with respect to the Product in the Field in the Territory. Without limiting the foregoing, Hansoh shall update Scynexis at JSC meeting regarding the Commercialization activities with respect to the Product in the Field in the Territory in a report summarizing significant Commercialization activities (which report may be in the form of a slide deck or a document prepared by Hansoh for its internal reporting purpose and shall cover subject matter at a level of detail reasonably agreed by the JSC). In addition, Hansoh shall make available to Scynexis such additional information about its Commercialization activities as may be reasonably requested by Scynexis from time to time. For clarity, such reports shall be Confidential Information of Hansoh.

## **ARTICLE 8 PAYMENTS AND MILESTONES**

### **8.1 Upfront Payment.**

**(a)** In partial consideration of the rights granted by Scynexis to Hansoh hereunder, Hansoh shall pay to Scynexis a one-time, non-refundable and non-creditable upfront payment of ten million Dollars (\$10,000,000) within [\*] after the Effective Date, provided that Scynexis issues an invoice to Hansoh for such amount at least [\*] prior to the due date.

**(b)** In partial consideration of the rights granted by Scynexis to Hansoh hereunder, Hansoh shall pay to Scynexis a one-time, non-refundable and non-creditable Manufacturing technology transfer fee of [\*], of which [\*] shall be payable upon receipt of invoice within [\*] after Scynexis has, pursuant to Section 6.2(a), provided Hansoh with access to the Manufacturing related documents and Know-How set forth in **Exhibit H** attached hereto, and the remaining [\*] shall be payable upon receipt of invoice within [\*] after completion of the Manufacturing technology transfer under Section 6.2(b). Hansoh shall notify Scynexis within [\*] after the Manufacturing technology transfer has been completed and Scynexis shall issue an invoice to Hansoh at least [\*] prior to the due date. For the purpose of this Section 8.1(b), Manufacturing technology transfer shall be deemed completed when Hansoh Manufactures the first batch of the Product in the Oral Formulation that meets the applicable specifications.

**8.2 Cost Reimbursement.** Hansoh shall reimburse Scynexis for the reasonable out-of-pocket cost (including travel and accommodation) and internal cost (calculated at the FTE Rate but excluding the Initial Support) actually incurred by Scynexis to provide assistance to Hansoh under Sections 4.4, 5.4, and 6.2(b). Such costs should be estimated by Scynexis and approved by

Hansoh in writing prior to reimbursement. Scynexis shall invoice Hansoh for such cost on a monthly basis and Hansoh shall pay the amount invoiced within [\*] after the receipt of the invoice.

### 8.3 Development Milestones Payments.

(a) **Development Milestone Events.** In partial consideration of the rights granted by Scynexis to Hansoh hereunder and subject to the remainder of this Section 8.3, Hansoh shall pay to Scynexis the following one-time, non-refundable and non-creditable Development milestone payments set forth in the table below upon the first achievement of the corresponding milestone event:

Development Milestone Event	Milestone Payment
1.[*]	[*]
2.[*]	[*]
3.[*]	[*]
4.(A) [*] or (B) [*]	[*]
<b>Total</b>	[*]

### (b) Development Milestone Conditions.

(i) Each milestone payment set forth above shall be due and payable only once, regardless of how many times such milestone event is achieved and/or the number of Products that achieves such milestone event.

(ii) Milestone #4 shall be due and payable only once, even in the event where both milestone event 4(A) and 4(B) and regardless of the number of times such milestone event is achieved and/or the number of Products that achieves either or both milestone event 4(A) and 4(B).

(iii) Each milestone payment set forth above shall be due and payable irrespective of whether such milestone event is achieved by Hansoh, their Affiliates or sublicensee.

(iv) For the purpose of this Agreement, “**Acute VVC**” means the treatment of any episode of vulvovaginal candidiasis (VVC), and “**Recurrent VVC**” means prevention of recurrent vulvovaginal candidiasis (VVC).

(v) In the event that a single NMPA approval covers more than one Indication (e.g., both Acute VVC and Recurrent VVC), then the Development milestones for each Indication covered by such approval shall deemed achieved and the corresponding milestone payments shall become due and payable pursuant to Section 8.3(c).



(vi) The maximum aggregate amount payable by Hansoh pursuant to this Section 8.3 is [\*].

(c) **Notice and Payment.** Hansoh shall notify Scynexis in writing within [\*] days after the first achievement of each Development milestone set forth above by Hansoh or any of its Affiliates, or within [\*] after the achievement of the applicable Development milestone event by a sublicensee. Scynexis will invoice Hansoh following receipt of such written notice and Hansoh shall pay to Scynexis the corresponding Development milestone payment within [\*] after receipt of such invoice.

#### 8.4 Sales Milestone Payments.

(a) **Sales Milestone Events.** In partial consideration of the rights granted by Scynexis to Hansoh hereunder and subject to the remainder of this Section 8.4, Hansoh shall pay to Scynexis the following one-time, non-refundable and non-creditable sales milestone payments set forth in the table below when the aggregated Net Sales of all Products sold in the Field in the Territory in a given Calendar Year upon the first achievement of the corresponding threshold value indicated below.

Aggregate Net Sales of all Products in the Territory in any Calendar Year	Milestone Payment
1.[*]	[*]
2.[*]	[*]
3.[*]	[*]
4.[*]	[*]
<b>Total</b>	[*]

(b) **Sales Milestone Conditions.** Each sales milestone payment set forth above shall be due and payable only once, regardless of how many times such milestone event is achieved. For clarity, the sales milestone payments in this Section 8.4 are additive, such that if more than one sales milestone set forth above is achieved in the same Calendar Year, then the milestone payments for all such sales milestones shall be payable. The maximum aggregate amount payable by Hansoh pursuant to this Section 8.4 is [\*].

(c) **Notice and Payment.** Within [\*] after Hansoh expects to achieve any sales milestone(s), Hansoh will provide notice to Scynexis and Scynexis will invoice Hansoh for the corresponding milestone payment(s) based on Hansoh's estimates set forth in its notice. Hansoh shall pay Scynexis the corresponding milestone payment(s) within [\*] after receipt of such invoice. As part of the royalty report in Section 8.5(d), Hansoh shall provide written notice to Scynexis if the aggregated annual Net Sales of all Products in the Territory first reach any threshold value set forth in Section 8.4(a) above during the time period to which such royalty report pertains. The Parties shall work in good faith to reconcile (if necessary) the amounts paid by Hansoh to Scynexis pursuant to the invoice with the amounts set forth in the semi-annual final royalty report. Should

issues with accounting or revenue recognition arise, the parties shall work together in good faith to adjust this notice and payment procedure.

## 8.5 Royalty Payments.

(a) **Royalty Rates.** In partial consideration of the rights granted by Scynexis to Hansoh hereunder and subject to the remainder of this Section 8.5, during the applicable Royalty Term on a Region-by-Region basis, Hansoh shall make quarterly non-refundable royalty payment, if any accrued in a given Calendar Quarter, to Scynexis on the annual aggregate Net Sales of all Products sold in the Territory, as calculated by multiplying the applicable royalty rate set forth in the table below by the corresponding amount of incremental, aggregated annual Net Sales of the Products sold in the Territory in the applicable Calendar Year:

For that portion of annual Net Sale of the Products in the Territory	Royalty Rate
1)[*][*]	[*]
2)[*][*]	[*]

(b) **Royalty Term.** Hansoh's obligation to pay royalties pursuant to this Section 8.5 shall begin from the First Commercial Sale of any Product in the Territory and continue, on a Product-by-Product and Region-by-Region basis, until the latest of: (i) the expiration of the last Valid Claim in the Licensed Patent in such Region that claims such Product, including the composition of matter of or the formulation, method of making or method of using such Product (including any components thereof); (ii) the expiration of the all Regulatory Exclusivities covering such Product in such Region; and (iii) the date that is [\*] after the First Commercial Sale of such Product in such Region (the "**Royalty Term**").

### (c) Royalty Reduction.

(i) If a Product is sold in a Region in the Territory in a Calendar Quarter in the applicable Royalty Term when a Generic Product is being sold in such Region, and the Net Sales of the Product sold by Hansoh, its Affiliates and sublicensees in such Calendar Quarter in such Region is less than [\*] of the total Net Sales of the Product combined with net sales of the Generic Product sold in such Calendar Quarter in such Region, then, subject to Section 8.5(c)(iii) below, the royalty rate applicable to the Net Sales of the Product sold in such Calendar Quarter in such Region shall be reduced by [\*]. The determination of the net sales of the Generic Product shall be based upon data provided by IQVIA (formerly IMS Health) or another mutually acceptable and reputable provider and the determination of Net Sales of the Product shall be determined by the terms and conditions of this Agreement. For clarity, the royalty reduction set forth in this Section 8.5(c)(i) shall not apply to any Calendar Quarter during which the Net Sales of the Product rise above the threshold set forth above.

(ii) If it is necessary for Hansoh to obtain a license from a Third Party to any Patent (and any Know-How licensed together with such Patent) owned by such Third Party in order to avoid infringement of such Patent by the practice of the Licensed IP in the Development, Manufacture, Commercialization or otherwise exploitation of the Compound or Product (excluding the part of a Combination Product that is not a Compound) in a Region in the Territory

and Hansoh obtains such a license, then, subject to Section 8.5(c)(iii) below, Hansoh shall have the right to deduct, from the royalty payment that would otherwise have been due pursuant to this Section 8.5 with respect to Net Sales of such Product in such Region in a particular Calendar Quarter, an amount equal to [\*] of the royalties, license fees, upfront fees and other milestone fees paid by or on behalf of Hansoh to such Third Party pursuant to such license on account of the sale of the Product in such Region during such Calendar Quarter.

(iii) Notwithstanding the foregoing, in no event shall the operation of Section 8.5(c)(i) or (ii), individually or in combination, reduce the royalties paid to Scynexis with respect to the Net Sales of the Product in any Region in the Territory in any Calendar Quarter to less than the royalties payable by Scynexis to its upstream licensors pursuant to the Upstream Agreements with respect to such sale of the Product.

(d) **Basis for Royalty.** This Section 8.5 is intended to provide for payments to Scynexis and through Scynexis, to its upstream licensors equal to the percentages of Net Sales set forth in this Section 8.5 for the duration of the applicable Royalty Term. In establishing this payment structure, the Parties recognize and acknowledge, the substantial value of the various actions and investments undertaken by Scynexis and its upstream licensors prior to the Effective Date and that Scynexis will undertake under this Agreement, and that the value of the Licensed IP licensed to Hansoh hereunder resides substantially in Licensed Know-How. As a result, the Parties attribute such value to Scynexis' and its upstream licensors' leading proprietary knowledge in the subject matter, including trade secrets, preclinical and clinical data pertaining to the Compound and Product, and regulatory filings made by or on behalf Scynexis prior to the Effective Date, in each case created or generated by Scynexis through the expenditure of significant resources and as a result of Scynexis' unique innovative capabilities. The Parties have agreed to the payment structure set forth herein as a convenient and fair mechanism for both Parties in order to compensate Scynexis and its upstream licensors during the applicable Royalty Term for these additional benefits as part of the overall consideration for Scynexis to enter into this Agreement.

(e) **Royalty Report and Payment.** Within [\*] after the end of each Calendar Quarter, commencing with the first Calendar Quarter in which there is any Net Sales of any Product anywhere in the Territory, Hansoh shall provide Scynexis with a preliminary report that contains the following information for the applicable Calendar Quarter: (i) the aggregate amount of gross sales of each Product in each Region during the applicable Calendar Quarter, (ii) an itemized calculation of Net Sales showing separately each type of deduction provided for in the definition of "Net Sales," (iii) a calculation of the royalty payment due on such sales in Dollars, including the exchange rate used in such calculation in accordance with Section 8.6, and (iv) whether any sales milestone has been achieved. Upon receipt of the applicable quarterly preliminary royalty report, Scynexis will invoice Hansoh based on such preliminary royalty report and Hansoh shall pay to Scynexis in Dollars the royalties owed with respect to Net Sales for such Calendar Quarter based on such preliminary report within [\*] after receipt of such invoice. Hansoh shall provide semi-annual final royalty report within [\*] after the second and fourth Calendar Quarters of each Calendar Year instead of the foregoing preliminary report. Such final royalty report will reconcile (if necessary) the amounts paid by Hansoh to Scynexis pursuant to the invoice in the prior Calendar Quarter with the royalty amounts set forth in the semi-annual final royalty report for the two Calendar Quarters covered by such final report. Upon receipt of the applicable semi-annual final royalty report, Scynexis will invoice Hansoh based on such final report and

Hansoh shall pay to Scynexis in Dollars the royalties owned with respect to Net Sales based on the semi-annual final royalty report within [\*] after receipt of such invoice.

**8.6 Currency; Exchange Rate.** All payments to be made by Hansoh to Scynexis under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds to a bank account designated by written notice from Scynexis. The rate of exchange to be used in computing the amount of currency equivalent in Dollars shall be made at the average of the closing exchange rates reported in The Wall Street Journal (U.S., Eastern Edition) for the first, middle and last business days of the applicable reporting period for the payment due.

**8.7 Late Payments.** If Scynexis does not receive payment of any sum due to it on or before the due date as set forth in this Agreement, simple interest shall thereafter accrue on the sum due to Scynexis from the due date until the date of payment at a per-annum rate of prime (as reported in The Wall Street Journal (U.S., Eastern Edition)) plus two percentage points or the maximum rate allowable by Applicable Laws, whichever is less.

**8.8 Financial Records and Audits.** Hansoh shall (and shall ensure that its Affiliates and sublicensees will) maintain complete and accurate records in accordance with GAAP, IFRS or equivalent internal standard policies and procedures of the applicable Selling Party and in sufficient detail to permit Scynexis to confirm the accuracy of Net Sales reported by Hansoh and amounts payable under this Agreement. Upon no less than [\*] prior written notice, such records shall be available for examination, during regular business hours of Hansoh or its Affiliate or sublicensee, for a period of [\*] from the creation of individual records, and not more often than once each Calendar Year, by an independent certified public accountant mutually agreed by Scynexis and Hansoh (any independent certified public accountant from Deloitte, PricewaterhouseCoopers (PwC), Ernst & Young (EY) or Klynveild Peat Marwick Goerdier (KPMG) shall be considered acceptable), for the sole purpose of verifying for Scynexis the accuracy of the Net Sales and royalty reports provided by Hansoh under this Agreement. Such independent certified public accountant may only share in a report its final determination of whether there has been an underpayment or overpayment and the amount of such underpayment or overpayment based on such audit with the Parties. In no event may such independent certified public accountant shall share any copies of or a portion of the underlying records with Scynexis, its Affiliates or any of its upstream licensors. Scynexis shall bear the cost of such audit unless such audit reveals an underpayment by Hansoh of more than [\*] of the amount actually due for the period of time being audited, in which case Hansoh shall reimburse Scynexis for the costs of such audit. Hansoh shall pay to Scynexis any underpayment discovered by such audit within [\*] after the accountant's report, plus interest (as set forth in Section 8.7) from the original due date. Scynexis shall reimburse to Hansoh any overpayment discovered by such audit within [\*] after the accountant's report. Hansoh shall include in each relevant sublicense granted by it a provision requiring the sublicensee to maintain records of sales of the Product made pursuant to such sublicense and to grant access to such records to the same extent and under the same obligations as required of Hansoh under this Agreement.

## **8.9 Tax Withholding.**

(a) As between the Parties, each Party shall bear all taxes, fees, duties, levies or similar amounts imposed on its net income (however denominated), franchise taxes and any branch profit taxes arising directly or indirectly from the activities of the Parties and payments made under this Agreement.

(b) The Parties shall cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of the payments made hereunder. To the extent Hansoh is required by Applicable Laws to withhold or deduct any tax on any payment to Scynexis, (i) the sum payable by Hansoh to Scynexis for the upfront payment set forth in Section 8.1(a) shall be increased to the extent necessary to ensure that Scynexis receives a sum equal to the sum that Scynexis would have received had there been no such deduction or withholding, (ii) the sum payable by Hansoh to Scynexis for the technology transfer fee, and all milestone payments shall be made to Scynexis after deduction [\*] of the amount required to be so deducted or withheld (which withheld amount shall be treated as paid to Scynexis), and Hansoh shall be required to increase the amount associated with the remaining [\*] of the amount required to be withheld to the extent necessary to ensure that Scynexis receives a sum equal to the sum that Scynexis would have received had there been no such deduction or withholding of such remaining [\*] and (iii) the sum payable by Hansoh to Scynexis for all royalty payments shall be made to Scynexis after deduction [\*] of the amount required to be so deducted or withheld (which withheld amount shall be treated as paid to Scynexis), and Hansoh shall be required to increase the amount associated with the remaining [\*] of the amount required to be withheld to the extent necessary to ensure that Scynexis receives a sum equal to the sum that Scynexis would have received had there been no such deduction or withholding of such remaining [\*]. For purposes of clarity and avoidance of doubt, any such withholding taxes required under Applicable Laws to be paid or withheld in connection with payments of technology transfer fee and milestones shall be an expense of, and borne [\*] by Hansoh and [\*] by Scynexis. For purposes of clarity and avoidance of doubt, any such withholding taxes required under Applicable Laws to be paid or withheld in connection with royalty payments shall be an expense of, and borne [\*] by Hansoh and [\*] by Scynexis. Upon Hansoh's request, Scynexis shall use reasonable efforts to provide Hansoh any tax form that may be reasonably necessary in order for Hansoh to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Both Parties shall also provide the other Party reasonable assistance and cooperation to enable the recovery, to the extent permitted by Applicable Laws, of withholding taxes or similar obligations resulting from the payments made under this Agreement. All amounts deducted or withheld shall be remitted to appropriate Government Authority in accordance with Applicable Laws.

## **ARTICLE 9 INTELLECTUAL PROPERTY**

### **9.1 Arising Product IP.**

(a) Ownership of Arising Product IP shall follow inventorship as determined in accordance with U.S. patent laws. Each Party shall solely own Arising Product IP invented or developed solely by or on behalf of such Party, including its and its Affiliate's employees, contractors and/or agents. The Parties shall jointly own Arising Product IP invented or developed

jointly by both Parties. Except to the extent restricted by the licenses and other rights granted to other Party under this Agreement or any other agreement between the Parties, each Party, as joint owners, shall be entitled to practice, license, assign and otherwise exploit its interest in the jointly owned Arising Product IP without the duty of accounting or seeking consent from the other Party.

**(b)** Hansoh shall and hereby does grant to Scynexis a non-exclusive, sublicenseable (through multiple tiers), royalty free, fully paid, perpetual and irrevocable license under its Arising Product IP (including its interest in jointly owned Arising Product IP) to Develop, use, promote, sell, offer for sale, import and otherwise Commercialize the Compound and Product outside the Field and/or outside the Territory and to make and have made the Compound and Product anywhere in the world solely for use outside the Field and/or outside of the Territory. For clarity, Arising Product IP owned by Scynexis shall be included in Licensed IP and licensed to Hansoh under Section 2.1.

**(c)** Each Party shall promptly disclose to the other Party all Arising Product IP invented or generated by or on behalf of such Party under this Agreement, including any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing such Arising Product IP, and shall promptly respond to reasonable request from the other Party for additional information relating to such Arising Product IP.

## **9.2 Patent Prosecution.**

**(a)** As between the Parties, Scynexis shall have the first right (but not the obligation) to file, prosecute and maintain all Licensed Patents including Patents claiming jointly owned Arising Product IP) throughout the world at Scynexis' own cost and expense.

**(b)** Scynexis shall consult with Hansoh and keep Hansoh reasonably informed of the status of the Licensed Patents in the Territory and shall provide Hansoh with all material correspondence received from any patent authority in the Territory in connection therewith. In addition, Scynexis shall provide Hansoh with drafts of all proposed material filings and correspondence to any patent authority in the Territory with respect to the Licensed Patents for Hansoh's review and comment prior to the submission of such proposed filings and correspondences. Scynexis shall confer with Hansoh and consider in good faith Hansoh's comments prior to submitting such filings and correspondences in the Territory, provided that Hansoh shall provide such comments within [\*] (or a shorter period reasonably designated by Scynexis if [\*] is not practicable given the filing deadline) of receiving the draft filings and correspondences from Scynexis.

**(c)** Scynexis shall notify Hansoh of any decision to cease prosecution and/or maintenance of any Licensed Patents in any Region in the Territory. Scynexis shall provide such notice at least [\*] prior to any filing or payment due date, or any other material due date that requires action in order to avoid loss of rights, in connection with such Licensed Patent in such Region. In such event, Scynexis shall permit Hansoh, at Hansoh's discretion and expense, to continue the prosecution and maintenance of such Licensed Patent in such Region in the Territory.

**(d)** Hansoh shall have right to file, prosecute and maintain Licensed Patent in any Region in the Territory if Scynexis fails to provide any notice to Hansoh pursuant to Section

9.2(c) and does not taking proper actions within [\*] after Hansoh provides notice to Scynexis specifying its intent to file, prosecute and/or maintaining certain Licensed Patents (or [\*] in the event there is an upcoming filing or payment due date or other material due date that requires action).

(e) Hansoh may request that Scynexis file a new Patent application within Licensed Patent in a Region in the Territory, and Scynexis shall respond to such request within [\*] as to whether Scynexis will file such Patent application in such Region. If Scynexis notifies Hansoh that Scynexis does not wish to file such Patent application in such Region, then Scynexis shall permit Hansoh to file and prosecute such Patent application in such Region at Hansoh's own cost and expense.

(f) If Hansoh elects to file, prosecute or maintain a Licensed Patent in a Region pursuant to Section 9.2(c), 9.2(d) or 9.2(e), then Section 9.2(b) shall apply mutatis mandis with respect to Hansoh's prosecution efforts. Hansoh's filing, prosecution or maintenance of such Licensed Patent in such Region shall not require Scynexis to assign such Licensed Patent to Hansoh in such Region and shall not change the Parties' respective rights and obligations under this Agreement with respect to such Licensed Patent other than those expressly set forth in this Section 9.2.

(g) Each Party shall provide the other Party all reasonable assistance and cooperation in the patent prosecution efforts under this Section 9.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution.

### **9.3 Patent Enforcement.**

(a) Each Party shall promptly notify the other Party if it becomes aware of any alleged or threatened infringement by a Third Party of any of the Licensed Patents in the Territory, and any related declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any of the Licensed Patents in the Territory.

(b) As between the Parties, Hansoh shall have the first right (but not the obligation) to bring and control any legal action in connection with any infringement of the Licensed Patents that involves the Development, Manufacture or Commercialization of the Compound or Product in the Field in the Territory (an "**Infringement**") at its own expense as it reasonably determines appropriate after consultation with Scynexis. If Hansoh does not bring such legal action within [\*] after the notice provided pursuant to Section 9.3(a), Scynexis shall have the right (but not the obligation) to bring and control any legal action in connection with such Infringement in the Territory at its own expense as it reasonably determines appropriate.

(c) At the request and expense of the Party bringing an action under Section 9.3(b) above, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required by Applicable Laws to pursue such action. In connection with any such enforcement action, the enforcing Party shall keep the other Party reasonably informed on the status of such action and shall not enter into any settlement admitting the invalidity or non-

infringement of, or otherwise impairing the other Party's rights in the Licensed Patents without the prior written consent of the other Party. The non-enforcing Party shall be entitled to separate representation in such enforcement action by counsel of its own choice and at its own expense.

(d) Any recoveries resulting from enforcement action relating to a claim of Infringement in the Territory shall be first applied against payment of each Party's costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses shall be shared between the Parties as follows: (i) if Hansoh is the enforcing Party, [\*] of such excess recovery shall be retained by Hansoh (and treated as Net Sales); (ii) if Scynexis is the enforcing Party, retained by Scynexis.

(e) Scynexis shall have the exclusive right to bring and control any legal action to enforce the Licensed Patents against any infringement that does not involve the Development, Manufacture or Commercialization of the Compound or Product in the Field in the Territory, at Scynexis' own expense and as Scynexis reasonably determines appropriate, and Scynexis shall have the right to retain all recoveries.

#### 9.4 Infringement of Third Party Rights.

(a) Each Party shall notify the other Party of any written allegations it receives from a Third Party that the Development, Manufacture or Commercialization of any Compound or Product in the Field in the Territory under this Agreement infringes the intellectual property rights of such Third Party (each a "**Third Party Claim**"). Such notice shall be provided promptly, but in no event after more than [\*] following receipt of such Third Party Claim. Such notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Thereafter, the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a "common interest agreement" wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties.

(b) As between the Parties and subject to the indemnification provisions in Article 12, Hansoh shall have the first right (but not the obligation) to defend and control the defense of any such Third Party Claims, at Hansoh's own cost and expense; provided, provided, that, (a) if Hansoh decides not to defend any such Third Party Claim, then Hansoh shall provide reasonable prior written notice to Scynexis of such intention (which notice shall, where reasonably practical, be given no later than [\*] prior to the next deadline for any action that may be taken with respect to such Third Party Claim) or (b) if Hansoh fails to take steps to defend such Third Party Claim within [\*] after the date it first receives notice of such Third Party Claim, in each case ((a) or (b)), Scynexis shall thereupon have the option to assume the control and direction of the defense, at its sole cost and expense.

9.5 **Patents Licensed From Third Parties.** Each Party's rights under this Article 9 with respect to the prosecution and enforcement of any Licensed Patent that is in-licensed by Scynexis from a Third Party under an Upstream Agreement shall be subject to the rights retained by such Third Party to prosecute and enforce such Patent.



**9.6 Patent Marking.** Hansoh shall mark the Product sold in the Territory in accordance with the applicable patent marking laws, and shall require all of its Affiliates and sublicensees to do the same. To the extent permitted by Applicable Laws, Hansoh shall indicate on the product packaging, advertisement and promotional materials that the Product is in-licensed from Scynexis.

**9.7 Trademarks.**

(a) Hansoh acknowledges that Scynexis may develop a global branding strategy for the Product and adopt the key distinctive colors, logos, images, symbols, and trademarks, including those set forth in **Exhibit I**, to be used in connection with the Commercialization of the Product throughout the world (collectively and including any Chinese language versions thereof, the “**Scynexis Trademarks**”). Scynexis shall own all rights in the Scynexis Trademarks and shall have the sole right (but not the obligation) to register, maintain and enforce the Scynexis Trademarks in any country in the world as it determines appropriate, at Scynexis’ own cost and expense.

(b) Subject to the terms and conditions of this Agreement and for no additional considerations, Scynexis hereby grants to Hansoh an exclusive, royalty-free license, with the right to grant sublicenses through multiple tiers, to use the Scynexis Trademarks solely in connection with the Commercialization of the Product in the Field in the Territory, and Hansoh shall Commercialize the Product in the Territory using the Scynexis Trademarks (and no other trademarks other than Hansoh’s corporate name and logo and any Product Marks) in a manner consistent with Scynexis’ global branding strategy for the Product.

(c) The Parties acknowledge that the linguistic or cultural particularities, Applicable Laws of the Territory, market research, Scynexis’ global branding strategy and other relevant information may be considered when determine the appropriate trademark, logo or trade name to use in connection with the Product in the Territory. Hansoh shall have the right to determine whether to use another trademark, logo or trade name (e.g. a Chinese name for the Product) in addition to the Scynexis Trademarks that it determines appropriate for the Licensed Product, which may vary by Region or within a Region (the “**Product Marks**”). Hansoh shall own all rights in the Product Marks in the Territory and shall register and maintain the Product Marks in the Territory that it determines reasonably necessary. Upon Hansoh’s request, Scynexis shall reasonable assist Hansoh in the selection and design of the Product Marks at Hansoh’s cost.

**ARTICLE 10  
CONFIDENTIALITY**

**10.1 Confidentiality.** Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that, for the Term and for a period of [\*] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party pursuant to this Agreement.

**10.2 Exceptions.** The foregoing confidentiality and non-use obligations shall not apply to any portion of the Confidential Information that the receiving Party can demonstrate by competent written proof:

- (a) was already known to the receiving Party at the time of disclosure by the other Party;
- (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;
- (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement;
- (d) is subsequently disclosed to the receiving Party by a Third Party who has a legal right to make such disclosure; or
- (e) is subsequently independently discovered or developed by the receiving Party without the reference or use of the disclosing Party's Confidential Information.

**10.3 Authorized Disclosure.** Notwithstanding the obligations set forth in Section 10.1, a Party may disclose the other Party's Confidential Information and the terms of this Agreement to the extent:

- (a) such disclosure is reasonably necessary: (i) for the filing, prosecution or maintenance of Patents as contemplated by this Agreement; (ii) in connection with conducting pre-clinical studies or Clinical Trials or submitting regulatory filings for the Product; (iii) maintaining Regulatory Approval of a Product, or (iv) for the prosecuting, defending or enforcing litigation as contemplated by this Agreement;
- (b) such disclosure is reasonably necessary: (i) to such Party's directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to the receiving Party, provided that in each such case on the condition that such directors, attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; or (ii) to actual or potential investors, acquirors, licensors, licensees, collaborators or other business or financial partners (including royalty financing partners) solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, license, collaboration, financing or other business transaction; provided that in each such case on the condition that such disclosees are bound by confidentiality and non-use obligations consistent with those contained in the Agreement; provided further, that the term of such confidentiality obligations in such agreements (other than an actual license or collaboration agreement) may be limited to [\*];
- (c) such disclosure is reasonably necessary or reasonably useful to such Party's officers, employees and contractors in order to carry out the obligations and activities of such Party under this Agreement; provided that in each such case on the condition that such officers,

employees and are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; or

(d) such disclosure is required by judicial or administrative process, provided that in such event such Party shall promptly inform the other Party such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Article 10, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment of such Confidential Information.

**10.4 Scientific Publication.** Except to the extent required by Applicable Laws or by Regulatory Authorities, Hansoh (including its Affiliates and sublicensees) shall not publish any peer-reviewed manuscripts, or give other forms of public disclosure such as abstracts and presentations, relating to the Compound or Product, including the data and results of the Development of the Compound or Product, without Scynexis' review and approval, such approval not to be unreasonably withheld, conditioned or delayed. Hansoh shall deliver to Scynexis for review and approval a copy of any proposed scientific publication or presentation relating to the Compound or Product at least [\*] before its intended submission for publication. Scynexis shall have the right to require necessary modifications of the proposed publication or presentation to protect Scynexis' Confidential Information and for trade secret reasons or other business reasons; provided that Scynexis provides Hansoh with its requested modifications in writing within such [\*] period. Scynexis may also delay the submission of the proposed publication or presentation for an additional [\*] as may be reasonably necessary to seek patent protection for the information disclosed in such proposed publication or presentation. Scynexis shall keep Hansoh reasonably informed on scientific publications related to the Compound or Product by Scynexis, its Affiliates, licensees and sublicensees outside the Territory, which shall not require prior review or approval by Hansoh; provided that, to the extent Scynexis' scientific publications includes or is based on data generated by or on behalf of Hansoh, Scynexis shall not publish such publication without Hansoh's prior review and approval, such approval not to be unreasonably withheld, conditioned or delayed. Each Party agrees to acknowledge the contribution of the other Party and the other Party's employees in all publication as scientifically appropriate.

#### **10.5 Publicity.**

(a) The Parties have agreed on language of a joint press release announcing this Agreement, which is attached hereto as **Exhibit J**, to be issued by the Parties promptly after the Effective Date. Subject to this Article 10, no disclosure of the terms of this Agreement, and no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by Applicable Laws. Following the initial joint press release announcing this Agreement, either Party shall be free to disclose or publicize, without the other Party's prior written consent, the existence of this Agreement, the identity of the other Party, and those terms of this Agreement that have already been publicly disclosed in accordance herewith.

(b) A Party may disclose this Agreement and its terms in securities filings with the Securities Exchange Commission (or equivalent foreign agency) (“SEC”) to the extent required by Applicable Laws after complying with the procedure set forth in this Section 10.5. In such event, the Party seeking such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than [\*] after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the time lines proscribed by applicable SEC regulations. The Party seeking such disclosure shall exercise commercially reasonable efforts to obtain confidential treatment of this Agreement from the SEC as represented by the redacted version reviewed by the other Party.

(c) Each Party acknowledges that the other Party may be legally required to make public disclosures (including in filings with the SEC or other agency) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by Applicable Laws, *provided* that the Party seeking such disclosure first provides the other Party a copy of the proposed disclosure, and provided further that (except to the extent that the Party seeking disclosure is required to disclose such information to comply with Applicable Laws) if the other Party demonstrates to the reasonable satisfaction of the Party seeking disclosure, within [\*] of such Party’s providing the copy, that the public disclosure of previously undisclosed information will materially adversely affect the development and/or commercialization of a Product being developed and/or commercialized, the Party seeking disclosure will remove from the disclosure such specific previously undisclosed information as the other Party shall reasonably request to be removed.

**10.6 Prior CDA.** This Agreement supersedes any prior Confidentiality Agreement between the Parties (the “**Prior CDA**”) with respect to information disclosed thereunder. All information exchanged between the Parties under the Prior CDA shall be deemed Confidential Information of the disclosing Party and shall be subject to the terms of this Article 10.

**10.7 Equitable Relief.** Each Party acknowledges that a breach of this Article 10 cannot reasonably or adequately be compensated in damages in an action at law and that such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set forth herein.

**10.8 Attorney-Client Privilege.** Neither Party is waiving, nor shall be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges or the like as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the other Party, regardless of whether the disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties: (a) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections; (b) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates; (c) intend that such privileges and protections

remain intact should either Party become subject to any actual or threatened proceeding to which the disclosing Party's Confidential Information covered by such protections and privileges relates; and (d) intend that after the Effective Date both the receiving Party and the disclosing Party shall have the right to assert such protections and privileges

## **ARTICLE 11 REPRESENTATIONS AND WARRANTIES**

**11.1 Representations and Warranties of Each Party.** Each Party represents, warrants, and covenants (as applicable) to the other Party as of the Effective Date that:

(a) it is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement;

(b) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder, and this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors' rights and remedies generally;

(c) it is not a party to, and will not enter into during the Term, any agreement that would prevent it from granting the rights granted to the other Party under this Agreement or performing its obligations under the Agreement; and

(d) in the course of performing its obligations or exercising its rights under this Agreement, it shall comply with all Applicable Laws, in including as applicable, cGMP, GCP, and GLP standards, and shall not employ or engage any person or entity who has been debarred by any Regulatory Authority, or, to such Party's knowledge, is the subject of debarment proceedings by a Regulatory Authority.

**11.2 Representations and Warranties of Scynexis.** Scynexis represents, warrants, and covenants (as applicable) to Hansoh as of the Effective Date that:

(a) it has the right under the Licensed IP and the Scynexis Trademarks to grant the licenses to Hansoh as purported to be granted under this Agreement;

(b) it has not nor has any of its Affiliates entered into any agreement or otherwise granted, and will not grant during the Term, any liens, charges, security interest, encumbrances, license, claim, covenants or other right under the Licensed IP or the Scynexis Trademarks in the Territory to any Third Party that would conflict with or limit the scope of any of the rights or licenses granted to Hansoh under this Agreement;

(c) **Exhibit B** includes all Patents Controlled by Scynexis or its Affiliates as of the Effective Date that claim the Compound or Product, including composition of matter,

formulation, method of make or use, and that are necessary or reasonably useful for the Development, Manufacture and Commercialization of the Compound and Products in the Field in the Territory as of the Effective Date. To Scynexis' Knowledge, all Licensed Patents have been and are being prosecuted in accordance with Applicable Law, have been and are being filed and maintained properly and correctly and all applicable fees have been paid on or before the due date;

**(d)** to its Knowledge, all intellectual property rights relating to the Compounds or Products that are necessary for the Development, Manufacture or Commercialization of such Compounds or Products in the Field are owned or in-licensed by Scynexis and are included in the Licensed IP. All Licensed IP existing as of the Effective Date is in-licensed or exclusively owned by Scynexis;

**(e)** to its Knowledge, Scynexis is not aware of (i) any Know-How that Scynexis or its Affiliate plans to in-license or acquire from a Third Party after the Effective Date that is necessary or useful for the Development, Manufacture or Commercialization of the Compound or Product in the Field in the Territory and (ii) any Patent that Scynexis or its Affiliate plans to in-license or acquire from a Third Party after the Effective Date that claim the Compound or Product. For the purpose of this clause, "plans to in-license or acquire" shall require that Scynexis has submitted a term sheet to with the Third Party therefor before the Effective Date.

**(f)** to its Knowledge, Scynexis is not aware of any issued Patent that Hansoh or its Affiliate will need to in-license or acquire from a Third Party after the Effective Date in order to avoid infringement or misappropriation of such Third Party Patent by the practice of the Licensed IP pursuant to this Agreement.

**(g)** Scynexis has set forth in **Exhibit C** (Upstream Agreements) a true, correct, and complete list of all agreements pursuant to which a Third Party has granted Scynexis or any of its Affiliates a license under any Licensed IP, excluding licenses granted by a vendor or other services providers to Scynexis or its Affiliates in the ordinary course of business;

**(h)** to its Knowledge, Scynexis and its Affiliates have provided or made available to Hansoh prior to the Effective Date copies of all material and relevant information related to the safety and efficacy of the Compound that is material to Hansoh's evaluation of the Compound.

**(i)** it has not received any written notice from any Third Party asserting or alleging that the Development, Manufacture or Commercialization of the Compound or Product infringed or misappropriated the intellectual property rights of such Third Party;

**(j)** there is no pending or, to Scynexis' Knowledge, threatened (in writing), adverse actions, claims, suits or proceedings against Scynexis or any of its Affiliate involving the Licensed IP, Compound or Product;

**(k)** it is not aware of any action or petition for bankruptcy or insolvency of it or any of its Affiliates that is pending in any court in any state, country or other jurisdiction;

**(l)** As of the Effective Date, Scynexis and its Affiliates have secured from all those who have contributed to the development, creation, conception or invention of any of the

Licensed IP owned by Scynexis or its Affiliates a written agreement assigning to Scynexis or any of its Affiliates all rights to such developments, creations, conceptions or inventions of Licensed IP and its Affiliates have assigned all such rights to Scynexis or its Affiliates; and

(m) Neither Scynexis nor any of its Affiliates, or to its Knowledge, any of their respective licensors or licensees, have received any written notice from any Regulatory Authority regarding (i) any actual, alleged, possible, or potential violation of or failure to comply with any Applicable Law in connection with the Development of the Compound or Product, or (ii) any actual, proposed, or potential revocation, withdrawal, suspension, cancellation, or termination of any regulatory filing for a Compound or Product.

**11.3 Representations and Warranties of Hansoh.** Hansoh represents, warrants, and covenants (as applicable) to Scynexis as of the Effective Date that:

(a) to Hansoh's Knowledge, neither Hansoh nor any of its Affiliate owns or controls any Patent that claim or cover the Compound or Product;

(b) there is no pending or, to Hansoh's Knowledge, threatened (in writing), adverse actions, claims, suits or proceedings against Hansoh or any of its Affiliate in the Territory that involve any antitrust, anti-competition, anti-bribery or corruption violations or that may reasonably be expected to materially and adversely affect Hansoh's ability to perform its obligations under this Agreement;

(c) it has sufficient financial wherewithal to (i) perform all of its obligations pursuant to this Agreement, and (ii) meet all of its obligations that come due in the ordinary course of business; and

(d) it has, and will at all times throughout the Term have, the requisite approvals, permits, licenses, expertise, resources, experience and skill reasonably required to perform its obligations under this Agreement.

**11.4 NO OTHER WARRANTIES.** EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. Hansoh acknowledges and agrees that the Product is the subject of ongoing clinical research and development and that Scynexis cannot assure the safety, usefulness or successful Development or Commercialization of the Product.

## **ARTICLE 12 INDEMNIFICATION**

**12.1 Indemnification by Hansoh.** Hansoh shall indemnify and hold harmless Scynexis, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the "Scynexis Indemnitee(s)") from and against all losses, liabilities, damages and expenses

(including reasonable attorneys' fees and costs) incurred in connection with any claims, demands, actions or other proceedings by any Third Party (individually and collectively, "**Losses**") to the extent arising from:

(a) the Development, Manufacture and Commercialization of the Product in the Territory by Hansoh or any of its Affiliates or sublicensee, including product liability claims relating to the Product in the Territory; or

(b) the negligence, willful misconduct or breach of this Agreement by any Hansoh Indemnitee;

except in each case to the extent such Losses arise out of (i) the Development, Manufacture and Commercialization of the Product outside the Territory by Scynexis or any of its Affiliates, licensees or sublicensee (other than Hansoh, its Affiliates and sublicensees), including product liability claims relating to the Product outside the Territory or (ii) the negligence, willful misconduct or breach of this Agreement by any Scynexis Indemnitee.

**12.2 Indemnification by Scynexis.** Scynexis shall indemnify and hold harmless Hansoh, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the "**Hansoh Indemnitee(s)**") from and against all Losses to the extent arising from:

(a) the Development, Manufacture and Commercialization of the Product outside the Territory by Scynexis or any of its Affiliates, licensees or sublicensee (other than Hansoh, its Affiliates and sublicensees), including product liability claims relating to the Product (i) worldwide prior to the Effective Date and, (ii) outside the Territory following the Effective Date; or

(b) the negligence, willful misconduct or breach of this Agreement by any Scynexis Indemnitee;

except in each case to the extent such Losses arise out of (i) the Development, Manufacture and Commercialization of the Product in the Territory by Hansoh or any of its Affiliates or sublicensee, including product liability claims relating to the Product in the Territory or (ii) the negligence, willful misconduct or breach of this Agreement by any Hansoh Indemnitee.

**12.3 Indemnification Procedure.** If either Party is seeking indemnification under Sections 12.1 or 12.2 (the "**Indemnified Party**"), it shall inform the other Party (the "**Indemnifying Party**") of the claim giving rise to the obligation to indemnify pursuant to such Section within [\*] after receiving notice of the claim (it being understood and agreed, however, that the failure or delay by an Indemnified Party to give such notice of a claim shall not affect the indemnification provided hereunder except to the extent the Indemnifying Party shall have been prejudiced as a result of such failure or delay to give notice). The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party's insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party's cost and expense. The Indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim that has been assumed by the Indemnifying Party. Neither Party shall have the obligation to indemnify the other Party in



connection with any settlement made without the Indemnifying Party's written consent, which consent shall not be unreasonably withheld or delayed. If the Parties cannot agree as to the application of Section 12.1 or 12.2 as to any claim, pending resolution of the dispute pursuant to Article 14, the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 12.1 or 12.2 upon resolution of the underlying claim.

**12.4 Mitigation of Loss.** Each Indemnified Party shall take and shall procure that its Affiliates take such reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any claims (or potential losses or damages) under this Article 12. Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it.

**12.5 Limitation of Liability.** NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS UNDER SECTION 12.1 OR 12.2, OR DAMAGES AVAILABLE FOR BREACH OF SECTION 2.6 OR ARTICLE 10.

**12.6 Insurance.** Each Party shall procure and maintain insurance, including product liability insurance, with respect to its activities hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Product is being clinically tested in human subjects or commercially distributed or sold. Each Party shall provide the other Party with evidence of such insurance upon written request by the other Party and shall provide the other Party with written notice at least [\*] prior to the cancellation, non-renewal or material changes in such insurance. Such insurance shall not be construed to create a limit of either Party's liability under this Agreement.

## **ARTICLE 13 TERMS AND TERMINATION**

**13.1 Term.** The term of this Agreement shall commence upon the Effective Date and continue in full force and effect, on a Product-by-Product and Region-by-Region basis, until the expiration of the Royalty Term for such Product in such Region, unless earlier terminated as set forth in Section 13.2 below (the "Term"). Upon expiration of the Royalty Term with respect to a particular Product in a particular Region, the license granted by Scynexis to Hansoh under Section 2.1 and Section 9.7(b) with respect to such Product and Scynexis Trademarks for such Product in such Region shall remain in effect but shall become fully paid-up, royalty-free, perpetual and irrevocable.

### **13.2 Termination.**

**(a) Termination by Hansoh for Convenience.** At any time, Hansoh may terminate this Agreement in its entirety by providing written notice of termination to Scynexis,

which notice includes an effective date of termination at least [\*] after the date of the notice unless otherwise agreed by the Parties.

**(b) Termination for Material Breach.** If either Party believes that the other is in material breach of its obligations hereunder or material breach of any representation or warranty set forth in this Agreement, then the non-breaching Party may deliver written notice of such breach to the other Party. The allegedly breaching Party shall have [\*] from the date of such notice to cure such material breach. If the Party receiving notice of material breach fails to cure such material breach within the [\*] cure period, then the Party originally delivering the notice of material breach may terminate this Agreement in its entirety upon written notice to the other Party.

**(c) Termination for Insolvency.** Each Party shall have the right to terminate this Agreement in its entirety upon written notice to the other Party in the event that (i) such other Party files in any court or agency pursuant to any statute or regulation of any jurisdiction a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of such other Party or its assets, (ii) such other Party is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within [\*] of its filing, or (iii) such other Party makes an assignment of substantially all of its assets for the benefit of its creditors.

**(d) Termination for Patent Challenge.** If Hansoh or its Affiliates or sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of any Patents owned or Controlled by Scynexis covering a Compound or Product anywhere in the world (a “**Challenged Patent**”), then Scynexis shall be entitled to terminate this Agreement in its entirety by providing written notice to Hansoh of such termination; provided that, if it is a sublicensee that commences such legal action, Scynexis shall give written notice to Hansoh identifying the sublicensee and if such sublicensee has not terminated such legal action within [\*] after such notice to Hansoh, then Scynexis may terminate this Agreement; provided further that (a) this provision shall not apply and Scynexis may not terminate this Agreement if Hansoh or its Affiliate or its sublicensee acquires or is acquired by a Third Party already engaged in a challenge action described above with respect to any Challenged Patent and has not terminated such proceeding [\*] of the closing of such acquisition; and (b) this provision shall not apply to the extent such a provision is prohibited or deemed unenforceable by Applicable Law.

**(e) Termination for FCPA Violation.** Each Party may terminate this Agreement in its entirety upon written notice to the other Party if the other Party or its Affiliates or sublicensees materially breaches FCPA or Section 15.6.

### **13.3 Effect of Termination.**

**(a)** Upon any termination of this Agreement, the following will apply:

**(i) Licenses.** All licenses and other rights granted by Scynexis to Hansoh under the Licensed IP shall terminate and all sublicenses granted by Hansoh shall also terminate. For clarity, the license granted by Hansoh to Scynexis under Section 9.1(b) shall continue. In addition, upon Scynexis’ request, Hansoh shall (and hereby does, but effective only

after termination of this Agreement) grant to Scynexis a non-exclusive, sublicenseable (through multiple tiers), perpetual and irrevocable license under its Arising Product IP (including its interest in jointly owned Arising Product IP) to Develop, use, promote, sell, offer for sale, import and otherwise Commercialize the Compound and Product in the Field in the Territory after the termination of this Agreement, which license shall be (A) royalty bearing as set forth in Section 13.3(b), if this Agreement is terminated by Hansoh under Section 13.2(b), 13.2(c) or 13.2(e); and (B) otherwise, royalty free and fully paid.

**(ii) Regulatory Materials.** Hansoh shall (and shall cause its Affiliates and sublicensees to), as instructed by Scynexis, either (i) if permitted by Applicable Laws, promptly transfer and assign to Scynexis or its designee all Regulatory Materials and Regulatory Approvals for the Product that are held by Hansoh or its Affiliate or sublicensees, (ii) continue to hold any such Regulatory Materials and Regulatory Approvals for the sole benefit of Scynexis or its designee (in which case, Hansoh shall appoint Scynexis or its designee as the exclusive distributor (with the right to subcontract and appoint subdistributors) under such Regulatory Materials and Regulatory Approvals for the Product in the Territory, and also as its agent to interact with the applicable Regulatory Authority in the Territory with respect to such Regulatory Materials and Regulatory Approvals), until such time Scynexis or its designee files its own Regulatory Materials and obtains its own Regulatory Approvals for the Product in the Territory; and/or (iii) terminate or withdraw any such Regulatory Materials and Regulatory Approvals. Upon Scynexis' reasonable written request, Hansoh shall provide Scynexis with reasonable assistance and cooperation regarding any inquiries and correspondence with Regulatory Authorities relating to the Product, and Scynexis shall reimburse Hansoh for the reasonable cost and expense of such assistance and cooperation; provided, that such assistance is limited to [\*] If such assistance is beyond [\*], both Parties will discuss in good faith on the appropriate further arrangement.

**(iii) Data.** Hansoh shall (and shall cause its Affiliates and sublicensees to) promptly transfer and assign to Scynexis, at no cost to Scynexis, all data generated from the Development, Manufacture and Commercialization of the Product, including all Clinical Trials conducted by or on behalf of Hansoh, its Affiliates and sublicensees, and all pharmacovigilance data (including all adverse event databases) relating to the Product in the Territory.

**(iv) Inventory.** Hansoh shall have the right (but not the obligation) to sell or have sold any or all of the inventory of the Product held by Hansoh or its Affiliates or sublicensees as of the date of termination within [\*] after the date of termination; provided that Hansoh continues to pay royalty to Scynexis on the Product sold during such time period.

**(v) Transition Assistance.** Hansoh shall (and shall cause its Affiliates and sublicensees to) reasonably cooperate with Scynexis to facilitate orderly transition of the Development, Manufacture and Commercialization of the Product to Scynexis, including (i) assigning or amending as appropriate, upon request of Scynexis, any agreements or arrangements with Third Party vendors (including distributors) to Develop, Manufacture, supply, promote, distribute, sell or otherwise Commercialize the Product or, to the extent any such Third Party agreement or arrangement is not assignable to Scynexis, reasonably cooperating with Scynexis to arrange to continue to provide such services for a reasonable time after termination; (ii) to the extent that Hansoh or its Affiliate or sublicensee is performing any activities described above in (i), reasonably cooperating with Scynexis to transfer such activities to Scynexis or its

designee, and continuing to perform such activities on Scynexis' behalf for a reasonable time after termination until such transfer is completed, including continuing to Manufacture and supply the Product to Scynexis at cost; and (iii) providing Scynexis with reasonable quantities of materials used or generated by Hansoh, its Affiliates and sublicensees in the Development and Commercialization of the Product in the Territory, such as clinical brochures and promotional materials, or any chemical or biological materials, that were not received from Scynexis.

(vi) **Ongoing Clinical Trials.** If at the time of such termination, any Clinical Trials for the Product are being conducted by or on behalf of Hansoh, its Affiliates or sublicensees, then, at Scynexis' election on a trial-by-trial basis: (i) Hansoh shall (and shall cause its Affiliates and sublicensees to) fully cooperate with Scynexis to transfer the conduct of all such Clinical Trials to Scynexis, and Scynexis shall assume any and all liability and costs for such Clinical Trials after the effective date of such termination; or (ii) Hansoh shall (and shall cause its Affiliates and sublicensees to) at its own cost and expense, orderly wind down in compliance with Applicable Laws the conduct of any such Clinical Trial which is not assumed by Scynexis under clause (i).

(vii) **Return of Confidential Information.** Each Party shall (and shall cause its Affiliates and sublicensees to) promptly return or destroy (at the other Party' election) all tangible materials comprising, bearing or containing any Confidential Information of the other Party that are in the other Party's or its Affiliates' or sublicensees' possession or control; provided that, each Party may retain one (1) copy of such Confidentiality Information in order to comply with Regulatory Authorities, Applicable Law or otherwise enforce and confirm its rights and obligations under this Agreement, and Scynexis may also retain and use Hansoh's Confidential Information in order to exercise its license under Section 9.1(b) and the last sentence of 13.3(a)(i); provided further, that such copy shall remain subject to the confidentiality obligations set forth in Article 10.

(viii) **Publicity.** Neither Party shall, except to the extent required by Applicable Laws, will make any statement to any Third Party, whether written, verbal, electronic other otherwise, that discloses any Confidential Information related to the termination of this Agreement without the prior approval of the other Party.

(ix) **Bankruptcy of Scynexis.** Notwithstanding any other provision of this Agreement to the contrary, the Parties acknowledge and expressly agree that in the event Scynexis becomes a debtor under Title 11 of the United States Code (the "**Bankruptcy Code**"), or such equivalent law in the United States or any other country, and rejects (either as a debtor or on its behalf by a bankruptcy trustee) this Agreement pursuant to Section 365 of the Bankruptcy Code or any such other equivalent law (a "**Bankruptcy Rejection**"), (i) any and all rights of Hansoh arising under or otherwise set forth in this Agreement shall be deemed for purposes of Section 365(n) of the Bankruptcy Code as licenses of right to "intellectual property" pursuant to and in accordance with Section 101 of the Bankruptcy Code regardless of whether such intellectual property is domestic or foreign, and shall include without limitation all trademarks licensed to Hansoh under this Agreement, and all such intellectual property shall be fully retained by and vested in Hansoh as protected (or deemed to be protected) intellectual property rights under Section 365(n) of the Bankruptcy Code regardless of whether Scynexis files for bankruptcy in the United States or other jurisdiction; (ii) Hansoh shall have all of the rights and elections afforded

to non-debtor licensees under Section 365(n) of the Bankruptcy Code, and in the event Hansoh elects to retain its rights to all intellectual property licensed to it under this Agreement in accordance with Section 365(n), Hansoh shall be entitled to a complete duplicate of or complete access to any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments thereof shall be promptly delivered to Hansoh (i) upon any such commencement of a bankruptcy proceeding by or against Scynexis upon written request therefor by Hansoh, unless Scynexis (or the equivalent of a bankruptcy trustee appointed in the bankruptcy proceeding) elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the Bankruptcy Rejection of this Agreement upon written request therefor by Hansoh. Hansoh shall under no circumstances be required to terminate this Agreement after a Bankruptcy Rejection in order to enjoy or acquire any of its rights under this Agreement.

**(b) Royalty on Reversion License.** If this Agreement is terminated by Hansoh under Section 13.2(b), 13.2(c) or 13.2(e), then the license granted by Hansoh to Scynexis under the last sentence of Section 13.3(a)(i) shall be royalty bearing in the Territory at the applicable royalty rate set forth in the table below based on the timing of the termination:

The effective date of termination	Royalty rate
1)[*]	[*]
2)[*]	[*]
3)[*]	[*]

If such license is royalty bearing, then the definition of Net Sales and Section 8.5 shall apply *mutatis mutandis* with respect to the royalty payment from Scynexis to Hansoh on the sale of the Product in the Territory after termination.

**(c) In Lieu of Termination.** If Hansoh is entitled to terminate this Agreement under 13.2(b) (Termination for Material Breach), Hansoh may, at its sole discretion, upon written notice to Scynexis, elect not to do so and notwithstanding anything to the contrary in this Agreement, all applicable royalties, milestones and other amounts due to Scynexis under this Agreement after the date of such notice shall be reduced by [\*], provided, however, that Hansoh’s payments to Scynexis will in no event be less than the amounts Scynexis is obligated to pay to Merck under the Upstream Agreement.

**13.4 Survival.** Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Without limiting the foregoing, the following provisions shall survive the termination or expiration of this Agreement for any reason: Article 1 (to the extent such definitions are used), Article 8 (to the extent the obligation to make payment accrued prior to the effective date of termination of this Agreement), Section 9.1(b), Sections 9.1(c) and 9.2 (with respect to jointly owned Arising Product IP only), Article 10 (for the period of time set forth in Section 10.1), Article 12 (excluding Section 12.6), Article 13 through 15 (inclusive but excluding 15.6).

**13.5 Termination Not Sole Remedy.** Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein.

## **ARTICLE 14 DISPUTE RESOLUTION**

**14.1 Disputes.** The Parties recognize that disputes as to certain matters may from time to time arise during the Term which relate to either Party's rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 14 to resolve any controversy or claim arising out of, relating to or in connection with any provision of this Agreement, if and when a dispute arises under this Agreement.

**14.2 Internal Resolution.** With respect to all disputes arising between the Parties under this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute within [\*] after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to the Executive Officers of the Parties for attempted resolution by good faith negotiations within [\*] after such notice is received.

### **14.3 Binding Arbitration.**

**(a)** If the Parties fail to resolve the dispute through escalation to the Executive Officers under Section 14.2, and a Party desires to pursue resolution of the dispute, the dispute shall be submitted by either Party for resolution in arbitration administered by the International Chamber of Commerce ("ICC") pursuant to its arbitration rules and procedures then in effect.

**(b)** The arbitration shall be conducted by a panel of three arbitrators experienced in the pharmaceutical business: within [\*] after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator (who shall be the chairperson of the arbitration panel) within [\*] of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by ICC. If, however, the aggregate award sought by the Parties is less than [\*] and equitable relief is not sought, the arbitration shall be conducted by a single arbitrator agreed by the Parties (or appointed by ICC if the Parties cannot agree).

**(c)** The seat and location of the arbitration shall be London, United Kingdom (provided however that the Parties may agree to conduct the arbitration proceeding (or any part thereof) by teleconference if travel is restricted) and the language of the proceedings shall be English. The arbitral tribunal shall determine the dispute by applying the provisions of this Agreement and the governing law set forth in Section 15.5. The Parties agree that any award or decision made by the arbitral tribunal shall be final and binding upon them and may be enforced in the same manner as a judgment or order of a court of competent jurisdiction.

(d) By agreeing to arbitration, the Parties do not intend to deprive any court of its jurisdiction to issue, at the request of a Party, a pre-arbitral injunction, pre-arbitral attachment or other order to avoid irreparable harm, maintain the status quo, preserve the subject matter of the dispute, or aid the arbitration proceedings and the enforcement of any award. Without prejudice to such provisional or interim remedies in aid of arbitration as may be available under the jurisdiction of a competent court, the arbitral tribunal shall have full authority to grant provisional or interim remedies and to award damages for the failure of any Party to the dispute to respect the arbitral tribunal's order to that effect.

(e) Each Party shall bear its own attorney's fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the administrator and the arbitrator; provided, however, the arbitrator shall be authorized to determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys' fees, costs and disbursements (including, for example, expert witness fees and expenses, travel expenses, etc.), and/or the fees and costs of the administrator and the arbitrator.

(f) Notwithstanding anything in this Section 14.3, in the event of a dispute with respect to the validity, scope, enforceability or ownership of any Patent or other intellectual property rights, and such dispute is not resolved in accordance with Section 14.2, such dispute shall not be submitted to an arbitration proceeding in accordance with this Section 14.3, unless otherwise agreed by the Parties in writing, and instead either Party may initiate litigation in a court of competent jurisdiction in any country in which such rights apply.

## **ARTICLE 15 MISCELLANEOUS**

**15.1 Force Majeure.** Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, pandemic, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God or any other deity, or acts, omissions or delays in acting by any Governmental Authority. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake reasonable efforts necessary to mitigate such force majeure circumstances. For the avoidance of doubt, the Parties acknowledge and agree that a Party's ability to perform its obligations under this Agreement after the Effective Date may be affected by the COVID-19 pandemic ongoing at the time of execution of this Agreement.

### **15.2 Assignment.**

(a) Except as express permitted herein, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party. Any attempted assignment not in accordance with this Section 15.2 shall be null and void and of no legal effect. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. The terms

and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns.

**(b)** Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of such Party (so long as such entity remains an Affiliate), or in whole to its successor-in-interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction.

**(c)** Notwithstanding the foregoing, Scynexis may, without consent of Hansoh (but with prior written notice to Hansoh), sell or otherwise assign to any Third Party Scynexis' right to receive any payment (or portion thereof) from Hansoh under this Agreement, and/or grant a security interest in its rights, title and interest in and to this Agreement.

**(d)** Any permitted successor or assignee of rights or obligations hereunder will, in a writing to the other Party, expressly assume performance of such rights or obligations (and in any event, any Party assigning this Agreement to an Affiliate will remain bound by the terms and conditions hereof). Any permitted assignment will be binding on and inure to the benefit of the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 15.2 will be null, void and of no legal effect.

**15.3 Severability.** If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.

**15.4 Notices.** All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile or email (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

If to Scynexis:

Scynexis, Inc.  
Evertrust Plaza, 13th Floor  
Jersey City, NJ 07302  
USA  
Attn: Marco Taglietti  
Email: [\*]



with a copy to:

Cooley LLP  
IFC – Tower 2, Level 35, Unit 3510  
8 Century Avenue  
Pudong New Area  
Shanghai, China 200120  
Attn: Christina Zhang  
Email: [\*]

with a copy to:

Cooley LLP  
3175 Hanover Street  
Palo Alto, CA 94304-1130  
Attn: Matthew Hemington  
Email: [\*]

If to Hansoh:

Hansoh Bio LLC  
9900 Medical Center Drive, #200  
Rockville, MD 20850  
Attn: Zhen Yang  
Email: [\*]

with a copy to:

Morgan, Lewis & Bockius LLP  
1701 Market Street  
Philadelphia, PA 19103  
Attn: Aaron D. Suh  
Email: [\*]

with a copy to:

Morgan, Lewis & Bockius LLP  
One Market, Spear Street Tower  
San Francisco, CA 94105  
Attn: Key Shin  
Email: [\*]

or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a Business Day; (b) on the fifty (5<sup>th</sup>) Business Day after dispatch if sent by internationally-recognized overnight courier; or (c) on the eighth (8<sup>th</sup>) Business Day following the date of mailing if sent by mail.

**15.5 Governing Law.** This Agreement shall be governed by and construed in accordance with the laws of the State of New York, U.S., without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction. The application of the U.N. Convention on Contracts for the International Sale of Goods is excluded.

**15.6 Foreign Corrupt Practices Act Compliance.**

**(a) Compliance with FCPA.** The U.S. government imposes and enforces prohibitions on the payment or transfer of anything of value to governments, government officials, political parties or political party officials (or relatives or associates of such officials) (“**FCPA Covered Person**”) for the purpose of illegally influencing them, whether directly or indirectly, to obtain or retain business. This U.S. law is referred to as the Foreign Corrupt Practices Act (“**FCPA**”), and it can have application to conduct of a U.S. corporation’s foreign subsidiaries, employees, agents and distributors. A summary of the law and related information can be found at <http://www.justice.gov/criminal/fraud/fcpa>. By signing this Agreement, each Party represents, warrants and covenants (as applicable) to the other Party that:

- (i)** it is familiar with the provisions and restrictions contained in the OECD Convention and FCPA;
- (ii)** it shall comply with the FCPA in the Development and Commercialization of the Product inside and outside of the Territory;
- (iii)** it shall not, in the course of its duties under the Agreement, offer, promise, give, demand, seek or accept, directly or indirectly, any gift or payment, consideration or benefit in kind to any FCPA Covered Person that would or could be construed as an illegal or corrupt practice;
- (iv)** it is not an FCPA Covered Person or affiliated with any FCPA Covered Person; and
- (v)** it shall immediately notify the other Party of any attempt by any FCPA Covered Person to directly or indirectly solicit, ask for, or attempt to extort anything of

value from it, its Affiliates or sublicensees, and shall refuse any such solicitation, request or extortionate demand except a facilitating payment as expressly permitted under the FCPA.

**(b) No Action.** In no event shall any Party be obligated under the Agreement to take any action or omit to take any action that such Party believes, in good faith, would cause it to be in violation of any applicable laws and regulations, including the anti-bribery laws referenced in this Section 15.6.

**15.7 Entire Agreement; Amendments.** The Agreement, together with the Exhibits attached hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. All express or implied agreements and understandings, either oral or written, with regard to the subject matter hereof (including the licenses granted hereunder) are superseded by the terms of this Agreement. Neither Party is relying on any representation, promise, nor warranty not expressly set forth in this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto.

**15.8 Headings.** The captions to the several Sections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the Sections of this Agreement.

**15.9 Independent Contractors.** It is expressly agreed that Scynexis and Hansoh shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Scynexis nor Hansoh shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.

**15.10 Waiver.** The waiver by either Party of any right hereunder, or the failure of the other Party to perform, or a breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.

**15.11 Cumulative Remedies.** No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.

**15.12 Waiver of Rule of Construction.** Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.

**15.13 Business Day Requirements.** In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day.

**15.14 English Language.** This Agreement is in the English language only, which language shall be controlling in all respects, and all versions hereof in any other language shall be

for accommodation only and shall not be binding upon the Parties. All communications and notices to be made or given pursuant to this Agreement, and any dispute proceeding related to or arising hereunder, shall be in the English language. If there is a discrepancy between any translation of this Agreement and this Agreement, this Agreement shall prevail.

**15.15 Further Actions.** Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement.

**15.16 Construction.** Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”, (c) the word “will” shall be construed to have the same meaning and effect as the word “shall”, (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person shall be construed to include the person’s successors and assigns, (f) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, Schedules, or Exhibits shall be construed to refer to Sections, Schedules or Exhibits of this Agreement, and references to this Agreement include all Schedules and Exhibits hereto, (h) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree”, “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or Section, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term “or” shall be interpreted in the inclusive sense commonly associated with the term “and/or.”

**15.17 Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party shall be entitled to rely on the delivery of executed facsimile copies of counterpart execution pages of this Agreement and such facsimile copies shall be legally effective to create a valid and binding agreement among the Parties.

{Signature Page Follows}

IN WITNESS WHEREOF, the Parties intending to be bound have caused this Exclusive License and Collaboration Agreement to be executed by their duly authorized representatives as of the Effective Date.

SCYNEXIS, INC.

JIANGSU HANSOH PHARMACEUTICAL GROUP  
COMPANY LIMITED

By: /s/ Marco Taglietti

By: /s/ Yuan Sun

Name: Marco Taglietti, M.D.

Name: Yuan Sun

Title: President and CEO, SCYNEXIS

Title: Executive Director of the Board

Date: February 12, 2021

Date: February 11, 2021

HANSOH (SHANGHAI) HEALTH TECHNOLOGY CO., LTD.

By: /s/ Yuan Sun

Name: Yuan Sun

Title: Executive Director of the Board

Date: February 11, 2021 \_\_\_\_\_

---

## List of Exhibits

<b>Exhibit A:</b>	<b>Compound Structure</b>
<b>Exhibit B:</b>	<b>Existing Licensed Patents</b>
<b>Exhibit C:</b>	<b>Upstream Agreements</b>
<b>Exhibit D:</b>	<b>Initial Development Plan</b>
<b>Exhibit E:</b>	<b>Initial Technology Transfer Plan</b>
<b>Exhibit F:</b>	<b>Initial Clinical Trial Participation Plan</b>
<b>Exhibit G:</b>	<b>Terms of Supply Agreement</b>
<b>Exhibit H:</b>	<b>Transfer of Manufacturing Documents</b>
<b>Exhibit I:</b>	<b>Scynexis Trademarks</b>
<b>Exhibit J:</b>	<b>Joint Press Release</b>

[\*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) is the type of information that SCYNEXIS, Inc. treats as private or confidential.

## MASTER SERVICES AGREEMENT

THIS MASTER SERVICES AGREEMENT (the “**Agreement**”), effective as of **February 4, 2021** (the “**Effective Date**”), is by and between **SCYNEXIS, Inc., a corporation with offices at 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302** (“**Client**”) and **Amplity, Inc.**, with its principal place of business at 1000 Floral Vale Boulevard, Yardley, PA 19067 (“**Company**”). Client and Company are sometimes referred to herein individually as a “**Party**” and collectively as the “**Parties**”.

**WHEREAS**, Company is a services provider offering field, contact center, recruiting and other related services in the pharmaceutical industry; and

**WHEREAS**, Client is a biopharmaceutical company developing and planning to market novel drug therapies; and

**WHEREAS**, Client wishes to engage Company to provide the services as further described herein.

**NOW, THEREFORE**, in consideration of the premises and the mutual promises contained herein, and intending to be legally bound, the Parties hereto agree as follows:

### ARTICLE I AGREEMENT FRAMEWORK AND STRUCTURE

**1.1 Purpose of the Agreement.** The purpose of this Agreement is to establish an ongoing services arrangement between Client and Company for the provision of certain services in relation to Client’s product(s), as further described herein and in Statements of Work issued between the Parties from time to time, a form of which is attached as Exhibit A (each an “SOW”). Services may include, but may not be limited to, recruiting services, remote engagement center services, field services and other enhanced services as may be provided by Company from time to time (collectively the “Services”).

**1.2 Execution of Statements of Work.** Company shall provide Services only in accordance with an executed SOW, the terms of which shall include, at a minimum, a description of the Services to be provided, the anticipated period of performance, fees, payment terms and any other applicable terms and conditions as agreed to by the Parties.

## ARTICLE II SERVICES

**2.1 Scope of Services.** During the term of this Agreement, Company may provide to Client, in accordance with the terms of an executed SOW, one or more of the following Services:

- (a) Direct to Hire Recruiting;
- (b) Field Sales Services;
- (c) Field Medical and Patient Support services, and Nurse Educator services;
- (d) Remote Engagement services, including sales and non-sales;
- (e) Consulting services, including Capability Development services;
- (f) Other Contract Commercial services as may be agreed by the Parties from time to time.

**2.2 Use of Subcontractors or Third Party Vendors.** Company may, from time to time, engage Subcontractors to perform certain functions which are integral to the Services or Third Party Vendors to perform certain functions which are ancillary to the Services. In all such cases, the following shall apply.

2.2.1 Subcontractors. Client agrees that Company will be free to engage Subcontractors to provide Services to Client, with the consent of the Client not to be unreasonably withheld. The term “Subcontractor” shall mean any third party engaged by Company in connection with the Services to perform work integral to the Services which would customarily be performed solely and directly by Company. Company hereby assumes responsibility for the performance of such Subcontractors as if work performed by Subcontractor were performed by Company. Company shall ensure that Subcontractors comply with the terms and conditions of this Agreement in all material respects.

2.2.2 Third Party Vendors. Client agrees that Company may engage Third Party Vendors from time to time, to be communicated to Client in advance. The term “Third Party Vendor” shall mean a supplier of goods and/or services which are ancillary to or supplement the Services to be performed by Company hereunder and which Company engages on Client’s behalf but does not otherwise exercise any direct authority or control. Company shall use reasonable efforts to ensure Third Party Vendors comply with the terms and conditions of this Agreement in all material respects, provided, however, Company makes no representations or warranties with respect to such Third Party Vendors and shall not be liable for the performance of the same. Company shall notify Client in advance of any costs associated with the engagement of Third Party Vendors and no such costs shall be incurred without Client’s advance written approval. Execution of an SOW in which a Third Party Vendor is identified shall constitute written approval for purposes of this Section 2.3.2.



**ARTICLE III**  
**JOINT STEERING COMMITTEE**

**3.1 Formation.** On or within thirty (30) days after the Effective Date, the Parties shall establish a joint steering committee (“Joint Steering Committee” or “JSC”) to oversee and manage the relationship between the parties solely with respect to the Product, and to serve as a forum for review and discussion of promotional and marketing activities with respect to the Product in the United States. Without limiting the foregoing or any other functions the Parties agree to assign to the Joint Steering Committee and the Joint Steering Committee shall perform the following, as applicable:

- (a) Provide input and review the commercial plan for the Product and any annual updates thereto;
- (b) Reviewing key performance indicators and agreeing on changes indicated
- (c) establishing subcommittees of the JSC (e.g. a Operations Committee or a Compliance Committee);
- (d) such other functions as may be mutually agreed upon by the Parties from time to time.

**3.2 Membership and Governance of the JSC.**

3.2.1 Each Party shall select up to four (4) representatives to serve on the Joint Steering Committee. The Parties may replace its Joint Steering Committee representatives at any time, on written notice to the other Party. The parties shall ensure that all of their appointed members are of a suitable level of expertise, seniority and decision-making authority to deal with the issues that may arise in connection with matters to be considered by the JSC. The initial membership of the JSC shall be as follows: for Scynexis: the Chief Commercial Officer, VP of Medical Affairs, VP Sales and Marketing; head of Market Access; for Amplity it shall be a Head of Client Engagement, Chief Commercial Officer, the Project General Manager, and its Market Access practice

3.2.2 The JSC shall exercise its authority in good faith and in accordance with the terms of this Agreement. The JSC shall have no decision-making rights or responsibilities and no authority to bind the Parties, unless the Parties expressly delegate matters to the JSC. The Joint Steering Committee shall not have authority to amend or modify this Agreement.

**3.3 Meetings of the JSC.**

3.3.1 At least fourteen days (14) days prior to each regularly scheduled meeting of the JSC, notice shall be given to each member by the Party convening the meeting and at least ten (10) days prior to each such meeting, each Party shall provide to the other all written information expected to be disclosed at such meeting. In addition, special meetings of the JSC may be called on such shorter notice period as may be agreed between the Parties.

3.3.2 SCYNEXIS shall designate a JSC chairperson. The chairperson of the JSC shall set meeting agendas for the JSC, which shall include any matter that either party requests to be included. Such agendas shall be circulated to all members at least ten (10) business days prior to

the date of the relevant meeting. The JSC chairperson shall be responsible for recording, preparing and (within ten (10) business days) issuing draft minutes of the JSC meetings, which draft minutes shall be reviewed, modified and reasonably approved in writing by the all JSC members.

3.3.3 Other representatives of the Parties may attend Joint Steering Committee meetings as non-standing members.

3.3.4 The JSC shall have its first meeting within forty-five (45) days after the Effective Date, and thereafter shall hold meetings at least once per Calendar Quarter, or as frequently as otherwise agreed by the Parties, by telephone or video conference. Where possible, JSC meetings shall be held two weeks prior to the SCYNEXIS Board meetings.

3.3.5 Each party shall bear its own costs for its members to attend JSC meetings and, as applicable, for its obligations to host such meetings.

#### **ARTICLE IV** **RESPECTIVE OBLIGATIONS OF THE PARTIES**

#### **4.1 Obligations of Company.**

4.1.1 Company shall perform the Services in accordance with all laws governing the commercialization of prescription drugs applicable to its obligations hereunder, including but not limited to those pertaining to fraud and abuse, anti-kickback, physician self-referrals, off label promotion, interactions with healthcare professionals (“Applicable Laws”) and Client’s codes of conduct, as agreed.

4.1.2 Company shall perform such Services in accordance with the terms of an applicable SOW, prevailing industry professional and technical standards applicable thereto and shall employ only those personnel qualified with the technical skills, training, and experience needed to perform such Services.

#### **4.2 Obligations of Client.**

4.2.1 Client shall provide Company in a timely manner, all necessary information and materials which are reasonably required in order for Company to perform the Services, including such for training and content briefing.

4.2.2 Client shall provide Company with reasonable access to its employees and/or facilities as necessary in order for Company to provide the Services.

4.2.3 Client shall provide timely approval prior to Company’s performance of any Services, such approval not to be unreasonably withheld or delayed. Company shall not be responsible for any Services delays that result from Client’s unreasonable delay in providing approvals as contemplated herein.

4.2.4 Client shall be responsible for the truth, accuracy, and completeness of its promotional materials and all other information concerning its organization, products, services, competitors or its industry that Client furnishes to Company for use in providing the Services.

**ARTICLE V**  
**FEES AND INVOICING TERMS**

**5.1** Client shall pay Company the Fees for Services as set forth in an applicable SOW. Company shall submit invoices to Client in accordance with the payment schedule set forth in each applicable SOW, referencing the appropriate purchase order number (if applicable). Client shall pay all undisputed portions of invoices within [\*] from the date it receives the invoice. In addition to all other remedies Company may have, all past due payments will be subject to a late charge of 1% per month or such lower rate if required by applicable law.

**5.2** Should Client dispute any portion of an invoice, Client shall pay all undisputed amounts and provide Company written notice of the dispute within thirty (30) days of the date Client received the original invoice. The Parties shall negotiate in good faith to resolve the dispute within sixty (60) days after Company's receipt of notice thereof. Once resolved, if necessary, Company will issue a corrected invoice to Client and Client shall pay such corrected invoice within [\*] of receipt of the corrected invoice.

**ARTICLE VI**  
**CHANGES AND MODIFICATIONS**

**6.1** No changes or modifications to this Agreement shall be valid or enforceable unless agreed to in a written amendment, executed by both Parties.

**6.2** Client and Company may amend certain obligations related to the Services by written addendum to an SOW. In the event any change or modification to the Services results in an increase or decrease in Fees, Company and Client shall negotiate such Fee adjustments promptly and in good faith.

**ARTICLE VII**  
**REPRESENTATIONS AND WARRANTIES**

**7.1** Company represents and warrants to Client that Company (i) has the power and authority to enter into and perform its obligations under this Agreement; (ii) it is subject to no restrictions that would prevent its ability to perform its obligations under this Agreement; (iii) it possesses the skills, expertise and resources required to perform the Services in a professional manner, consistent with industry standards and in compliance with all Applicable Laws and regulations and (iv) to the best of its knowledge, no officers, directors, employees or subcontractors directly performing Services hereunder is listed by any US Federal agency as, or is the subject of an investigation or process that could result in, being suspended, debarred, excluded or otherwise ineligible to participate in Federal procurement or non-procurement programs.

**7.2** Client represents and warrants to Company that Client: (i) has the power and authority to enter into and perform its obligations under this Agreement; and (ii) is subject to no restrictions that would impair its ability to perform its obligations under this Agreement; and (iii) shall comply with all Applicable Laws and regulations in relation to the Services provided and performing its obligations under this Agreement.

## **ARTICLE VIII** **INDEMNIFICATION**

**8.1** Company shall indemnify, defend, and hold Client, its affiliates, directors, officers, and employees (collectively, the “Client Indemnitees”) harmless from and against any and all loss, liability, claim, damage, and expense, injury or alleged injury to third parties including reasonable attorney and litigation fees (collectively, “Losses”) that Client may incur resulting from any third party claim, suit or proceeding made or brought against Client relating to the performance of its obligations hereunder and arising from Company’s (i) negligence or willful misconduct, and/or (ii) breach of its representations and warranties under this Agreement; provided, however, that Company shall not be obligated to indemnify Client for any Losses to the extent that such Losses result from (a) the breach of this Agreement or any SOW by Client or the negligence or willful misconduct of any of the Client Indemnitees. Client shall give Company prompt written notice of any indemnifiable claim hereunder. Company’s obligation to indemnify Client shall survive the expiration or termination of this Agreement.

**8.2** Client shall indemnify, defend, and hold Company, its affiliates, directors, officers, and employers (collectively, the “Company Indemnitees”) harmless from and against any and all Losses Company may incur resulting from any third party claim, suit or proceeding made or brought against Company relating to the performance of its obligations hereunder and arising from: (i) Client’s negligence or willful misconduct, and/or (ii) a breach of its representations and warranties under this Agreement; (iii) product or other information, data or materials submitted by or on behalf of Client to Company Indemnitee, including without limitation any information, data or materials provided to Company by a third-party provider; (iv) the manufacture, promotion, sale, distribution or use of any of Client’s products or services (including, but not limited to, product liability claims, personal injury, death and claims that such manufacture, sale and/or distribution violates the rights of any third parties or that the advertising, publicity or promotion of Client’s products or services encourages or induces the violation of the rights of any third parties); (v) Company’s following of Client’s instructions; and (vi) for all claims in anyway related to the use of a Client owned motor vehicle; provided, however, except for the indemnity provided in Section 8.2(vi) for which there shall be no exceptions, Client shall not be obligated to indemnify Company for any Losses to the extent that such Losses result from the breach of this Agreement or any SOW by Company or the negligence or willful misconduct of the Company Indemnitees. . Company shall give Client prompt written notice of any indemnifiable claim hereunder. Client’s obligation to indemnify the Company Indemnitees shall survive the expiration or termination of this Agreement.

**8.3** For the purposes of this Article VIII, the indemnifying party shall have the right to control the defense and settlement (upon terms reasonably acceptable to the indemnitee) of any and all

claims, suits or administrative proceedings to which these indemnities relate. The indemnified party shall cooperate fully in the defense of any and all such claims, suits or administrative proceedings.

**8.4** Client shall reimburse Company under this Agreement. However, Client shall have no obligation to reimburse Company for any such expenses arising out of, in connection with or otherwise relating to actions or omissions of Company or its employees, officers, directors and/or affiliates that violate this Agreement or applicable law.

Company shall reimburse Client for all reasonable, actual, out-of-pocket expenses incurred by Client in connection with its response to any subpoena or other similar legal orders issued to Client in respect to any investigation where Company is the target. However, Company shall have no obligation to reimburse Client for any such expenses arising out of, in connection with or otherwise relating to actions or omissions of Client or its employees, officers, directors and/or affiliates that violate this Agreement or Applicable Laws.

**8.5** NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, LOSS OF PROFIT, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES OF ANY KIND WHATSOEVER.

**8.6** COMPANY SHALL NOT BE LIABLE FOR DAMAGES WHICH EXCEED TWELVE (12) MONTHS OF FEES IDENTIFIED IN THE APPLICABLE SOW AND PAID BY CLIENT FOR THE APPLICABLE SERVICES UNDER THE APPLICABLE SOW FROM WHICH THE CLAIM AT ISSUE ARISES.

## **ARTICLE IX** **CONFIDENTIALITY**

**9.1** Each Party (the "Receiving Party") shall keep in strict confidence all proprietary and confidential information (the "Confidential Information") supplied to it by the other Party (the "Disclosing Party") and shall not disclose such Confidential Information to any third party except with the prior written approval of the Disclosing Party. The Receiving Party will not disclose any Confidential Information except to its employees, agents and affiliates on a need-to-know basis and under the same obligations of confidentiality as contained in this Agreement, and will not use any Confidential Information except for to perform its obligations hereunder. The Receiving Party agrees that any Confidential Information disclosed to it by the Disclosing Party will remain the sole and exclusive property of the Disclosing Party and will be returned or destroyed at the request of the Disclosing Party, but in any event not later than thirty (30) days from the date of such request or on termination of this Agreement. Notwithstanding the foregoing provision, each Party may retain one copy of Confidential Information in its confidential files solely for archival purposes and any Confidential Information automatically stored as part of its electronic back-up procedures, provided such Confidential Information cannot be accessed in the ordinary course of business.

**9.2** The confidentiality obligation does not apply to any Confidential Information that the Receiving Party can establish by its contemporaneous written records:

- (a) was publicly known, or otherwise known by the Receiving Party, prior to disclosure by the Disclosing Party;
- (b) became publicly known after disclosure by the Disclosing Party without fault of the Receiving Party;
- (c) was received by the Receiving Party from a third party not under obligations of confidentiality with respect to the disclosure of such information; or
- (d) was independently developed by the Receiving Party without the use of any Confidential Information.

**9.3** In the event that the Receiving Party or anyone to whom it transmits the Confidential Information pursuant to this Agreement becomes legally required in any proceeding to disclose any of the Disclosing Party's Confidential Information, the Receiving Party shall, to the extent permitted by law and practicable, provide the Disclosing Party with prompt notice so that the Disclosing Party may either seek a protective order or other appropriate remedy and/or waive in writing compliance with the provisions of this Agreement and the Receiving Party will cooperate with the Disclosing Party in connection with seeking any such relief. In the event that such protective order or other similar remedy is not obtained, the Receiving Party shall furnish only that portion of the Confidential Information that it is required to furnish under applicable law, as determined by counsel for the Receiving Party. The obligations of this Article IX shall survive termination of the Agreement for a period of five (5) years.

## **ARTICLE X**

### **OWNERSHIP; INTELLECTUAL PROPERTY**

**10.1** Subject to payment by Client of all undisputed amounts payable under the applicable SOW, Company hereby assigns to Client all data, information, reports, results, and writings produced in final form and expressly identified as Work Product in an SOW ("Work Product") and all right, title, and interest in and to Work Product will be the sole and exclusive property of Client. Company will promptly disclose to Client any Work Product arising hereunder. Upon assignment, any Work Product resulting from the Services will be deemed "works for hire" to the extent permitted by U.S. copyright law.

**10.2** Notwithstanding anything to the contrary, in no event shall Client have any title or right to, and Company shall be the sole and exclusive owner of, any Company's proprietary business information, methods, processes, techniques, procedures or software, including, without limitation documentation, .fla files, object code, protected libraries, source code and development tools used, created or developed by Company either independently or in concert with any third party prior to, during or after Company's performance of Services hereunder; databases of information and specialized database applications, software applications, computer programming and/or coding developed by or for Company (other than any confidential, proprietary information, programs,

databases or applications specifically provided by Client to Company for use by Company in the performance of services hereunder) (“Company Materials”); *provided, however*, that effective upon assignment of the Work Product pursuant to Section 10.1, Company shall grant to Client, its successors, and assigns, the royalty-free, worldwide, paid-up, nonexclusive right and license, to the extent required by Client to use, execute, reproduce, display, and perform Company Materials which are embedded in or made an essential part of any Work Product to allow Client to exercise its full rights in such Work Product, solely as contemplated herein and in the applicable SOW.

**10.3** As part of its continuing program to monitor and improve its services generally, Company collects, analyzes, and uses certain data derived from the Services and from similar services provided to all of its clients. In doing so, Company may not share with any third party data that is created for Client as a Service or which otherwise reveals the identity of Client or its Confidential Information. From time to time, Company may share its findings with Client for benchmarking and other purposes.

**ARTICLE XI**  
**TAXES**

Any sales or use taxes or other taxes, fees, duties or levies (other than taxes on Company’s or an affiliate’s income and/or any personal property taxes) assessed in any state as a result of the Services covered by this Agreement shall be the sole responsibility of Client and Client shall indemnify and hold Company harmless for any failure of Client to pay any such taxes.

**ARTICLE XII**  
**INSURANCE**

**12.1** Company shall obtain and maintain during the term of this Agreement, at its sole expense, insurance policies in the following minimum amounts:

**Commercial General Liability Insurance**

Occurrence form including premises - operations coverage, products - completed operations coverage, coverage for independent Contractors, personal injury coverage and blanket contractual liability.

Limits of Liability

General Aggregate	\$2,000,000
Products - Completed Ops Aggregate	\$2,000,000
Personal & Adv. Injury Aggregate	\$2,000,000
Each Occurrence Limit	\$1,000,000

## **Worker's Compensation**

### Limits of Liability

Worker's Compensation	Statutory
Employer's Liability	
Each Accident	\$500,000
Policy Limit - Disease	\$500,000
Each Employee - Disease	\$500,000

Coverage shall include all states in which operations are conducted.

## **Umbrella Insurance**

### Limits of Liability

Annual Aggregate	\$1,000,000
Per Occurrence Limit	\$1,000,000

## **Automobile Liability Policy**

### Limits of Liability

\$1,000,000

**12.2** Client shall obtain and maintain during the term of this Agreement, at its sole expense, insurance policies in the following minimum amounts:

### Commercial General Liability Insurance

Occurrence form including premises - operations coverage, coverage for independent Contractors, personal injury coverage and blanket contractual liability.

### Limits of Liability

General Aggregate	\$2,000,000
Personal & Adv. Injury per Occurrence	\$4,000,000
Automobile Liability per Occurrence	\$1,000,000

Products Completed Operations coverage with \$5,000,000 per occurrence limit. If coverage is on a claims-made form, the policy must be kept for 3 years after the end of the contract.

**12.3** During the term of this Agreement, Company and Client shall not permit the required insurance coverage(s) to be reduced, expired, or canceled without reasonable written notice to the other Party. Upon request, each Party shall provide a Certificate of Insurance to the other Party.



**ARTICLE XIII**  
**TERM AND TERMINATION**

**13.1** This Agreement shall commence on the Effective Date and shall continue until terminated in accordance with the provisions contained in this Agreement.

**13.2** Except as otherwise agreed in an SOW, either Client or Company shall have the right to terminate this Agreement or any SOW, in whole or in part, to which it is a party, at any time, without cause, upon [\*] written notice to the other Party to such SOW (the "Termination Notice"). Unless otherwise expressly provided herein, any termination of this Agreement or a SOW hereunder shall be effective as of the last day of the applicable notice period or cure period (the "Termination Effective Date"). In the case of any termination, Client shall pay Company for all Services agreed to, work performed and expenses incurred by Company prior to the Termination Effective Date, as well as for all pre-approved, non-cancelable commitments incurred by Company prior to the Termination Effective Date. In addition, Client shall pay for any termination fees agreed to in an executed SOW.

**13.3** Company may terminate this Agreement or any SOWs hereunder upon [\*] written notice to Client if Client fails to make any payment to Company under this Agreement when due.

**13.4** In the event Company or Client becomes insolvent, makes an assignment for the benefit of creditors, files a petition for bankruptcy, is the subject of a petition in bankruptcy which is not dismissed within [\*] from the filing thereof, becomes the subject of any receivership proceeding or admits in writing its inability to pay its debts generally as they become due, the other Party may immediately terminate this Agreement by written notice of termination to the other Party.

**13.5** In the event either Party breaches a material obligation hereunder (the "Breaching Party"), the other Party (the "Non-Breaching Party") may give the Breaching Party notice specifying in reasonable detail the breach and requesting that the breach be cured (the "Cure Notice"). If the Breaching Party fails to cure the specified breach within [\*] after receipt of the Cure Notice, the Non-Breaching Party shall have the right to terminate this Agreement for cause effective upon notice to the Breaching Party (the "Termination for Cause Notice"). The Non-Breaching Party's right to terminate this Agreement under this paragraph shall automatically expire if the Breaching Party has cured the breach prior to receipt of the Termination Notice as evidenced by written agreement by the Non-Breaching Party that the breach has been cured. The Non-Breaching Party's right to terminate shall be in addition to any other rights and remedies it may have hereunder in law or in equity.

**ARTICLE XIV**  
**MISCELLANEOUS PROVISIONS**

**14.1** Force Majeure. Each Party shall be excused from the performance of its obligations under this Agreement in the event such performance is prevented by conditions arising out of an event of Force Majeure. For purposes of this Agreement, a Force Majeure event shall mean conditions beyond the reasonable control of the Party asserting existence of such conditions, including acts of God, acts of nature, epidemic, pandemic, regulation or law of any government, war, civil commotion, terrorists, or similar events which are entirely outside of a Party's control. Each Party shall use reasonable efforts to notify the other Party as promptly as practicable under the circumstances if it anticipates any delay in performance accordingly and shall resume its obligations promptly upon cessation of the Force Majeure event at issue. Each Party shall have the right to terminate this Agreement without penalty should any Force Majeure event continue, uninterrupted, for a period of sixty (60) days or more.

**14.2** Notices. Any notice required or permitted to be given under this Agreement to any Party shall be given by sending such notice, in writing, by certified mail, nationally recognized overnight courier or personally delivered to the addresses set forth below:

If to Client:  
**Scynexis, Inc.**  
1 Evertrust Plaza  
13th Floor  
Jersey City, NJ 07302  
Attn: General Counsel

If to Company:  
**Amplity, Inc.**  
Attn: Chief Financial Officer  
1000 Floral Vale Blvd., Ste. 400  
Yardley, PA 19067

A copy of notices shall be sent to:  
**Amplity, Inc.**  
Attn: General Counsel  
1000 Floral Vale Blvd., Ste. 400  
Yardley, PA 19067

**14.3** Assignment. Neither Party shall assign this Agreement except with the prior written consent of the other Party; provided, however, that any assignment resulting from a merger, sale of substantially all of the assets or an internal reorganization of Company shall not constitute an "assignment" for purposes of this Agreement if substantially all of the Company Personnel directly providing services to Client hereunder prior to such reorganization will continue to provide such services to Client after such reorganization. Each Party shall have the full right and authority to assign this Agreement without the consent of the other to an affiliate or to any entity

that acquires substantially all of its equity or assets with at least thirty (30) days' prior written notice to the other Party.

**14.4** Independent Contractor. Except with regard to the purchase of materials and services on Client's behalf as authorized under an SOW, Company and Client are independent contractors with all the attendant rights and liabilities and, Company is not an agent of or employee of Client.

**14.5** Non-Solicitation. Unless otherwise agreed by the Parties in an SOW, during the term of an SOW and for a period of six (6) months thereafter, neither Party shall directly or indirectly, hire or solicit for employment the personnel of the other Party of whom they first became aware because of Services under an applicable SOW without first obtaining the other Party's written consent. Nothing in this Section 14.5 shall prevent a Party from hiring an employee of the other Party where such individual (i) contacted a Party on his/her own initiative without direct or indirect solicitation or encouragement from the hiring Party or (ii) otherwise responds to an independent employment advertisement to the general public.

**14.6** Entire Agreement. This Agreement and the exhibits incorporated herein by reference constitute the entire agreement between the Parties relating to the subject matter hereof and supersede all previous understandings and agreements. In the event of any inconsistency between the terms of this Agreement and any SOW, the terms of this Agreement shall control unless otherwise specified in the SOW.

**14.7** Modification. This Agreement may not be modified orally and no modification or any claimed waiver of any of the provisions hereof shall be binding unless in writing and signed by both Parties hereto. An e-mail message shall not be deemed a writing for purposes of amending this Agreement.

**14.8** Severability. If any part of this Agreement shall be determined to be invalid or unenforceable by a court of competent jurisdiction or by any other legally constituted body having jurisdiction to make such determination, the remainder of this Agreement shall remain in full force and effect, provided that the part of the Agreement thus invalidated or declared unenforceable is not essential to the intended purposes of this Agreement.

**14.9** Waiver. No waiver of any provision or any breach of this Agreement shall constitute a waiver of any other provision or any other or further breach, and no such waiver shall be effective unless made in writing and signed by the Party making such waiver.

**14.10** Binding Effect. The terms of this Agreement shall be binding upon and inure to the benefit of Company, Client, and their respective successors and assigns.

**14.11** Governing Law. The terms of this Agreement shall be construed and interpreted under the laws of the State of New York.

**14.12** Dispute Resolution. In the event any dispute arises regarding the meaning or interpretation of this Agreement, the Parties shall first attempt to resolve such dispute informally within fifteen (15) business days using internal escalation procedures. In the event informal resolution is not

achieved within the stated time period, the Parties shall have the right to (1) extend the time period for informal resolution upon mutual agreement or (2) submit such dispute to be finally settled by an arbitration panel comprising one arbitrator appointed by Client, one arbitrator appointed by Company and a chair who shall be appointed by the other two arbitrators. Any such arbitration proceeding shall be conducted in accordance with the arbitration rules of the American Arbitration Association and shall be held in New York, New York (unless otherwise agreed by the Parties). The arbitration award shall be final and non-appealable and such award may be entered in any court having jurisdiction.

**14.13** Equitable Remedies: Each of the Parties agrees that it would be impossible or inadequate to measure and calculate a Non-Breaching Party's damages from any breach of the covenants or obligations set forth in Article IX of this Agreement (Confidentiality). Accordingly, each Party agrees that if it breaches any of such covenants, the Non-Breaching Party will be entitled to seek, in addition to any other rights or remedies available to the Non-Breaching Party at law or in equity, an injunction restraining any breach or threatened breach and to specific performance of any such provision of Article IX. Each Party agrees that no bond or other security shall be required in obtaining such equitable relief.

**14.14** Survival: The terms contained in Articles V, VIII, IX, X, and XIV, and any other obligations which, by their nature, are intended to survive shall survive the expiration or termination of this Agreement.

**14.15** Authorization: Each of the Parties to this Agreement warrants that it is permitted to enter into this Agreement and that the terms of this Agreement are not inconsistent with other contractual obligations that it has.

**14.16** Counterparts; Facsimile Signatures: This Agreement may be executed in counterparts, each of which shall be deemed to be an original but all of which taken together shall be deemed one and the same instrument. In the execution of this Agreement and delivery of signatures, facsimile or digitally scanned signatures will be treated in all respects as having the same effect as original signatures.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement, through their duly appointed and authorized officers and representatives, to be executed in duplicate as of the day and year first written above.

**Amplity, Inc.**                      **SCYNEXIS, Inc.**

By: <u>/s/ Mohan Ganesan</u>	By: <u>/s/ Marco Taglietti</u>
Print Name: <u>Mohan Ganesan</u>	Print Name: <u>Marco Taglietti</u>
Title: <u>CFO</u>	Title: <u>President and CEO</u>
Date: <u>2/19/2021</u>	Date: <u>2/19/2021</u>

**Exhibit A**  
Form of Statement of Work

**PROJECT:** \_\_\_\_\_

This Statement of Work #X (this "SOW#X"), effective \_\_\_\_\_ (the "SOW Effective Date"), is made and entered into pursuant to that certain Master Services Agreement dated [MSA EFFECTIVE DATE] (the "Agreement") by and between [CLIENT NAME], a corporation with offices at [CLIENT ADDRESS] ("Client") and Amplity, Inc., a New Jersey corporation with offices at 1000 Floral Vale Boulevard, Suite 400, Yardley, PA 19067 ("Company").

1. **Services.** Company will render in the services set forth in the attached **Schedule I: Scope of Services** ("Services"). Any additional work required beyond the Services set forth Schedule I must be agreed to in writing by Client and Company.

2. **Term and Termination.** Services will commence upon the SOW Effective Date and all Services, deliverables and payments properly due hereunder will be completed by \_\_\_\_\_ and this SOW will terminate on such date; provided, however, that either Client or Company may extend and/or terminate this SOW in accordance with the Agreement.

3. **Client Program Lead.**  
Client's Program Lead for this SOW#X is:

Name: [CLIENT CONTACT NAME]  
[CLIENT NAME]  
[CLIENT STREET ADDRESS]  
[CLIENT CITY, STATE, ZIP]  
Email: [CLIENT CONTACT EMAIL]

4. **Compensation and Invoicing.**

a. In consideration for the Services, Client agrees to pay Company the Fees set forth in **Schedule II: Project Fees & Payment Schedule** attached hereto. The total dollar amount payable by Client to Company under this SOW for all Fees and expenses shall not exceed the amount of \_\_\_\_\_ (\$XXX,XXX USD). The Fees and expenses specified in this SOW represent the total fees and pass through expenses to be paid by Client for the Services contemplated herein. Any changes to Fees and/or expenses shall be agreed upon by the Parties in a signed writing.

b. All Invoices shall be sent electronically via email to:  
[INSERT CLIENT DETAILS]

With a copy sent electronically via email to the Client Program Lead

**ACCEPTED AND AGREED:**

**SCYNEXIS, Inc.**

**Amplity, Inc.**

By: \_\_\_\_\_

By: \_\_\_\_\_

Name: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Title: \_\_\_\_\_

**STATEMENT OF WORK #1**

**PROGRAM: Ibrexafungerp Launch**

This Statement of Work #1 (this “SOW), effective **February 4, 2021** (the “SOW Effective Date”), is made and entered into pursuant to that certain Master Services Agreement dated February 4, 2021 (the “Agreement”) by and between **Scynexis, Inc.**, a corporation with offices at 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302 (“Client”) and Amplity Inc., a New Jersey corporation with offices at 1000 Floral Vale Boulevard, Suite 400, Yardley, PA 19067 (“Company”).

- 1. Services.** Company will render in the services set forth in the attached **Schedule I: Scope of Services** (“Services”). Any additional work required beyond the Services outlined in Schedule I must be agreed to in writing by Client and Company.
- 2. Term and Termination.** Services will commence upon the SOW Effective Date and all Services, deliverables and payments properly due hereunder will be completed on or around December 31, 2025, and this SOW will terminate on such date; provided, however, that either Client or Company may terminate this SOW earlier in accordance with Article XIII of the Master Service Agreement.
- 3. Client Program Lead.**  
Client’s Program Lead for this SOW is:

Jim Maffezzoli  
Scynexis, Inc.  
1 Evertrust Plaza, 13th Floor  
Jersey City, NJ 07302  
[\*]

**4. Compensation & Invoicing.**

a) In consideration for the Services, and subject to the terms of Schedule VIII: **Fee Deferral, Repayment and Success Premium Terms**, Client agrees to pay Company the Service Fees as set forth in **Schedule II: Program Fees & Payment Schedule**. Any changes to Service Fees and/or expenses shall be agreed upon by the parties in a signed writing.

b) All Invoices shall be sent electronically via email to:

Scynexis, Inc.  
Attention: Jane Soong  
1 Evertrust Plaza, 13th Floor  
Jersey City, NJ 07302

With a copy sent electronically via email to the Client Program Lead

c) Client shall pay Company upon receipt of a correct invoice in accordance with the payment terms of the Agreement. Payments under this SOW shall be made via electronic transfer to the following:

[\*]  
[\*]  
[\*]  
[\*]  
[\*]  
[\*]

**ACCEPTED AND AGREED:**

Scynexis, Inc.

Amplify, Inc.

By: /s/ Marco Taglietti

By: /s/ Mohan Ganesan

Name: Marco Taglietti

Name: Mohan Ganesan

Title: President and CEO

Title: CFO

Date: 2/19/2021

Date: 2/19/2021

List of Schedules

Schedule I:	Scope of Services
Schedule II:	Program Fees and Payment Schedule
Schedule III:	Hiring Profiles
Schedule IV:	Territories Listing
Schedule V:	Compliance Support
Schedule V(a):	Informational Meal Spend Reporting File Layout
Schedule VI:	Performance Metrics
Schedule VII:	Data Sharing Requirements
Schedule VIII:	Fee Deferral, Repayment, and Success Premium Terms
Appendix A:	Target Net Sales by Quarter





## CERTIFICATIONS

I, Marco Taglietti, certify that:

1. I have reviewed this Form 10-Q of SCYNEXIS, Inc.;
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
  4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
    - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
  5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
    - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
-

- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 16, 2021

/s/ Marco Taglietti, M.D.

---

Marco Taglietti, M.D.  
Chief Executive Officer  
Principal Executive Officer

**CERTIFICATIONS**

I, Eric Francois, certify that:

1. I have reviewed this Form 10-Q of SCYNEXIS, Inc.;
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
  4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
    - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
  5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
    - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
-

- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 16, 2021

/s/ Eric Francois

---

Eric Francois  
Chief Financial Officer  
Principal Financial Officer

**CERTIFICATION**

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Marco Taglietti, Chief Executive Officer of SCYNEXIS, Inc. (the “Company”), and Eric Francois, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2021, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and
2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of May 16, 2021.

/s/ Marco Taglietti, M.D.

\_\_\_\_\_  
Marco Taglietti, M.D.  
Chief Executive Officer

/s/ Eric Francois

\_\_\_\_\_  
Eric Francois  
Chief Financial Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of SCYNEXIS, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

**Document and Entity  
Information - shares**

**3 Months Ended  
Mar. 31, 2021**

**May 01, 2021**

**Cover [Abstract]**

<u>Entity Registrant Name</u>	SCYNEXIS, Inc.	
<u>Trading Symbol</u>	SCYX	
<u>Entity Central Index Key</u>	0001178253	
<u>Current Fiscal Year End Date</u>	--12-31	
<u>Entity Filer Category</u>	Non-accelerated Filer	
<u>Entity Small Business</u>	true	
<u>Entity Emerging Growth Company</u>	false	
<u>Document Type</u>	10-Q	
<u>Document Period End Date</u>	Mar. 31, 2021	
<u>Document Fiscal Year Focus</u>	2021	
<u>Document Fiscal Period Focus</u>	Q1	
<u>Amendment Flag</u>	false	
<u>Entity Common Stock, Shares Outstanding</u>		20,630,750
<u>Entity Current Reporting Status</u>	Yes	
<u>Entity Interactive Data Current</u>	Yes	
<u>Entity Shell Company</u>	false	
<u>Entity File Number</u>	001-36365	
<u>Entity Tax Identification Number</u>	56-2181648	
<u>Entity Incorporation, State or Country Code</u>	DE	
<u>Entity Address, Address Line One</u>	1 Evertrust Plaza	
<u>Entity Address, Address Line Two</u>	13th Floor	
<u>Entity Address, City or Town</u>	Jersey City	
<u>Entity Address, State or Province</u>	NJ	
<u>Entity Address, Postal Zip Code</u>	07302-6548	
<u>City Area Code</u>	201	
<u>Local Phone Number</u>	884-5485	
<u>Document Quarterly Report</u>	true	
<u>Document Transition Report</u>	false	
<u>Title of Each Class</u>	Common Stock, par value \$0.001 per share	
<u>Name of Each Exchange on Which Registered</u>	NASDAQ	

**Unaudited Condensed  
Consolidated Balance Sheets**  
- USD (\$)  
\$ in Thousands

**Mar. 31, Dec. 31,  
2021 2020**

**Current assets:**

<u>Cash and cash equivalents</u>	\$ 92,011	\$ 93,041
<u>Prepaid expenses and other current assets</u>	3,310	5,165
<u>Restricted cash</u>	55	0
<u>Total current assets</u>	95,376	98,206
<u>Other assets</u>	692	573
<u>Deferred offering costs</u>	187	187
<u>Restricted cash</u>	218	273
<u>Property and equipment, net</u>	271	298
<u>Intangible assets</u>	378	0
<u>Operating lease right-of-use asset (See Note 6)</u>	2,950	2,999
<u>Total assets</u>	100,072	102,536

**Current liabilities:**

<u>Accounts payable</u>	6,516	4,639
<u>Accrued expenses</u>	2,134	4,141
<u>Warrant liabilities</u>	16,225	17,564
<u>Operating lease liability, current portion (See Note 6)</u>	57	52
<u>Total current liabilities</u>	24,932	26,396
<u>Other liabilities</u>	140	0
<u>Warrant liabilities</u>	33,635	33,592
<u>Convertible debt and derivative liability (See Note 5)</u>	12,226	16,516
<u>Operating lease liability (See Note 6)</u>	3,215	3,274
<u>Total liabilities</u>	74,148	79,778
<u>Commitments and contingencies</u>		

**Stockholders' equity:**

<u>Preferred stock, \$0.001 par value, authorized 5,000,000 shares as of March 31, 2021 and December 31, 2020; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020</u>	0	0
<u>Common stock, \$0.001 par value, 100,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 20,625,637 and 19,663,698 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</u>	21	20
<u>Additional paid-in capital</u>	357,192	349,351
<u>Accumulated deficit</u>	(331,289)	(326,613)
<u>Total stockholders' equity</u>	25,924	22,758
<u>Total liabilities and stockholders' equity</u>	\$ 100,072	\$ 102,536

**Unaudited Condensed  
Consolidated Balance Sheets  
(Parenthetical) - \$ / shares**

**Mar. 31, 2021 Dec. 31, 2020**

**Statement Of Financial Position [Abstract]**

<u>Preferred stock, par value (in dollars per share)</u>	\$ 0.001	\$ 0.001
<u>Preferred stock, shares authorized (in shares)</u>	5,000,000	5,000,000
<u>Preferred stock, shares issued (in shares)</u>	0	0
<u>Preferred stock, shares outstanding (in shares)</u>	0	0
<u>Common stock, par value (in dollars per share)</u>	\$ 0.001	\$ 0.001
<u>Common stock, shares authorized (in shares)</u>	100,000,000	100,000,000
<u>Common stock, shares issued (in shares)</u>	20,625,637	19,663,698
<u>Common stock, shares outstanding (in shares)</u>	20,625,637	19,663,698



**Unaudited Condensed  
Consolidated Statements of  
Operations - USD (\$)  
\$ in Thousands**

**3 Months Ended  
Mar. 31, 2021 Mar. 31, 2020**

**Income Statement [Abstract]**

<u>Revenue</u>	\$ 12,050	\$ 0
<b><u>Operating expenses:</u></b>		
<u>Research and development</u>	6,948	9,866
<u>Selling, general and administrative</u>	6,696	2,613
<u>Total operating expenses</u>	13,644	12,479
<u>Loss from operations</u>	(1,594)	(12,479)
<b><u>Other expense (income):</u></b>		
<u>Loss on extinguishment of debt</u>	2,725	0
<u>Amortization of debt issuance costs and discount</u>	256	278
<u>Interest income</u>	(7)	(147)
<u>Interest expense</u>	214	210
<u>Other income</u>	0	(350)
<u>Warrant liabilities fair value adjustment</u>	(1,296)	(4,768)
<u>Derivative liabilities fair value adjustment</u>	90	(700)
<u>Total other expense (income)</u>	1,982	(5,477)
<u>Loss before taxes</u>	(3,576)	(7,002)
<u>Income tax expense</u>	1,100	0
<u>Net loss</u>	\$ (4,676)	\$ (7,002)
<b><u>Net loss per share attributable to common stockholders – basic</u></b>		
<u>Net loss per share – basic</u>	\$ (0.18)	\$ (0.72)
<b><u>Net loss per share attributable to common stockholders – diluted</u></b>		
<u>Net loss per share – diluted</u>	\$ (0.23)	\$ (0.72)
<b><u>Weighted average common shares outstanding – basic and diluted</u></b>		
<u>Basic</u>	25,802,700	9,744,577
<u>Diluted</u>	26,523,920	9,744,577

**Unaudited Condensed  
Consolidated Statements of  
Cash Flows - USD (\$)  
\$ in Thousands**

**3 Months Ended**  
**Mar. 31,      Mar. 31,**  
**2021            2020**

**Cash flows from operating activities:**

Net loss \$ (4,676) \$ (7,002)

**Adjustments to reconcile net loss to net cash used in operating activities:**

Depreciation 27 28

Stock-based compensation expense 398 410

Accretion of investments discount 0 (31)

Amortization of debt issuance costs and discount 256 278

Change in fair value of warrant liabilities (1,296) (4,768)

Change in fair value of derivative liabilities 90 (700)

Noncash operating lease expense for right-of-use asset 49 48

Loss on extinguishment of debt 2,725 0

**Changes in operating assets and liabilities:**

Prepaid expenses, other assets, deferred costs, and other 1,736 1,734

Accounts payable, accrued expenses, and other (68) (4,054)

Net cash used in operating activities (759) (14,057)

**Cash flows from investing activities:**

Maturities of investments 0 6,477

Purchases of property and equipment 0 (4)

Purchase of intangible assets (200) 0

Purchases of investments 0 (14,235)

Net cash used in investing activities (200) (7,762)

**Cash flows from financing activities:**

Proceeds from common stock issued 0 214

Payments of offering costs and underwriting discounts and commissions (62) (7)

Proceeds from common stock issuance under employee stock purchase plan 6 18

Repurchase of shares to satisfy tax withholdings (15) (73)

Net cash (used in) provided by financing activities (71) 152

Net decrease in cash, cash equivalents, and restricted cash (1,030) (21,667)

Cash, cash equivalents, and restricted cash at beginning of period 93,314 42,193

Cash, cash equivalents, and restricted cash at end of period 92,284 20,526

**Supplemental cash flow information:**

Cash paid for interest 420 420

Cash received for interest 5 129

**Noncash financing and investing activities:**

Common stock issued for settlement of senior convertible notes 7,452 0

Purchased intangible assets included in accounts payable and accrued expenses 178 0

Deferred offering and issuance costs included in accounts payable and accrued expenses \$ 0 \$ 40

**Description of Business and  
Basis of Preparation**

**3 Months Ended  
Mar. 31, 2021**

**Organization Consolidation  
And Presentation Of  
Financial Statements  
[Abstract]**

**Description of Business and  
Basis of Preparation**

**1. Description of Business and Basis of Preparation**

*Organization*

SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its lead product candidate, ibrexafungerp, as the first representative of a novel oral and intravenous triterpenoid antifungal family for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of \$331.3 million at March 31, 2021 and limited capital resources to fund ongoing operations. These capital resources primarily comprised cash and cash equivalents of \$92.0 million at March 31, 2021. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company’s liquidity could be materially affected over this period by, among other things: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to potentially commercialize ibrexafungerp for the treatment of vaginal yeast infections and; (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Company’s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation.

*Reverse Stock Split*

On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”), which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares. All share and per share amounts presented in these unaudited condensed consolidated financial statements have been retroactively adjusted for the reverse stock split and certain items in the prior period financial statements have been revised to conform to the current presentation. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding.

*Unaudited Interim Condensed Consolidated Financial Information*

The accompanying unaudited condensed consolidated financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”), as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 29, 2021.

#### *Use of Estimates*

The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses

during the reporting periods. Actual results could differ from those estimates. Significant estimates include: determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.

## Summary of Significant Accounting Policies

3 Months Ended  
Mar. 31, 2021

### Accounting Policies

#### [Abstract]

### Summary of Significant Accounting Policies

#### 2. Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2020, except as described below.

##### *Revenue Recognition*

The Company has entered into arrangements involving the sale or license of intellectual property and the provision of other services. When entering into any arrangement involving the sale or license of intellectual property rights and other services, the Company determines whether the arrangement is subject to accounting guidance in ASC 606, *Revenue from Contracts with Customers* ("Topic 606"), as well as ASC 808, *Collaborative Arrangements* ("Topic 808"). If the Company determines that an arrangement includes goods or services that are central to the Company's business operations for consideration, the Company will then identify the performance obligations in the contract using the unit-of-account guidance in Topic 606. For a distinct unit-of-account that is within the scope of Topic 606, the Company applies all of the accounting requirements in Topic 606 to that unit-of-account, including the recognition, measurement, presentation and disclosure requirements. For a distinct unit-of-account that is not within the scope of Topic 606, the Company will recognize and measure the distinct unit-of-account based on other authoritative ASC Topics or on a reasonable, rational, and consistently applied policy election.

Analyzing the arrangement to identify performance obligations requires the use of judgment. In arrangements that include the sale or license of intellectual property and other promised services, the Company first identifies if the licenses are distinct from the other promises in the arrangement. If the license is not distinct, the license is combined with other services into a single performance obligation. Factors that are considered in evaluating whether a license is distinct from other promised services include, for example, whether the counterparty can benefit from the license without the promised service on its own or with other readily available resources and whether the promised service is expected to significantly modify or customize the intellectual property.

The Company classifies non-refundable upfront payments, milestone payments and royalties received for the sale or license of intellectual property as revenues within its statements of operations because the Company views such activities as being central to its business operations. For the sale of intellectual property that is distinct, fixed consideration and variable consideration are included in the transaction price and recognized in revenue immediately to the extent that it is probable that there would not be a significant reversal of cumulative revenue in the future. For the license of intellectual property that is distinct, fixed and variable consideration (to the extent there will not be a significant reversal in the future) are also recognized immediately in income, except for consideration received in the form of royalty or sales-based milestones, which is recorded when the customer's subsequent sales or usages occur. If the sale or license of intellectual property is not distinct, revenue is deferred and recognized over the estimated period of the Company's combined performance obligation. For contractual arrangements that meet the definition of a collaborative arrangement under Topic 808, consideration received for any units-of-account that are outside the scope of Topic 606 are recognized in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company's business operations, and (iii) the contractual terms of the arrangement.

##### *Basic and Diluted Net Loss per Share of Common Stock*

The Company calculates net loss per common share in accordance with ASC 260, *Earnings Per Share*. Basic net loss per common share for the three months ended March 31, 2021 and 2020

was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, *Earnings Per Share*, the weighted average number of common shares outstanding utilized for determining the basic net loss per common share for the three months ended March 31, 2021 includes the pre-funded warrants to purchase 5,260,000 shares of common stock issued in the December 2020 Public Offering. Diluted net loss per common share for the three months ended March 31, 2021 and 2020 was determined as follows (in thousands, except share and per share amounts):

	Three Months Ended March 31,	
	2021	2020
Net loss	\$ (4,676)	\$ (7,002)
Dilutive effect of warrant liability	(1,323)	—
Net loss allocated to common shares	<u>\$ (5,999)</u>	<u>\$ (7,002)</u>
Weighted average common shares outstanding – basic	25,802,700	9,744,577
Dilutive effect of warrant liability	721,220	—
Weighted average common shares outstanding – diluted	<u>26,523,920</u>	<u>9,744,577</u>
Net loss per share – diluted	\$ (0.23)	\$ (0.72)

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three months ended March 31, 2021 and 2020, as the result would be anti-dilutive:

	Three Months Ended March 31,	
	2021	2020
Outstanding stock options	1,371,606	768,354
Outstanding restricted stock units	96,974	85,754
Warrants to purchase common stock associated with June 2016 public offering	421,867	421,867
Warrants to purchase common stock associated with March 2018 public offering – Series 2	798,810	798,810
Warrants to purchase common stock associated with December 2019 Public Offering	4,472,205	4,472,205
Warrants to purchase common stock associated with December 2020 Public Offering - Series 2	6,800,000	—
Common stock associated with March 2019 Notes	1,138,200	1,138,200
Warrants to purchase common stock associated with Solar loan agreement	12,243	12,243
Total	<u>15,111,905</u>	<u>7,697,433</u>

#### *Recently Issued Accounting Pronouncements*

In June 2016, the FASB issued ASU No. 2016-13, *Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, *Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)* (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.

In August 2020, the FASB issued ASU No. 2020-06, *Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity* (“ASU 2020-06”). The

amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.

#### *Recently Adopted Accounting Pronouncements*

In December 2019, the FASB issued ASU No. 2019-12, *Income Taxes: Simplifying the Accounting for Income Taxes* (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, *Income Taxes*, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance was adopted by the Company in the first quarter of 2021 and it did not have a material impact on its unaudited condensed consolidated financial statements.

**Prepaid Expenses and Other  
Current Assets**

**3 Months Ended  
Mar. 31, 2021**

[Deferred Costs Capitalized Prepaid And Other Assets  
Disclosure \[Abstract\]](#)

[Prepaid Expenses and Other Current Assets](#)

**3. Prepaid Expenses and Other Current Assets**

Prepaid expenses and other current assets consisted of the following (in thousands):

	<u>March 31, 2021</u>	<u>December 31, 2020</u>
Prepaid research and development services	\$ 1,300	\$ 1,535
Prepaid insurance	115	362
Other prepaid expenses	525	19
Other receivables	1,000	2,876
Other current assets	<u>370</u>	<u>373</u>
Total prepaid expenses and other current assets	<u>\$ 3,310</u>	<u>\$ 5,165</u>



## Accrued Expenses

**3 Months Ended  
Mar. 31, 2021**

### [Payables And Accruals \[Abstract\]](#)

#### [Accrued Expenses](#)

#### 4. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	March 31, 2021	December 31, 2020
Accrued research and development expenses	\$ 647	\$ 991
Accrued employee bonus compensation	433	2,190
Other accrued expenses	1,054	960
Total accrued expenses	<u>\$ 2,134</u>	<u>\$ 4,141</u>

## Borrowings

**3 Months Ended  
Mar. 31, 2021**

### [Debt Disclosure \[Abstract\]](#) [Borrowings](#)

#### 5. Borrowings

##### *April 2020 Note Purchase Agreement*

On April 9, 2020, the Company entered into the April 2020 Note Purchase Agreement with Puissance Life Science Opportunities Fund VI (“Puissance”) and issued and sold to Puissance \$10.0 million aggregate principal amount of its April 2020 Notes, resulting in net proceeds of approximately \$9.5 million after deducting \$0.5 million for an advisory fee and other issuance costs. At December 31, 2020, the fair value of the April 2020 Notes was \$7.4 million.

In January 2021, Puissance converted the remaining \$6.0 million of the April 2020 Notes for 959,080 shares of common stock. Upon conversion of the \$6.0 million of the April 2020 Notes, the Company recognized a \$2.7 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of \$4.8 million and the fair value of the consideration issued of \$7.5 million.

##### *March 2019 Note Purchase Agreement*

On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance \$16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 (“March 2019 Notes”), resulting in \$14.7 million in net proceeds after deducting \$1.3 million for an advisory fee and other issuance costs.

As of March 31, 2021, the Company’s March 2019 Notes consists of the convertible debt balance of \$9.6 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of \$0.4 million, and the bifurcated embedded conversion option derivative liability of \$2.6 million. In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, *Derivatives and Hedging*, at its initial fair value of \$7.0 million as the interest make-whole provision is settled in shares of common stock. For the three months ended March 31, 2021 and 2020, the Company recognized gains of \$42,000 and \$0.7 million, respectively, on the fair value adjustment for the derivative liability. For each of the three months ended March 31, 2021 and 2020, the Company recognized \$0.3 million in amortization of debt issuance costs and discount related to the March 2019 Notes.

The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At both March 31, 2021 and December 31, 2020, the fair value of the convertible debt and derivative liability for the March 2019 Notes is \$12.9 million.

The March 2019 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the March 2019 Notes being issued to one financially sophisticated investor. The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.

The holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. The initial conversion rate is 73.9096 shares of common stock per \$1,000 principal amount of March 2019 Notes, which is equivalent to an initial conversion price of approximately \$13.53 and is subject to adjustment in certain events

described in the March 2019 Note Purchase Agreement. The Holder upon conversion may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate if the holder elects to convert its March 2019 Notes in connection with such a corporate event. Subject to adjustment in the conversion rate, the number of shares that the Company may deliver in connection with a conversion of the March 2019 Notes, including those delivered in connection with an interest make-whole payment, will not exceed a cap of 81 shares of common stock per \$1,000 principal amount of the March 2019 Notes.

On or after March 15, 2022, the Company has the right, at its election, to redeem all or any portion of the March 2019 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the March 2019 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If a “fundamental change” (as defined in the March 2019 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the March 2019 Notes for cash at a repurchase price of 100% of the principal amount of the March 2019 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.

**Commitments and  
Contingencies**

**3 Months Ended  
Mar. 31, 2021**

**Commitments And  
Contingencies Disclosure**

**[Abstract]**

**Commitments and  
Contingencies**

**6. Commitments and Contingencies**

*Leases*

On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the "Lease"). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of \$7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of \$0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years. The security deposit is classified as restricted cash in the accompanying unaudited condensed consolidated balance sheets.

The consideration in the Lease allocated to the single lease component includes the fixed payments for the right to use the office space as well as common area maintenance. The Lease also contains costs associated with certain expense escalation, property taxes, insurance, parking, and utilities which are all considered variable payments and are excluded from the operating lease liability. The incremental borrowing rate utilized approximated the prevailing market interest rate the Company would incur to borrow a similar amount equal to the total Lease payments on a collateralized basis over the term of the Lease. The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands):

	<b>Three Months Ended March 31, 2021</b>	<b>Three Months Ended March 31, 2020</b>
Operating lease cost	\$ 166	\$ 166
Variable lease cost	(2)	21
<b>Total operating lease expense</b>	<b>\$ 164</b>	<b>\$ 187</b>
Cash paid for amounts included in the measurement of operating lease liability	\$ 170	\$ 167
	<b>March 31, 2021</b>	<b>March 31, 2020</b>
Remaining Lease term (years)	8.34	9.34
Discount rate	15%	15%

Future minimum lease payments for the Lease as of March 31, 2021 are as follows (in thousands):

	<b>March 31, 2021</b>
2021	\$ 347
2022	527
2023	715
2024	730
2025	744
Thereafter	<u>2,789</u>

Total	\$ 5,852
-------	----------

The presentations of the operating lease liability as of March 31, 2021 are as follows (in thousands):

	March 31, 2021
Present value of future minimum lease payments	\$ 3,272
Operating lease liability, current portion	\$ 57
Operating lease liability, long-term portion	3,215
Total operating lease liability	\$ 3,272
Difference between future minimum lease payments and discounted cash flows	\$ 2,580

#### *License Arrangement with Potential Future Expenditures*

As of March 31, 2021, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health. In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company. Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total \$19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits.

In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the "Deferred Milestone"). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound. In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of an NDA, triggered by the FDA acceptance for filing of the Company's NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for the Company's NDA for ibrexafungerp for the treatment of VVC. Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged.

#### *Clinical Development Arrangements*

The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.

## Stockholders' Equity

**3 Months Ended  
Mar. 31, 2021**

[Equity \[Abstract\]](#)  
[Stockholders' Equity](#)

### 7. Stockholders' Equity

#### *Authorized, Issued, and Outstanding Common Stock*

The Company's authorized common stock has a par value of \$0.001 per share and consists of 100,000,000 shares as of March 31, 2021, and December 31, 2020; 20,625,637 and 19,663,698 shares were issued and outstanding at March 31, 2021, and December 31, 2020, respectively.

On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Amendment"), which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company's common stock and (b) decreasing the number of authorized shares of the Company's common stock from 250,000,000 shares to 100,000,000 shares.

The following table summarizes common stock share activity for the three months ended March 31, 2021 and 2020 (dollars in thousands):

	Three Months Ended March 31, 2021				
	Shares of Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2020	19,663,698	\$ 20	\$349,351	\$ (326,613)	\$ 22,758
Net loss	—	—	—	(4,676)	(4,676)
Stock-based compensation expense	—	—	398	—	398
Common stock issued for conversion of April 2020 Notes	959,080	1	7,452	—	7,453
Common stock issued through employee stock purchase plan	2,184	—	6	—	6
Common stock issued for vested restricted stock units	675	—	(15)	—	(15)
<b>Balance, March 31, 2021</b>	<b>20,625,637</b>	<b>\$ 21</b>	<b>\$357,192</b>	<b>\$ (331,289)</b>	<b>\$ 25,924</b>
	Three Months Ended March 31, 2020				
	Shares of Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2019	9,741,372	\$ 10	\$284,313	\$ (271,428)	\$ 12,895
Net loss	—	—	—	(7,002)	(7,002)
Stock-based compensation expense	—	—	410	—	410
Common stock issued through employee stock purchase plan	2,215	—	18	—	18
Common stock issued, net of expenses	28,527	—	207	—	207
Common stock issued for vested restricted stock units	15,490	—	(73)	—	(73)
<b>Balance, March 31, 2020</b>	<b>9,787,604</b>	<b>\$ 10</b>	<b>\$284,875</b>	<b>\$ (278,430)</b>	<b>\$ 6,455</b>

### Shares Reserved for Future Issuance

The Company had reserved shares of common stock for future issuance as follows:

	March 31, 2021	December 31, 2020
Outstanding stock options	1,371,606	830,343
Outstanding restricted stock units	96,974	29,087
Warrants to purchase common stock associated with June 2016 Public Offering	421,867	421,867
Warrants to purchase common stock associated with March 2018 Public Offering – Series 2	798,810	798,810
Warrants to purchase common stock associated with December 2019 Public Offering	4,472,205	4,472,205
Warrants to purchase common stock associated with December 2020 Public Offering - Series 1	6,800,000	6,800,000
Warrants to purchase common stock associated with December 2020 Public Offering - Series 2	6,800,000	6,800,000
Prefunded warrants to purchase common stock associated with December 2020 Public Offering	5,260,000	5,260,000
Warrants to purchase common stock associated with Solar loan agreement	12,243	12,243
For possible future issuance for the conversion of the March 2019 Notes	1,138,200	1,138,200
For possible future issuance for the conversion of the April 2020 Notes	—	1,299,790
For possible future issuance under 2014 Equity Incentive Plan (Note 9)	318,097	146,488
For possible future issuance under Employee Stock Purchase Plan	6,652	5,895
For possible future issuance under 2015 Inducement Award Plan (Note 9)	14,050	14,050
Total common shares reserved for future issuance	<u>27,510,704</u>	<u>28,028,978</u>

### Common Stock Purchase Agreement

On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital pursuant to which the Company has the right to sell to Aspire Capital from time to time in its sole discretion up to \$20.0 million in shares of the Company's common stock over the next 30 months, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement. The aggregate number of shares that we can sell to Aspire Capital under the Common Stock Purchase Agreement may in no case exceed 1,956,547 shares of the Company's common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the Common Stock Purchase Agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the Common Stock Purchase Agreement exceeds \$8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company's common stock. During the three months ended March 31, 2021 and 2020, the Company did not sell any shares of its common stock under the Common Stock Purchase Agreement.

### Convertible Debt and Derivative Liabilities

In connection with the Company's issuances of its April 2020 Notes and March 2019 Notes, the Company bifurcated the embedded conversion options, inclusive of the interest make-whole provisions and make-whole fundamental change provisions, and recorded the embedded conversion options as long-term derivative liabilities in the Company's balance sheet in accordance with ASC 815, *Derivatives and Hedging*. The convertible debt and derivative liability associated with the March 2019 Notes are presented in total on the accompanying

unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. For the three months ended March 31, 2021 and 2020, the Company recorded a loss of \$0.1 million and a gain of \$0.7 million, respectively, due to the change in fair value of the derivative liabilities.

*Warrants Associated with June 2016, March 2018, December 2019, and December 2020 Public Offerings*

The outstanding warrants associated with the June 2016, March 2018, December 2019, and December 2020 public offerings contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, *Distinguishing Liabilities from Equity*, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying unaudited condensed consolidated statements of operations. During the three months ended March 31, 2021 and 2020, the Company recorded gains of \$1.3 million and \$4.8 million, respectively, in the warrant liabilities fair value adjustment. As of March 31, 2021 and 2020, the fair value of the warrant liabilities was \$49.9 million and \$51.2 million, respectively.

*Warrant Associated with Solar Loan Agreement*

On the closing date of the Company's previous loan agreement with Solar, pursuant to the loan agreement the Company issued to Solar the warrant to purchase an aggregate of up to 12,243 shares of the Company's common stock at an exercise price of \$36.754 per share. The warrant will expire five years from the date of the grant. The warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders' equity section of the balance sheet.



## Stock-based Compensation

3 Months Ended  
Mar. 31, 2021

[Disclosure Of Compensation  
Related Costs Sharebased  
Payments \[Abstract\]  
Stock-based Compensation](#)

### 8. Stock-based Compensation

Pursuant to the terms of the Company's 2014 Equity Incentive Plan ("2014 Plan"), on January 1, 2021 and 2020, the Company automatically added 786,547 and 389,650 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of March 31, 2021, there were 318,097 shares of common stock available for future issuance under the 2014 Plan.

As of March 31, 2021, there were 14,050 shares of common stock available for future issuance under the Company's 2015 Inducement Award Plan ("2015 Plan"). During the three months ended March 31, 2021 and 2020, there were zero and 17,500 granted options of the Company's common stock under the 2015 Plan, respectively. On April 30, 2021, the Company's board of directors amended the 2015 Plan, and the share reserve for the 2015 Plan was increased from 90,000 to 500,000 shares of common stock.

The activity for the Company's 2009 Stock Option Plan, 2014 Plan, and 2015 Plan, for the three months ended March 31, 2021, is summarized as follows:

	Number of Shares	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (\$000)
Outstanding — December 31, 2020	830,343	\$ 21.52	7.71	\$ 96
Granted	545,450	\$ 7.57		
Forfeited/Cancelled	(4,187)	\$ 8.48		
Outstanding — March 31, 2021	1,371,606	\$ 16.01	8.33	\$ 355
Exercisable — March 31, 2021	500,625	\$ 29.27	6.72	\$ 37
Vested or expected to vest — March 31, 2021	1,371,606	\$ 16.01	8.33	\$ 355

Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the three months ended March 31, 2021, is summarized as follows:

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Non-vested at December 31, 2020	29,087	\$ 9.52
Granted	73,675	\$ 7.55
Vested	(5,788)	\$ 10.68
Non-vested at March 31, 2021	96,974	\$ 7.95

The fair value of RSUs is based on the market price of the Company's common stock on the date of grant. RSUs generally vest 25% annually over a four-year period from the date of grant. Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period.

#### Compensation Cost

The compensation cost that has been charged against income for stock awards under the 2014 Plan and the 2015 Plan was \$0.4 million for both the three months ended March 31, 2021 and 2020. The total income tax benefit recognized in the statements of operations for share-based

compensation arrangements was zero for each of the three months ended March 31, 2021 and 2020.

Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands):

	Three Months Ended March 31,	
	2021	2020
Research and development	\$ 126	\$ 136
Selling, general and administrative	272	274
Total	<u>\$ 398</u>	<u>\$ 410</u>

## Fair Value Measurements

**3 Months Ended  
Mar. 31, 2021**

### [Fair Value Disclosures](#)

#### [\[Abstract\]](#)

#### [Fair Value Measurements](#)

### 9. Fair Value Measurements

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.

#### *Assets and Liabilities Measured at Fair Value on a Recurring Basis*

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of March 31, 2021 and December 31, 2020 for financial instruments measured at fair value on a recurring basis (in thousands):

	Balance	Fair Value Hierarchy Classification		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>March 31, 2021</b>				
Cash	\$ 236	\$ 236	—	—
Restricted cash	273	273	—	—
Money market funds	91,775	91,775	—	—
<b>Total assets</b>	<b>\$ 92,284</b>	<b>\$ 92,284</b>	<b>—</b>	<b>—</b>
Warrant liabilities	\$ 49,860	—	—	\$ 49,860
Derivative liability	2,618	—	—	2,618
<b>Total liabilities</b>	<b>\$ 52,478</b>	<b>—</b>	<b>—</b>	<b>\$ 52,478</b>
<b>December 31, 2020</b>				
Cash	\$ 117	\$ 117	—	—
Restricted cash	273	273	—	—
Money market funds	92,924	92,924	—	—
<b>Total assets</b>	<b>\$ 93,314</b>	<b>\$ 93,314</b>	<b>—</b>	<b>—</b>
Warrant liabilities	\$ 51,156	—	—	\$ 51,156
Derivative liabilities	5,954	—	—	5,954
<b>Total liabilities</b>	<b>\$ 57,110</b>	<b>—</b>	<b>—</b>	<b>\$ 57,110</b>

The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.

Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction

details such as the Company's stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical volatility of the Company, using its closing common stock prices, is utilized to reflect future volatility over the expected term of the warrants. At March 31, 2021, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 69.6% to 82.5% and 77.6%, respectively. Additionally, the expected term associated with the December 2019 Public Offering warrants is an unobservable unit given that the expiration of the warrants is the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023. The Company utilized a probability assessment to estimate the likelihood of occurrence for the two potential expiration dates and allocated the probability of occurrence percentage to the fair values calculated based on the two potential expected terms. The weighted average expected term is 0.9 years as of March 31, 2021 for the December 2019 Public Offering warrants with a range of 0.66 to 2.2 years.

The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company's stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of March 31, 2021, these inputs were 61.5%, 1,451 basis points, and 15.1%, respectively. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The discount for lack of marketability, 7.1% as of March 31, 2021, is applied to the value of the March 2019 Notes. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis.

A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

	<b>Warrant Liabilities</b>
Balance – December 31, 2020	\$ 51,156
Gain adjustment to fair value	(1,296)
Balance – March 31, 2021	<u>\$ 49,860</u>
	<b>Derivative Liabilities</b>
Balance – December 31, 2020	\$ 5,954
Adjustment for conversion of April 2020 Notes	(3,426)
Gain adjustment to fair value	90
Balance – March 31, 2021	<u>\$ 2,618</u>

[Organization Consolidation  
And Presentation Of  
Financial Statements](#)

[\[Abstract\]](#)

[License Agreement Revenue](#)

**10. License Agreement Revenue**

In February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the "Agreement") with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, "Hansoh"), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the "Territory"). The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory. Under the terms of the Agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in the Territory.

Pursuant to the terms of the Agreement, the Company received as consideration for the licenses a nonrefundable upfront cash payment of \$10.0 million and is entitled to an additional payment that was payable upon the transfer of certain data related to the manufacturing license. In addition, the Company will also be eligible to receive up to \$110.0 million in potential development and commercial milestones. In addition, during the term of the licensing agreement, the Company is entitled to low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances. The Company is also eligible to receive a milestone related to the successful completion of a manufacturing batch by Hansoh.

The Company evaluated the Agreement and concluded that it was subject to ASC 606 as the Company viewed the Agreement as a contract with a customer as the activities were central to its business operations. As such, the Company assessed the terms of the Agreement and identified one performance obligation for the licenses to research, develop, manufacture and commercialize ibrexafungerp in the Territory, including the underlying know-how related to such licenses. The Company also evaluated options for additional goods and services included in the Agreement related to (1) optional technical assistance related to development, regulatory or manufacturing activities and (2) an optional supply agreement for ibrexafungerp. Such options for additional goods or services were not considered to contain material rights as pricing approximated standalone selling prices and therefore the Company concluded that such options did not represent performance obligations and will be accounted for as separate transactions if and when they occur in the future.

The Company determined that the transaction price of \$12.1 million included the fixed upfront cash payment of \$10.0 million, an additional amount that was payable upon the transfer of certain data related to the manufacturing license, and \$1.1 million related to withholding tax obligations that Hansoh remitted on behalf of the Company. The remaining amounts related to the successful completion of a manufacturing batch by Hansoh and potential development milestones represent variable consideration and were constrained as it was concluded that it was not probable that a significant reversal in cumulative revenue recognized will not occur and therefore not included in the transaction price as of March 31, 2021. Potential

commercial milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were determined to relate to the license. The transaction price was recorded in revenue during the quarter March 31, 2021 at a point in time upon control of the license transferring to Hansoh. The Company will reevaluate the transaction price at the end of each reporting period as uncertain events or resolved, or as other changes in circumstances occur.

Additionally, pursuant to the Agreement, both the Company and Hansoh agreed to make reasonable efforts to account for applicable taxes, fees, duties, levies, or similar amounts imposed on net income, franchise taxes and profits arising directly or indirectly from the activities of the Agreement. To the extent Hansoh is required by applicable laws to withhold or deduct any tax on any payment to the Company, Hansoh agreed to make certain increases on payments to the Company to ensure that the Company receives a sum equal to what the Company would have received had there been no deduction or withholding. As a result, the Company has recorded revenue and tax withholding expense primarily associated with the up-front payment received by the Company on a gross basis. For the three months ended March 31, 2021, the Company recognized \$1.1 million in revenue and \$1.1 million in income tax expense to account for the tax withholding expense primarily on the \$10.0 million up-front that the Company is responsible to remit under applicable tax law.

In July 2016, the Company entered into an asset purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the asset purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized. For the three months ended March 31, 2021, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained as of March 31, 2021. Additionally, in October 2014 the Company entered into a license agreement with Waterstone Pharmaceutical HK Limited (or "Waterstone") and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds. The Company is entitled to receive potential milestones and royalties from Waterstone; however, there was no revenue recognized by the Company associated with this agreement given the variable consideration was fully constrained as of March 31, 2021.

## Subsequent Events

**3 Months Ended  
Mar. 31, 2021**

[Subsequent Events](#)

[\[Abstract\]](#)

[Subsequent Events](#)

### 11. Subsequent Events

In May 2021, the Company entered into an agreement with a third party to sell a portion of its unused New Jersey net operating losses (NOLs) for approximately \$4.2 million.

In May 2021, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Hercules Capital, Inc. ("Hercules"), as administrative agent and collateral agent (in such capacity, the "Agent") and a lender, and Silicon Valley Bank, as a lender ("SVB," and collectively with Hercules, the "Lenders") for an aggregate principal amount of \$60.0 million (the "Term Loan"). Pursuant to the Loan Agreement, the Term Loan is available to the Company in four tranches, subject to certain terms and conditions.

Under the terms of the Loan Agreement, the Company received an initial tranche of \$20.0 million from the Lenders on the Closing Date. The second tranche of the Term Loan, consisting of up to an additional \$10.0 million, will become available to the Company upon receipt of approval from the Food and Drug Administration of ibrexafungerp for the treatment of vaginal yeast infections (the "First Performance Milestone") and will be available, if specified conditions are met, during the period beginning on June 1, 2021 through June 30, 2022. The third tranche of the Term Loan, consisting of an additional \$5.0 million, will be available to the Company upon (a) the First Performance Milestone and (b) the achievement of the primary endpoint from the Phase 3 study of ibrexafungerp in patients with recurrent vulvovaginal candidiasis, and will be available, if specified conditions are met, from September 30, 2021 through June 30, 2022. The fourth tranche of the Term Loan, consisting of up to an additional \$25.0 million, will be available to the Company from January 1, 2022 through December 31, 2023 in \$5.0 million increments, subject to certain terms and conditions, including in maintaining a ratio of total outstanding Term Loan principal to net product revenues for ibrexafungerp below a certain specified level for a given draw period.

The Term Loan will mature on March 3, 2025 (the "Maturity Date"); provided that, the Maturity Date shall be automatically extended to May 1, 2025 subject to the occurrence of certain conditions set forth in the Loan Agreement. The Term Loan bears interest at a variable annual rate equal to the greater of (a) 9.05% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 5.80% (the "Interest Rate"). The Company may make payments of interest only through November 1, 2023, which may be extended to May 1, 2024 upon the achievement of the First Performance Milestone prior to November 1, 2023, and which is further extendable in quarterly increments until the Maturity Date, subject to continued compliance with the financial covenant of the Loan Agreement (the "interest-only period"). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date.

The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring the Company to maintain certain levels of trailing three-month net product revenue solely from the sale of ibrexafungerp commencing on June 30, 2022. The financial covenant will be waived at any time in which the Company maintains unrestricted and unencumbered cash in accounts maintained with SVB equal to at least 50.0% of the total outstanding Term Loan principal amount, subject to certain requirements.

In connection with the entry into the Loan Agreement, the Company issued to each of Hercules and SVB a warrant (collectively, the "Warrants") to purchase shares of SCYNEXIS's common stock, par value \$0.001 per share (the "Shares"). The amount of shares that may be purchased for the Warrants, collectively between Hercules and SVB, will not exceed 0.04 multiplied by the aggregate amount of the term loan advances, divided by the exercise price of the Warrants.

**Summary of Significant  
Accounting Policies (Policies)**

**[Accounting Policies](#)**

**[\[Abstract\]](#)**

**[Basic and Diluted Net Loss  
per Share of Common Stock](#)**

**3 Months Ended  
Mar. 31, 2021**

*Basic and Diluted Net Loss per Share of Common Stock*

The Company calculates net loss per common share in accordance with ASC 260, *Earnings Per Share*. Basic net loss per common share for the three months ended March 31, 2021 and 2020 was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, *Earnings Per Share*, the weighted average number of common shares outstanding utilized for determining the basic net loss per common share for the three months ended March 31, 2021 includes the pre-funded warrants to purchase 5,260,000 shares of common stock issued in the December 2020 Public Offering. Diluted net loss per common share for the three months ended March 31, 2021 and 2020 was determined as follows (in thousands, except share and per share amounts):

	<b>Three Months Ended March 31,</b>	
	<b>2021</b>	<b>2020</b>
Net loss	\$ (4,676)	\$ (7,002)
Dilutive effect of warrant liability	(1,323)	—
Net loss allocated to common shares	<u>\$ (5,999)</u>	<u>\$ (7,002)</u>
Weighted average common shares outstanding – basic	25,802,700	9,744,577
Dilutive effect of warrant liability	721,220	—
Weighted average common shares outstanding – diluted	<u>26,523,920</u>	<u>9,744,577</u>
Net loss per share – diluted	\$ (0.23)	\$ (0.72)

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three months ended March 31, 2021 and 2020, as the result would be anti-dilutive:

	<b>Three Months Ended March 31,</b>	
	<b>2021</b>	<b>2020</b>
Outstanding stock options	1,371,606	768,354
Outstanding restricted stock units	96,974	85,754
Warrants to purchase common stock associated with June 2016 public offering	421,867	421,867
Warrants to purchase common stock associated with March 2018 public offering – Series 2	798,810	798,810
Warrants to purchase common stock associated with December 2019 Public Offering	4,472,205	4,472,205
Warrants to purchase common stock associated with December 2020 Public Offering - Series 2	6,800,000	—
Common stock associated with March 2019 Notes	1,138,200	1,138,200
Warrants to purchase common stock associated with Solar loan agreement	12,243	12,243
Total	<u>15,111,905</u>	<u>7,697,433</u>

**[Recently Issued Accounting  
Pronouncements](#)**

*Recently Issued Accounting Pronouncements*

In June 2016, the FASB issued ASU No. 2016-13, *Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, *Financial Instruments – Credit Losses (Topic 326)*,



*Derivatives and Hedging (Topic 815), and Leases (Topic 842)* (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.

In August 2020, the FASB issued ASU No. 2020-06, *Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity* (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.

#### *Recently Adopted Accounting Pronouncements*

In December 2019, the FASB issued ASU No. 2019-12, *Income Taxes: Simplifying the Accounting for Income Taxes* (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, *Income Taxes*, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance was adopted by the Company in the first quarter of 2021 and it did not have a material impact on its unaudited condensed consolidated financial statements.

**Summary of Significant  
Accounting Policies (Tables)**

[Accounting Policies \[Abstract\]](#)  
[Schedule of Diluted Net Loss Per  
Common Share](#)

**3 Months Ended  
Mar. 31, 2021**

Diluted net loss per common share for the three months ended March 31, 2021 and 2020 was determined as follows (in thousands, except share and per share amounts):

	<u>Three Months Ended March 31,</u>	
	<u>2021</u>	<u>2020</u>
Net loss	\$ (4,676)	\$ (7,002)
Dilutive effect of warrant liability	(1,323)	—
Net loss allocated to common shares	<u>\$ (5,999)</u>	<u>\$ (7,002)</u>
Weighted average common shares outstanding – basic	25,802,700	9,744,577
Dilutive effect of warrant liability	721,220	—
Weighted average common shares outstanding – diluted	<u>26,523,920</u>	<u>9,744,577</u>
Net loss per share – diluted	\$ (0.23)	\$ (0.72)

[Summary of Antidilutive Securities  
Excluded from Computation of Weighted  
Average Common Stock Outstanding](#)

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for the three months ended March 31, 2021 and 2020, as the result would be anti-dilutive:

	<u>Three Months Ended March 31,</u>	
	<u>2021</u>	<u>2020</u>
Outstanding stock options	1,371,606	768,354
Outstanding restricted stock units	96,974	85,754
Warrants to purchase common stock associated with June 2016 public offering	421,867	421,867
Warrants to purchase common stock associated with March 2018 public offering – Series 2	798,810	798,810
Warrants to purchase common stock associated with December 2019 Public Offering	4,472,205	4,472,205
Warrants to purchase common stock associated with December 2020 Public Offering - Series 2	6,800,000	—
Common stock associated with March 2019 Notes	1,138,200	1,138,200
Warrants to purchase common stock associated with Solar loan agreement	12,243	12,243
Total	<u>15,111,905</u>	<u>7,697,433</u>

**Prepaid Expenses and Other  
Current Assets (Tables)**

**3 Months Ended  
Mar. 31, 2021**

[Deferred Costs Capitalized Prepaid And Other Assets  
Disclosure \[Abstract\]](#)

[Schedule of Prepaid Expenses and Other Current Assets](#)

Prepaid expenses and other current assets consisted of the following (in thousands):

	<u>March 31, 2021</u>	<u>December 31, 2020</u>
Prepaid research and development services	\$ 1,300	\$ 1,535
Prepaid insurance	115	362
Other prepaid expenses	525	19
Other receivables	1,000	2,876
Other current assets	<u>370</u>	<u>373</u>
Total prepaid expenses and other current assets	<u>\$ 3,310</u>	<u>\$ 5,165</u>

## Accrued Expenses (Tables)

**3 Months Ended  
Mar. 31, 2021**

[Payables And Accruals \[Abstract\]](#)  
[Schedule of Accrued Expenses](#)

Accrued expenses consisted of the following (in thousands):

	March 31, 2021	December 31, 2020
Accrued research and development expenses	\$ 647	\$ 991
Accrued employee bonus compensation	433	2,190
Other accrued expenses	1,054	960
Total accrued expenses	<u>\$ 2,134</u>	<u>\$ 4,141</u>

**Commitments and  
Contingencies (Tables)**

**3 Months Ended  
Mar. 31, 2021**

**Commitments And Contingencies  
Disclosure [Abstract]**

**Summary of Quantitative Information  
Associated with Amounts Recognized in  
Unaudited Condensed Consolidated Financial  
Statements for Lease**

The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands):

	Three Months Ended March 31, 2021	Three Months Ended March 31, 2020
Operating lease cost	\$ 166	\$ 166
Variable lease cost	(2)	21
Total operating lease expense	<u>\$ 164</u>	<u>\$ 187</u>
Cash paid for amounts included in the measurement of operating lease liability		
	\$ 170	\$ 167
	March 31, 2021	March 31, 2020
Remaining Lease term (years)	8.34	9.34
Discount rate	15%	15%

**Future Minimum Lease Payments**

Future minimum lease payments for the Lease as of March 31, 2021 are as follows (in thousands):

	March 31, 2021
2021	\$ 347
2022	527
2023	715
2024	730
2025	744
Thereafter	2,789
Total	<u>\$ 5,852</u>

**Presentation of Operating Lease Liability**

The presentations of the operating lease liability as of March 31, 2021 are as follows (in thousands):

	March 31, 2021
Present value of future minimum lease payments	\$ 3,272
Operating lease liability, current portion	\$ 57
Operating lease liability, long-term portion	3,215
Total operating lease liability	<u>\$ 3,272</u>
Difference between future minimum lease payments and discounted cash flows	\$ 2,580

**Stockholders' Equity  
(Tables)**

**3 Months Ended  
Mar. 31, 2021**

[Equity \[Abstract\]](#)

[Summary of Common Stock  
Shares Activity](#)

The following table summarizes common stock share activity for the three months ended March 31, 2021 and 2020 (dollars in thousands):

	Three Months Ended March 31, 2021				
	Shares of Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2020	19,663,698	\$ 20	\$349,351	\$ (326,613)	\$ 22,758
Net loss	—	—	—	(4,676)	(4,676)
Stock-based compensation expense	—	—	398	—	398
Common stock issued for conversion of April 2020 Notes	959,080	1	7,452	—	7,453
Common stock issued through employee stock purchase plan	2,184	—	6	—	6
Common stock issued for vested restricted stock units	675	—	(15)	—	(15)
<b>Balance, March 31, 2021</b>	<b>20,625,637</b>	<b>\$ 21</b>	<b>\$357,192</b>	<b>\$ (331,289)</b>	<b>\$ 25,924</b>

	Three Months Ended March 31, 2020				
	Shares of Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Balance, December 31, 2019	9,741,372	\$ 10	\$284,313	\$ (271,428)	\$ 12,895
Net loss	—	—	—	(7,002)	(7,002)
Stock-based compensation expense	—	—	410	—	410
Common stock issued through employee stock purchase plan	2,215	—	18	—	18
Common stock issued, net of expenses	28,527	—	207	—	207
Common stock issued for vested restricted stock units	15,490	—	(73)	—	(73)
<b>Balance, March 31, 2020</b>	<b>9,787,604</b>	<b>\$ 10</b>	<b>\$284,875</b>	<b>\$ (278,430)</b>	<b>\$ 6,455</b>

[Common Stock Reserved For  
Future Issuances](#)

The Company had reserved shares of common stock for future issuance as follows:

	March 31, 2021	December 31, 2020
Outstanding stock options	1,371,606	830,343
Outstanding restricted stock units	96,974	29,087
Warrants to purchase common stock associated with June 2016 Public Offering	421,867	421,867
Warrants to purchase common stock associated with March 2018 Public Offering – Series 2	798,810	798,810
Warrants to purchase common stock associated with December 2019 Public Offering	4,472,205	4,472,205

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1	6,800,000	6,800,000
Warrants to purchase common stock associated with December 2020 Public Offering - Series 2	6,800,000	6,800,000
Prefunded warrants to purchase common stock associated with December 2020 Public Offering	5,260,000	5,260,000
Warrants to purchase common stock associated with Solar loan agreement	12,243	12,243
For possible future issuance for the conversion of the March 2019 Notes	1,138,200	1,138,200
For possible future issuance for the conversion of the April 2020 Notes	—	1,299,790
For possible future issuance under 2014 Equity Incentive Plan (Note 9)	318,097	146,488
For possible future issuance under Employee Stock Purchase Plan	6,652	5,895
For possible future issuance under 2015 Inducement Award Plan (Note 9)	14,050	14,050
Total common shares reserved for future issuance	<u>27,510,704</u>	<u>28,028,978</u>

**Stock-based Compensation  
(Tables)**

**3 Months Ended  
Mar. 31, 2021**

[Disclosure Of Compensation  
Related Costs Sharebased  
Payments \[Abstract\]  
Schedule of Share-based  
Compensation, Stock Options,  
Activity](#)

The activity for the Company's 2009 Stock Option Plan, 2014 Plan, and 2015 Plan, for the three months ended March 31, 2021, is summarized as follows:

	Number of Shares	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (\$000)
Outstanding — December 31, 2020	830,343	\$ 21.52	7.71	\$ 96
Granted	545,450	\$ 7.57		
Forfeited/Cancelled	(4,187)	\$ 8.48		
Outstanding — March 31, 2021	<u>1,371,606</u>	\$ 16.01	8.33	\$ 355
Exercisable — March 31, 2021	<u>500,625</u>	\$ 29.27	6.72	\$ 37
Vested or expected to vest — March 31, 2021	<u>1,371,606</u>	\$ 16.01	8.33	\$ 355

[Schedule of Restricted Stock Units  
\("RSU"\) Activity](#)

Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the three months ended March 31, 2021, is summarized as follows:

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Non-vested at December 31, 2020	29,087	\$ 9.52
Granted	73,675	\$ 7.55
Vested	(5,788)	\$ 10.68
Non-vested at March 31, 2021	<u>96,974</u>	\$ 7.95

[Stock-Based Compensation Expense  
Related to Stock Options](#)

Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands):

	Three Months Ended March 31,	
	2021	2020
Research and development	\$ 126	\$ 136
Selling, general and administrative	272	274
Total	<u>\$ 398</u>	<u>\$ 410</u>



**Fair Value Measurements  
(Tables)**

**3 Months Ended  
Mar. 31, 2021**

[Fair Value Disclosures \[Abstract\]  
Summary of Financial Instruments  
Measured on a Recurring Basis](#)

The following table summarizes the conclusions reached as of March 31, 2021 and December 31, 2020 for financial instruments measured at fair value on a recurring basis (in thousands):

	Balance	Fair Value Hierarchy Classification		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>March 31, 2021</b>				
Cash	\$ 236	\$ 236	—	—
Restricted cash	273	273	—	—
Money market funds	91,775	91,775	—	—
<b>Total assets</b>	<b>\$92,284</b>	<b>\$92,284</b>	<b>—</b>	<b>—</b>
<b>December 31, 2020</b>				
Warrant liabilities	\$49,860	—	—	\$ 49,860
Derivative liability	2,618	—	—	2,618
<b>Total liabilities</b>	<b>\$52,478</b>	<b>—</b>	<b>—</b>	<b>\$ 52,478</b>
<b>December 31, 2020</b>				
Cash	\$ 117	\$ 117	—	—
Restricted cash	273	273	—	—
Money market funds	92,924	92,924	—	—
<b>Total assets</b>	<b>\$93,314</b>	<b>\$93,314</b>	<b>—</b>	<b>—</b>
Warrant liabilities	\$51,156	—	—	\$ 51,156
Derivative liabilities	5,954	—	—	5,954
<b>Total liabilities</b>	<b>\$57,110</b>	<b>—</b>	<b>—</b>	<b>\$ 57,110</b>

[Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis](#)

A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

	Warrant Liabilities
Balance – December 31, 2020	\$ 51,156
Gain adjustment to fair value	(1,296)
<b>Balance – March 31, 2021</b>	<b>\$ 49,860</b>
	<b>Derivative Liabilities</b>
Balance – December 31, 2020	\$ 5,954
Adjustment for conversion of April 2020 Notes	(3,426)
Gain adjustment to fair value	90
<b>Balance – March 31, 2021</b>	<b>\$ 2,618</b>

**Description of Business and  
Basis of Preparation -  
Additional Information  
(Detail)  
\$ in Thousands**

**Organization Consolidation And Presentation Of  
Financial Statements [Abstract]**

	<b>Jul. 16, 2020 shares</b>	<b>Mar. 31, 2021 USD (\$) shares</b>	<b>Dec. 31, 2020 USD (\$) shares</b>	<b>Jul. 17, 2020 shares</b>
<u>Accumulated deficit</u>		\$ (331,289)	\$ (326,613)	
<u>Cash and cash equivalents</u>		\$ 92,011	\$ 93,041	
<u>Reverse stock split, ratio</u>	0.1			
<u>Common stock, shares authorized (in shares)   shares</u>	250,000,000	100,000,000	100,000,000	100,000,000

**Summary of Significant  
Accounting Policies -  
Additional Information  
(Details)**

**Mar. 31, 2021  
shares**

[ASU 2019-12](#)

**[Subsidiary Sale Of Stock \[Line Items\]](#)**

[Change in Accounting Principle, Accounting Standards Update, Adopted](#) true

[Change in Accounting Principle, Accounting Standards Update, Adoption Date](#) Mar. 31, 2021

[Change in Accounting Principle, Accounting Standards Update, Immaterial Effect](#) true

[December 2020 Public Offering | Pre-funded Warrants](#)

**[Subsidiary Sale Of Stock \[Line Items\]](#)**

[Number of warrants issued to purchase common stock \(in shares\)](#) 5,260,000

**Summary of Significant  
Accounting Policies -  
Schedule of Diluted Net Loss  
Per Common Share (Details)  
- USD (\$)  
\$ / shares in Units, \$ in  
Thousands**

**3 Months Ended**

**Mar. 31, 2021 Mar. 31, 2020**

**Accounting Policies [Abstract]**

<u>Net loss</u>	\$ (4,676)	\$ (7,002)
<u>Dilutive effect of warrant liability</u>	(1,323)	0
<u>Net loss allocated to common shares</u>	\$ (5,999)	\$ (7,002)
<u>Weighted average common shares outstanding – basic</u>	25,802,700	9,744,577
<u>Dilutive effect of warrant liability</u>	721,220	0
<u>Weighted average common shares outstanding – diluted</u>	26,523,920	9,744,577
<u>Net loss per share – diluted</u>	\$ (0.23)	\$ (0.72)

**Summary of Significant  
Accounting Policies -  
Schedule of Potentially  
Dilutive Shares (Details) -  
shares**

**3 Months Ended**

**Mar. 31,  
2021      Mar. 31,  
2020**

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	15,111,905	7,697,433
<u>Outstanding stock options</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	1,371,606	768,354
<u>Outstanding restricted stock units</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	96,974	85,754
<u>Warrants to purchase common stock associated with June 2016 Public Offering   Warrant</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	421,867	421,867
<u>March 2018 Public Offering Series 2   Warrant</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	798,810	798,810
<u>December 2019 Public Offering   Warrant</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	4,472,205	4,472,205
<u>December 2020 Public Offering Series 2   Warrant</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	6,800,000	0
<u>Common stock associated with March 2019 Notes</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	1,138,200	1,138,200
<u>Warrants to purchase common stock associated with Solar loan agreement   Warrant</u>		

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Anti-dilutive securities (in shares)</u>	12,243	12,243
---	--------	--------

**Prepaid Expenses and Other  
Current Assets (Detail) -  
USD (\$)  
\$ in Thousands**

**Mar. 31, 2021 Dec. 31, 2020**

**Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]**

<u>Prepaid research and development services</u>	\$ 1,300	\$ 1,535
<u>Prepaid insurance</u>	115	362
<u>Other prepaid expenses</u>	525	19
<u>Other receivables</u>	1,000	2,876
<u>Other current assets</u>	370	373
<u>Total prepaid expenses and other current assets</u>	\$ 3,310	\$ 5,165

**Accrued Expenses - Schedule  
of Accrued Expenses  
(Details) - USD (\$)  
\$ in Thousands**

**Mar. 31, 2021 Dec. 31, 2020**

**Payables And Accruals [Abstract]**

<u>Accrued research and development expenses</u>	\$ 647	\$ 991
<u>Accrued employee bonus compensation</u>	433	2,190
<u>Other accrued expenses</u>	1,054	960
<u>Total accrued expenses</u>	\$ 2,134	\$ 4,141

Borrowings - Additional Information (Details)	Apr. 09, 2020 USD (\$)	Mar. 07, 2019 USD (\$) d \$ / shares	1 Months Ended	3 Months Ended			
			Jan. 31, 2021 USD (\$) shares	Mar. 31, 2021 USD (\$)	Mar. 31, 2020 USD (\$)	Dec. 31, 2020 USD (\$)	
<b><u>Debt Instrument [Line Items]</u></b>							
<u>Loss on extinguishment of debt</u>				\$ 2,725,000		\$ 0	
<u>Net carrying amount of convertible debt and derivative liability</u>				12,226,000			\$ 16,516,000
<u>Amortization of debt issuance costs and discount</u>				256,000		278,000	
<u>April 2020 Note Purchase Agreement</u>							
<b><u>Debt Instrument [Line Items]</u></b>							
<u>Date of issuance and sale of notes</u>	Apr. 09, 2020						
<u>Face amount</u>	\$ 10,000,000.0						
<u>Proceeds from debt, net of issuance costs</u>	9,500,000						
<u>Payment of debt issuance costs</u>	\$ 500,000						
<u>Fair value of notes</u>							7,400,000
<u>Conversion of convertible note, amount</u>				\$ 6,000,000.0			
<u>Conversion of convertible note exchanged for shares   shares</u>				959,080			
<u>Loss on extinguishment of debt</u>				\$ 2,700,000			
<u>Net carrying amount of convertible debt and derivative liability</u>				4,800,000			
<u>Fair value of the consideration issued</u>				\$ 7,500,000			
<u>Senior Convertible Note Purchase Agreement</u>							
<b><u>Debt Instrument [Line Items]</u></b>							
<u>Date of issuance and sale of notes</u>		Mar. 07, 2019					



<u>Face amount</u>	\$		
		16,000,000.0	
<u>Proceeds from debt, net of issuance costs</u>		14,700,000	
<u>Payment of debt issuance costs</u>	\$	1,300,000	
<u>Senior convertible notes</u>		9,600,000	
<u>Unamortized debt issuance cost</u>		400,000	
<u>Bifurcated embedded conversion option derivative liability</u>		2,600,000	
<u>Derivative, fair value</u>		7,000,000.0	
<u>Gain (loss) on fair value adjustment of derivative liability</u>		42,000	700,000
<u>Amortization of debt issuance costs and discount</u>		300,000	\$ 300,000
<u>Fair value of convertible debt and derivative liability</u>		\$ 12,900,000	\$ 12,900,000
<u>Purchase price as percentage of principal amount</u>	100.00%		
<u>Interest rate</u>	6.00%		
<u>Payment terms</u>			The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased.
<u>Notes maturity date</u>	Mar. 15,		
	2025		
<u>Notes maturity description</u>			The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased or repurchased holder of the March 2019 Notes may
<u>Conversion terms</u>			

convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company's common stock.

<u>Conversion rate, number of shares to be issued per \$1000 of principal (in shares)</u>	73.9096
<u>Principal amount of notes used as the denominator for conversion into notes</u>	\$ 1,000
<u>Initial conversion price of notes   \$ / shares</u>	\$ 13.53
<u>Conversion rate, number of shares to be issued per \$1000 of principal (in shares) after adjustment to certain events</u>	81
<u>Principal amount of notes used as the denominator for conversion into notes after adjustment of certain events</u>	\$ 1,000
<u>Convertible notes, redemption start date</u>	Mar. 15, 2022
<u>Convertible notes, threshold percentage of stock price trigger</u>	130.00%
<u>Convertible notes, threshold trading days   d</u>	20
<u>Convertible notes, threshold consecutive trading days   d</u>	30
<u>Redemption price as percentage of the principal amount</u>	100.00%
<u>Redemption price as percentage of the principal amount subject to certain exceptions</u>	100.00%

3 Months Ended

Commitments and Contingencies - Additional Information (Detail)	Mar. 01, 2018 USD (\$) ft <sup>2</sup>	Mar. 31, 2021 USD (\$)	Mar. 31, 2020 USD (\$)
<b><u>Commitment And Contingencies [Line Items]</u></b>			
<u>Long-term lease agreement, area of office space   ft<sup>2</sup></u>	19,275		
<u>Lease term</u>	11 years		
<u>Total lease payments</u>	\$ 7,300,000	\$ 170,000	\$ 167,000
<u>Lessee, operating lease, existence of option to extend</u>	true		
<u>Renewal term</u>	5 years		
<u>Renewal term, description</u>		<p>The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of \$0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years.</p>	
<u>Security deposit in the form of a standby letter of credit</u>	\$ 300,000		
<u>Decrease in security deposit</u>	\$ 55,000		
<u>Maximum</u>			
<b><u>Commitment And Contingencies [Line Items]</u></b>			
<u>Milestone payments from the Company</u>		\$ 19,000,000.0	

**Commitments and  
Contingencies - Summary of  
Quantitative Information  
Associated with Amounts  
Recognized in Unaudited  
Condensed Consolidated  
Financial Statements for  
Lease (Detail) - USD (\$)  
\$ in Thousands**

**3 Months Ended**

**Mar. 01,  
2018                      Mar. 31, 2021                      Mar. 31, 2020**

**Commitments And Contingencies Disclosure**

**[Abstract]**

<u>Operating lease cost</u>		\$ 166	\$ 166
<u>Variable lease cost</u>		(2)	21
<u>Total operating lease expense</u>		164	187
<u>Total lease payments</u>	\$ 7,300	\$ 170	\$ 167
<u>Remaining Lease term (years)</u>		8 years 4 months 2 days	9 years 4 months 2 days
<u>Discount rate</u>		15.00%	15.00%

**Commitments and  
Contingencies - Future  
Minimum Lease Payments  
(Detail)**

**Mar. 31, 2021  
USD (\$)**

**\$ in Thousands**

**[Commitments And Contingencies Disclosure \[Abstract\]](#)**

<u>2021</u>	\$ 347
<u>2022</u>	527
<u>2023</u>	715
<u>2024</u>	730
<u>2025</u>	744
<u>Thereafter</u>	2,789
<u>Total</u>	\$ 5,852

**Commitments and  
Contingencies - Presentation  
of Operating Lease Liability  
(Detail) - USD (\$)  
\$ in Thousands**

**Mar. 31, 2021 Dec. 31, 2020**

**Commitments And Contingencies Disclosure [Abstract]**

<u>Present value of future minimum lease payments</u>	\$ 3,272	
<u>Operating lease liability, current portion</u>	57	\$ 52
<u>Operating lease liability, long-term portion</u>	3,215	\$ 3,274
<u>Total operating lease liability</u>	3,272	
<u>Difference between future minimum lease payments and discounted cash flows</u>	\$ 2,580	

Stockholders' Equity - Additional Information (Detail) \$ / shares in Units, \$ in Thousands	3 Months Ended						
	Jul. 16, 2020 shares	Apr. 10, 2020 USD (\$) \$ / shares shares	Sep. 30, 2016 \$ / shares shares	Mar. 31, 2021 USD (\$) \$ / shares shares	Mar. 31, 2020 USD (\$)	Dec. 31, 2020 \$ / shares shares	Jul. 17, 2020 shares
<b>Schedule Of Capitalization Equity</b>							
<b>[Line Items]</b>							
<u>Common stock, par value (in dollars per share)   \$ / shares</u>				\$ 0.001		\$ 0.001	
<u>Common stock, shares authorized (in shares)   shares</u>	250,000,000			100,000,000		100,000,000	100,000,000
<u>Common stock, shares issued (in shares)   shares</u>				20,625,637		19,663,698	
<u>Common stock, shares outstanding (in shares)   shares</u>				20,625,637		19,663,698	
<u>Common stock, reverse stock split</u>				1-for-10			
<u>Common stock, reverse stock split ratio</u>	0.1						
<u>Proceeds from common stock issued   \$</u>				\$ 0		\$ 214	
<u>Derivative liability fair value adjustment   \$</u>				(90)		700	
<u>Warrant liabilities fair value adjustment   \$</u>				1,296		4,768	
<u>Warrant liabilities   \$</u>				49,900		51,200	
<u>Warrants to purchase common stock associated with Loan Agreement</u>							
<b>Schedule Of Capitalization Equity</b>							
<b>[Line Items]</b>							
<u>Number of warrants issued to purchase common stock (in shares)   shares</u>				12,243			
<u>Exercise price of warrants (in dollars per share)   \$ / shares</u>				\$ 36.754			
<u>Warrant expiration period</u>				5			
				years			
<u>Senior Convertible Note Purchase Agreement   Other (Income) Expense</u>							
<b>Schedule Of Capitalization Equity</b>							
<b>[Line Items]</b>							
<u>Derivative liability fair value adjustment   \$</u>				\$ (100)		\$ 700	

Aspire Capital | Common Stock

Purchase Agreement

**Schedule Of Capitalization Equity**

**[Line Items]**

Number of purchase aggregate  
shares of common stock | shares 1,956,547

Percentage of common stock  
outstanding 19.99%

Number of shares committed |  
shares 70,910

Average purchase price of shares  
sold | \$ / shares \$ 8.461

Percentage of common stock owned 19.99%

Aspire Capital | Common Stock

Purchase Agreement | Maximum

**Schedule Of Capitalization Equity**

**[Line Items]**

Sale of common stock at sole  
discretion | \$ \$ 20,000



**Stockholders' Equity -  
Summary of Common Stock  
Shares Activity (Detail) -  
USD (\$)  
\$ in Thousands**

**3 Months Ended**

**Mar. 31, 2021 Mar. 31, 2020**

**Common Stock Outstanding Roll Forward [Roll Forward]**

<u>Beginning balance</u>	\$ 22,758	\$ 12,895
<u>Beginning balance (in shares)</u>	19,663,698	
<u>Net loss</u>	\$ (4,676)	(7,002)
<u>Stock-based compensation expense</u>	398	410
<u>Common stock issued, net of expenses</u>	0	207
<u>Common stock issued through employee stock purchase plan</u>	6	18
<u>Common stock issued for vested restricted stock units</u>	(15)	(73)
<u>Ending balance</u>	\$ 25,924	6,455
<u>Ending balance (in shares)</u>	20,625,637	

April 2020 Notes

**Common Stock Outstanding Roll Forward [Roll Forward]**

<u>Common stock issued for conversion of Notes</u>	\$ 7,453	
--	----------	--

Common Stock

**Common Stock Outstanding Roll Forward [Roll Forward]**

<u>Beginning balance</u>	\$ 20	\$ 10
<u>Beginning balance (in shares)</u>	19,663,698	9,741,372
<u>Net loss</u>	\$ 0	\$ 0
<u>Stock-based compensation expense</u>	0	0
<u>Common stock issued, net of expenses</u>	\$ 0	\$ 0
<u>Common stock issued, net of expenses (in shares)</u>	0	28,527
<u>Common stock issued through employee stock purchase plan</u>	\$ 0	\$ 0
<u>Common stock issued through employee stock purchase plan (in shares)</u>	2,184	2,215
<u>Common stock issued for vested restricted stock units</u>	\$ 0	\$ 0
<u>Common stock issued for vested restricted stock units (in shares)</u>	675	15,490
<u>Ending balance</u>	\$ 21	\$ 10
<u>Ending balance (in shares)</u>	20,625,637	9,787,604

Common Stock | April 2020 Notes

**Common Stock Outstanding Roll Forward [Roll Forward]**

<u>Common stock issued for conversion of Notes</u>	\$ 1	
<u>Common stock issued for conversion of Notes (in shares)</u>	959,080	

Additional Paid-in Capital

**Common Stock Outstanding Roll Forward [Roll Forward]**

<u>Beginning balance</u>	\$ 349,351	\$ 284,313
<u>Net loss</u>	0	0
<u>Stock-based compensation expense</u>	398	410
<u>Common stock issued, net of expenses</u>	0	207
<u>Common stock issued through employee stock purchase plan</u>	6	18
<u>Common stock issued for vested restricted stock units</u>	(15)	(73)

<u>Ending balance</u>	357,192	284,875
<u>Additional Paid-in Capital   April 2020 Notes</u>		
<b><u>Common Stock Outstanding Roll Forward [Roll Forward]</u></b>		
<u>Common stock issued for conversion of Notes</u>	7,452	
<u>Accumulated Deficit</u>		
<b><u>Common Stock Outstanding Roll Forward [Roll Forward]</u></b>		
<u>Beginning balance</u>	(326,613)	(271,428)
<u>Net loss</u>	(4,676)	(7,002)
<u>Stock-based compensation expense</u>	0	0
<u>Common stock issued, net of expenses</u>	0	0
<u>Common stock issued through employee stock purchase plan</u>	0	0
<u>Common stock issued for vested restricted stock units</u>	0	0
<u>Ending balance</u>	(331,289)	\$ (278,430)
<u>Accumulated Deficit   April 2020 Notes</u>		
<b><u>Common Stock Outstanding Roll Forward [Roll Forward]</u></b>		
<u>Common stock issued for conversion of Notes</u>	\$ 0	

**Stockholders' Equity -  
Schedule of Reserved Shares  
of Common Stock for Future  
Issuance (Detail) - shares**

	<b>Mar. 31, 2021</b>	<b>Dec. 31, 2020</b>
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	27,510,704	28,028,978
<a href="#"><u>Stock options</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	1,371,606	830,343
<a href="#"><u>Restricted Stock Units</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	96,974	29,087
<a href="#"><u>Warrant   June 2016 Public Offering</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	421,867	421,867
<a href="#"><u>Warrant   December 2019 Public Offering</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	4,472,205	4,472,205
<a href="#"><u>Warrant   December 2020 Public Offering Series 1</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	6,800,000	6,800,000
<a href="#"><u>Warrant   December 2020 Public Offering Series 2</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	6,800,000	6,800,000
<a href="#"><u>Warrant   Prefunded Warrants to Purchase Common Stock Associated with December 2020 Public Offering</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	5,260,000	5,260,000
<a href="#"><u>Warrant   Warrants to purchase common stock associated with Solar loan agreement</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	12,243	12,243
<a href="#"><u>Series 1 Warrant   March 2018 Public Offering</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	798,810	798,810
<a href="#"><u>March 2019 Notes</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	1,138,200	1,138,200
<a href="#"><u>April 2020 Notes</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	0	1,299,790
<a href="#"><u>2014 Equity Incentive Plan</u></a>		
<a href="#"><u>Class of Stock [Line Items]</u></a>		
<a href="#"><u>Common shares reserved for future issuance</u></a>	318,097	146,488
<a href="#"><u>2014 Employee Stock Purchase Plan</u></a>		

**Class of Stock [Line Items]**

Common shares reserved for future issuance  
2015 Inducement Award Plan

6,652 5,895

**Class of Stock [Line Items]**

Common shares reserved for future issuance

14,050 14,050

**Stock-based Compensation -  
2014 Equity Incentive Plan  
(Details) - 2014 Equity  
Incentive Plan - shares**

	<b>Jan. 01, 2021</b>	<b>Jan. 01, 2020</b>	<b>Mar. 31, 2021</b>
<b><u>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</u></b>			
<u>Share-based compensation arrangement by share-based payment award, number of additional shares authorized</u>	786,547	389,650	
<u>Possible future issuance under equity compensation plan (in shares)</u>			318,097

Stock-based Compensation - 2015 Inducement Award Plan (Details) - shares	3 Months Ended			
	Mar. 31, 2021	Mar. 31, 2020	Apr. 30, 2021	Apr. 29, 2021
<b><u>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</u></b>				
<u>Granted (shares)</u>	545,450			
<u>2015 Inducement Award Plan</u>				
<b><u>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</u></b>				
<u>Possible future issuance under equity compensation plan (in shares)</u>	14,050			
<u>Granted (shares)</u>	0	17,500		
<u>2015 Inducement Award Plan   Subsequent Event</u>				
<b><u>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</u></b>				
<u>Shares authorized under the plan (in shares)</u>			500,000	90,000

<b>Stock-based Compensation - Stock Option Activity (Details) - USD (\$) \$ / shares in Units, \$ in Thousands</b>	<b>3 Months Ended</b>	<b>12 Months Ended</b>
	<b>Mar. 31, 2021</b>	<b>Dec. 31, 2020</b>
<b><u>Number of Shares</u></b>		
<u>Beginning balance - Outstanding (shares)</u>	830,343	
<u>Granted (shares)</u>	545,450	
<u>Forfeited/Cancelled (shares)</u>	(4,187)	
<u>Ending balance - Outstanding (shares)</u>	1,371,606	830,343
<u>Exercisable (shares)</u>	500,625	
<u>Vested or expected to vest (shares)</u>	1,371,606	
<b><u>Weighted- Average Exercise Price</u></b>		
<u>Beginning balance - Outstanding (in dollars per share)</u>	\$ 21.52	
<u>Granted (in dollars per share)</u>	7.57	
<u>Forfeited/Cancelled (in dollars per share)</u>	8.48	
<u>Ending balance - Outstanding (in dollars per share)</u>	16.01	\$ 21.52
<u>Exercisable (in dollars per share)</u>	29.27	
<u>Vested or expected to vest (in dollars per share)</u>	\$ 16.01	
<b><u>Weighted- Average Remaining Contractual Life (in years)</u></b>		
<u>Balance - Outstanding</u>	8 years 3 months 29 days	7 years 8 months 15 days
<u>Exercisable</u>	6 years 8 months 19 days	
<u>Vested or expected to vest</u>	8 years 3 months 29 days	
<b><u>Aggregate Intrinsic Value (\$000)</u></b>		
<u>Balance - Outstanding</u>	\$ 355	\$ 96
<u>Exercisable</u>	37	
<u>Vested and expected to vest</u>	\$ 355	

**Stock-based Compensation -  
Schedule of Restricted Stock  
Units ("RSU") Activity  
(Details) - Outstanding  
restricted stock units**

**3 Months Ended  
Mar. 31, 2021  
\$ / shares  
shares**

**Number of Shares**

<u>Beginning balance - Outstanding (shares)   shares</u>	29,087
<u>Options granted in period (shares)   shares</u>	73,675
<u>Vested (shares)   shares</u>	(5,788)
<u>Ending balance - Outstanding (shares)   shares</u>	96,974

**Weighted Average Grant Date Fair Value Per Share**

<u>Beginning balance - Outstanding (in dollars per share)   \$ / shares</u>	\$ 9.52
<u>Granted (in dollars per share)   \$ / shares</u>	7.55
<u>Vested (in dollars per share)   \$ / shares</u>	10.68
<u>Ending balance - Outstanding (in dollars per share)   \$ / shares</u>	\$ 7.95
<u>Vesting percentage</u>	25.00%
<u>Vesting period of options</u>	4 years



**Stock-based Compensation -  
Compensation Cost (Details)  
- USD (\$)**

**3 Months Ended  
Mar. 31, 2021 Mar. 31, 2020**

**Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]**

<u>Stock-based compensation expense</u>	\$ 398,000	\$ 410,000
<u>Tax benefit from compensation expense</u>	\$ 0	\$ 0

**Stock-based Compensation -  
Expense Related to Stock  
Options (Detail) - USD (\$)  
\$ in Thousands**

**3 Months Ended**  
**Mar. 31,      Mar. 31,**  
**2021            2020**

**Share Based Compensation Arrangement By Share Based Payment Award [Line  
Items]**

<u>Stock-based compensation expense related to stock options</u>	\$ 398	\$ 410
<u>Research and development, net</u>		

**Share Based Compensation Arrangement By Share Based Payment Award [Line  
Items]**

<u>Stock-based compensation expense related to stock options</u>	126	136
<u>Selling, general and administrative</u>		

**Share Based Compensation Arrangement By Share Based Payment Award [Line  
Items]**

<u>Stock-based compensation expense related to stock options</u>	\$ 272	\$ 274
--	--------	--------

**Fair Value Measurements -  
Summary of Financial  
Instruments Measured on a  
Recurring Basis (Details) -  
Fair Value, Measurements,  
Recurring - USD (\$)  
\$ in Thousands**

	Mar. 31, 2021	Dec. 31, 2020
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial assets</u>	\$ 92,284	\$ 93,314
<u>Fair value of financial liabilities</u>	52,478	57,110
<u>Warrant liabilities</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial liabilities</u>	49,860	51,156
<u>Derivative liabilities</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial liabilities</u>	2,618	5,954
<u>Cash</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial assets</u>	236	117
<u>Restricted cash</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial assets</u>	273	273
<u>Money market funds</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial assets</u>	91,775	92,924
<u>Quoted Prices in Active Markets for Identical Assets (Level 1)</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial assets</u>	92,284	93,314
<u>Fair value of financial liabilities</u>	0	0
<u>Quoted Prices in Active Markets for Identical Assets (Level 1)   Warrant liabilities</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial liabilities</u>	0	0
<u>Quoted Prices in Active Markets for Identical Assets (Level 1)   Derivative liabilities</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial liabilities</u>	0	0
<u>Quoted Prices in Active Markets for Identical Assets (Level 1)   Cash</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial assets</u>	236	117
<u>Quoted Prices in Active Markets for Identical Assets (Level 1)   Restricted cash</u>		
<b><u>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</u></b>		
<u>Fair value of financial assets</u>	273	273
<u>Quoted Prices in Active Markets for Identical Assets (Level 1)   Money market funds</u>		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	91,775	92,924
Significant Other Observable Inputs (Level 2)		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	0	0
Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2)   Warrant liabilities		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2)   Derivative liabilities		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial liabilities	0	0
Significant Other Observable Inputs (Level 2)   Cash		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	0	0
Significant Other Observable Inputs (Level 2)   Restricted cash		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	0	0
Significant Other Observable Inputs (Level 2)   Money market funds		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3)		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	0	0
Fair value of financial liabilities	52,478	57,110
Significant Unobservable Inputs (Level 3)   Warrant liabilities		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial liabilities	49,860	51,156
Significant Unobservable Inputs (Level 3)   Derivative liabilities		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial liabilities	2,618	5,954
Significant Unobservable Inputs (Level 3)   Cash		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3)   Restricted cash		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	0	0
Significant Unobservable Inputs (Level 3)   Money market funds		

**Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]**

Fair value of financial assets	\$ 0	\$ 0
--------------------------------	------	------

**Fair Value Measurements -  
Additional Information  
(Details) - Significant  
Unobservable Inputs (Level  
3)**

**Mar. 31, 2021**

**Dec. 31, 2019**

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Warrant liabilities, maturity date

Jun. 12, 2023

Stock Price Volatility

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Derivative liabilities, unobservable inputs rate

61.5

Stock Price Volatility | Minimum

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Warrant liabilities, stock price volatility rate

69.6

Stock Price Volatility | Maximum

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Warrant liabilities, stock price volatility rate

82.5

Stock Price Volatility | Weighted Average

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Warrant liabilities, stock price volatility rate

77.6

Weighted Average Expected Term

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Warrant liabilities, expected term

10 months 24  
days

Weighted Average Expected Term | Minimum

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Warrant liabilities, expected term

7 months 28 days

Weighted Average Expected Term | Maximum

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Warrant liabilities, expected term

2 years 2 months 12  
days

Market Credit Spread

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

Derivative liabilities, unobservable inputs rate

1,451

Estimated Yield

**Fair Value Balance Sheet Grouping Financial Statement Captions  
[Line Items]**

<a href="#"><u>Derivative liabilities, unobservable inputs rate</u></a>	15.1
<a href="#"><u>Discounts for Lack of Marketability   March 2019 Notes</u></a>	
<a href="#"><b><u>Fair Value Balance Sheet Grouping Financial Statement Captions</u></b></a>	
<a href="#"><b><u>[Line Items]</u></b></a>	
<a href="#"><u>Senior convertible notes, unobservable inputs rate</u></a>	7.1

**Fair Value Measurements -  
Summary of Reconciliation  
of Beginning and Ending  
Balances for Liabilities  
Measured at Fair Value on  
Recurring Basis (Details)  
\$ in Thousands**

**3 Months  
Ended**

**Mar. 31, 2021  
USD (\$)**

Warrant liabilities

**Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation  
[Line Items]**

<u>Beginning balance</u>	\$ 51,156
<u>Gain (loss) adjustment to fair value</u>	(1,296)
<u>Ending balance</u>	49,860

Derivative liabilities

**Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation  
[Line Items]**

<u>Beginning balance</u>	5,954
<u>Adjustment for conversion of April 2020 Notes</u>	(3,426)
<u>Gain (loss) adjustment to fair value</u>	90
<u>Ending balance</u>	\$ 2,618

**License Agreement Revenue**  
**- Additional Information**  
**(Detail) - USD (\$)**

**3 Months Ended**  
**Mar. 31, Mar. 31, Feb. 28, 2021**  
**2021 2020**

**Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]**

Income tax expense \$ 1,100,000 \$ 0

Exclusive License And Collaboration Agreement

**Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]**

Non refundable upfront payment received 10,000,000.0

Transaction price 12,100,000

Fixed upfront cash payment 10,000,000.0

Amount related to withholding tax obligations 1,100,000

Revenue recognized 1,100,000

Income tax expense 1,100,000

Exclusive License And Collaboration Agreement | Maximum

**Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]**

Potential development and commercial milestones yet to receive \$ 110,000,000.0

Asset Purchase Agreement | Cypralis Limited

**Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]**

Revenue recognized 0

License Agreement | Waterstone Pharmaceutical HK Limited

**Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]**

Revenue recognized \$ 0



**Subsequent Events -  
Additional Information  
(Details)**

	<b>1 Months Ended</b>		
	<b>May 31, 2021</b>	<b>Mar. 31, 2021</b>	<b>Dec. 31, 2020</b>
	<b>USD (\$) Tranche \$/ shares</b>	<b>\$/ shares</b>	<b>\$/ shares</b>
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Common stock, par value (in dollars per share)   \$ / shares</u></a>		\$ 0.001	\$ 0.001
<a href="#"><u>Subsequent Event   SVB</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Minimum outstanding term loan principal percentage for financial covenant waived</u></a>	50.00%		
<a href="#"><u>Subsequent Event   Loan and Security Agreement   Hercules Capital Inc. and Silicon Valley Bank</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Common stock, par value (in dollars per share)   \$ / shares</u></a>		\$ 0.001	
<a href="#"><u>Multiplier value by aggregate amount of the term loan advances divided by exercise price of warrants to calculate number of shares for purchase</u></a>	0.04		
<a href="#"><u>Subsequent Event   Loan and Security Agreement   Term Loan</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Notes maturity date</u></a>		Mar. 03, 2025	
<a href="#"><u>Basis spread on variable rate (as a percent)</u></a>	9.05%		
<a href="#"><u>Debt instrument maturity date subject to occurrence of certain conditions</u></a>		May 01, 2025	
<a href="#"><u>Subsequent Event   Loan and Security Agreement   Term Loan   Prime Rate</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Basis spread on variable rate (as a percent)</u></a>	5.80%		
<a href="#"><u>Subsequent Event   Loan and Security Agreement   Term Loan   Hercules Capital Inc. and Silicon Valley Bank</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Face amount</u></a>		\$ 60,000,000.0	
<a href="#"><u>Number of available tranches   Tranche</u></a>		4	
<a href="#"><u>Subsequent Event   Loan and Security Agreement   Initial Tranche of Term Loan</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Additional borrowing amount available</u></a>		\$ 20,000,000.0	
<a href="#"><u>Subsequent Event   Loan and Security Agreement   Second Tranche of Term Loan</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Additional borrowing amount available</u></a>		10,000,000.0	
<a href="#"><u>Subsequent Event   Loan and Security Agreement   Third Tranche of Term Loan</u></a>			
<a href="#"><u>Subsequent Event [Line Items]</u></a> <a href="#"><u>Additional borrowing amount available</u></a>		5,000,000.0	

Subsequent Event | Loan and Security Agreement | Fourth Tranche of Term Loan

**Subsequent Event [Line Items]**

Additional borrowing amount available 25,000,000.0

Increment debt amount 5,000,000.0

Subsequent Event | New Jersey

**Subsequent Event [Line Items]**

Selling value of unused net operating losses and research and development credit \$ 4,200,000

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the experimental procedures and the statistical techniques employed to interpret the results.

3. The third part of the document presents the findings of the study. It shows that there is a significant correlation between the variables being studied, which supports the hypothesis that was tested.

4. The fourth part of the document discusses the implications of the findings for future research and practice. It suggests that the results could be used to inform policy decisions and to guide the development of new interventions.

5. The fifth part of the document concludes the study by summarizing the key points and reiterating the importance of the research. It also acknowledges the limitations of the study and offers suggestions for how these could be addressed in future work.





















1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze data. It includes a detailed description of the sampling process and the statistical techniques employed to ensure the reliability of the results.

3. The third part of the document presents the findings of the study. It highlights the key trends and patterns observed in the data, as well as the implications of these findings for the industry and the broader economy.

4. The fourth part of the document discusses the limitations of the study and the potential areas for future research. It acknowledges the challenges faced during the data collection and analysis process and offers suggestions for how these challenges can be addressed in future studies.

5. The fifth part of the document provides a conclusion and a summary of the main points discussed throughout the document. It reiterates the importance of accurate record-keeping and the need for ongoing research in this field.

1. The first step in the process of identifying a problem is to define the problem clearly. This involves identifying the symptoms and the underlying causes of the problem. Once the problem is defined, the next step is to gather information about the problem. This can be done through research, interviews, and observation. The information gathered should be used to identify the scope of the problem and the resources available to solve it. The next step is to develop a plan of action. This plan should outline the steps that need to be taken to solve the problem and the resources that will be needed. Once the plan is developed, the next step is to implement the plan. This involves putting the plan into action and monitoring the progress. The final step is to evaluate the results of the plan. This involves comparing the actual results with the expected results and identifying any areas for improvement.



